



Jeevan Scientific Technology Limited

20th Annual Report 2017 - 2018





UHPLC & LC-MS/MS



Processing Area



Deep Freezers



Centrifuge



QA Team



Clinic

Twentieth Annual Report 2017-2018

CORPORATE INFORMATION

BOARD OF DIRECTORS

Mr. SSR Koteswara Rao	–	Chairman, Independent Director	(DIN: 00964290)
Mr. K. Krishna Kishore	–	Vice Chairman & Managing Director	(DIN: 00876539)
Mr. M. Rajendra Prasad	–	Whole-Time Director & CEO	(DIN: 06781058)
Mrs. K. Vanaja	–	Non-Executive Director	(DIN: 01030437)
Mr. T. Ravi Babu	–	Independent Director	(DIN: 01274099)
Mr. G. Bhanu Prakash	–	Independent Director	(DIN: 00375298)
Mr. K. Rama Krishna Prasad	–	Independent Director	(DIN: 00754823)

CHIEF FINANCIAL OFFICER

Mr. G. Ravi Kumar

REGISTERED OFFICE

Plot No. 1 & 2,
Sai Krupa Enclave, Manikonda Jagir,
Near Lanco Hills, Goloconda Post,
Hyderabad, Telangana -500008.
Ph No 040-67364700, Fax: 040-67364707

PHARMACOLOGY UNIT

B-17, TIE, Phase II, Balanagar,
Hyderabad, Telangana - 500037.
Ph No : 040-23721008

STATUTORY AUDITORS

M/s. Pavuluri & Co
Chartered Accountants
Plot No. 48, Flat No. 301,
Sucasa, Phase - I,
Kavuri Hills,
Hyderabad - 500 033.

INTERNAL AUDITORS

M/s. K P & Associates
Chartered Accountants
Hyderabad

BANKERS

Karur Vysya Bank Ltd.
Oriental Bank of Commerce.
Andhra Bank.
State Bank of India.

SECRETARIAL AUDITORS

M/s. S. S. Reddy & Associates
Practicing Company Secretaries
Plot No.6-3-354/13, A1,
Suryateja Apartments,
Hindi Nagar, Panjagutta,
Hyderabad-500034

AUDIT COMMITTEE

Mr. K. Rama Krishna Prasad	-	Chairman
Mr. SSR Koteswara Rao	-	Member
Mr. K. Krishna Kishore	-	Member
Mr. G. Bhanu Prakash	-	Member

Jeevan Scientific Technology Limited

NOMINATION & REMUNERATION COMMITTEE

Mr. T. Ravi Babu	-	Chairman
Mr. SSR Koteswara Rao	-	Member
Mrs. K. Vanaja	-	Member
Mr. K. Krishna Kishore	-	Member

STAKEHOLDERS RELATIONSHIP COMMITTEE

Mr. K. Rama Krishna Prasad	-	Chairman
Mr. S S R Koteswara Rao	-	Member
Mr. K. Krishna Kishore	-	Member
Mr. G. Bhanu Prakash	-	Member

INDEPENDENT DIRECTORS COMMITTEE

Mr. SSR Koteswara Rao	-	Chairman
Mr. K. Rama Krishna Prasad	-	Member
Mr. G. Bhanu Prakash	-	Member
Mr. T. Ravi Babu	-	Member

RISK MANAGEMENT COMMITTEE

Mr. K. Rama Krishna Prasad	-	Chairman
Mr. S S R Koteswara Rao	-	Member
Mr. K. Krishna Kishore	-	Member
Mr. T. Ravi Babu	-	Member

ANTI - SEXUAL HARRASSMENT COMMITTEE

Mrs. Nalini Rama. Y	-	Chairman
Mrs. Lakshmi I	-	Member
Mrs. Krishnaveni N	-	Member
Mrs. K. Rajani	-	Outside Member

REGISTRAR & SHARE TRANSFER AGENTS

M/s. CIL Securities Limited,
214, Raghavaratna Towers,
Chiragali Lane, Hyderabad -500001
Phone Number: 040-23202465 / 66612093
Fax: 040-23203028

CORPORATE IDENTITY NUMBER

L72200TG1999PLC031016

LISTED AT: BSE Limited.

ISIN : INE237B01018

WEBSITE: www.jeevanscientific.com

INVESTOR E-MAIL ID: shareholders@jeevanscientific.com

Twentieth Annual Report 2017-2018

NOTICE

Notice is hereby given that the 20th Annual General Meeting of the Shareholders of Jeevan Scientific Technology Limited will be held on 28th day of September, 2018 at 9.30 A.M at 3rd floor, North Block, Raghava Ratna Towers, Chirag Ali Lane, Abids, Hyderabad-500001 to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Balance Sheet as at March 31, 2018, the Statement of Profit & Loss and Cash Flow Statement (including consolidated financial statements) for the year ended on that date together with the Notes attached thereto, along with the Reports of Auditors and Directors thereon.
2. To appoint a director in place of Mrs. K. Vanaja (DIN 01030437) who retires by rotation and being eligible, offers herself for re-appointment.

SPECIAL BUSINESS:

3. APPOINTMENT AND REVISION OF REMUNERATION OF MR. K. KRISHNA KISHORE (DIN: 00876539) AS MANAGING DIRECTOR OF THE COMPANY:

To consider and if, thought fit to pass with or without modification(s), the following resolution as an Ordinary Resolution:-

“**RESOLVED THAT** pursuant to the provisions of Sections 196, 197, read with Schedule V and other applicable provisions if any, of the Companies Act, 2013 including any statutory modification(s) or re-enactment thereof for the time being in force and Articles of Association of the Company, the consent of the members of the company be and is hereby accorded for appointment of Mr. K. Krishna Kishore (DIN: 00876539) as Managing Director of the Company for a period of five years and to pay a remuneration of Rs. 4,50,000/- p.m as recommended by the nomination and remuneration committee.”

“**RESOLVED FURTHER THAT** in terms of Schedule V of the Companies Act, 2013, as amended from time to time, the Board of Directors be and is hereby authorized to vary or increase the remuneration, perquisites, and allowances etc. within such prescribed limits”.

“**RESOLVED FURTHER THAT** in the event of losses or inadequacy of profits in any financial year during his tenure the Company shall pay to Mr. K. Krishna Kishore, remuneration by way of salaries and allowances as specified above as minimum remuneration and in accordance with the limits specified under the Companies Act, 2013 read with Schedule V to the Companies Act 2013, or such other limit as may be prescribed by the Government from time to time”.

“**RESOLVED FURTHER THAT** the Board is here by authorized to take all necessary steps as may be necessary to give effect to the above resolution including filing of all such necessary documents as may be required in this regard.”

4. RE-APPOINTMENT OF MR. S. S. R. KOTESWARA RAO (DIN: 00964290) AS AN INDEPENDENT DIRECTOR OF THE COMPANY:

To consider and if thought fit, pass with or without modification(s), the following resolutions as **Special Resolution**.

“**RESOLVED THAT** pursuant to the provisions of Section 149, 152, 160 and any other applicable provisions of the Companies Act, 2013 and rules made thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force) read with Schedule IV to the Companies Act, 2013, Mr. S. S. R. Koteswara Rao holding (DIN- 00964290)

Jeevan Scientific Technology Limited

who was appointed as Independent Director by the Members in the meeting held on 30.09.2015 for a term of three years and whose term of office expires at the ensuing i.e., 20th Annual General Meeting of the Company be and is hereby re-appointed as an Independent Director of the Company to hold office for five (5) consecutive years till the conclusion of 25th Annual General Meeting to be held in the calendar year 2023 or till 30.09.2023, whichever is earlier .”

“**RESOLVED FURTHER THAT** Mr. K.Krishna Kishore, Vice Chairman and Managing Director be and is hereby authorized to do all such deeds necessary and incidental there to including filing of requisite forms with Registrar of Companies, Telangana and Andhra Pradesh. Hyderabad.”

5. RE-APPOINTMENT AND REVISION OF REMUNERATION OF MR. M. RAJENDRA PRASAD (DIN: 06781058) AS WHOLE-TIME DIRECTOR AND CEO OF THE COMPANY:

To consider and if, thought fit to pass with or without modification(s), the following resolution as an Ordinary Resolution:-

“**RESOLVED THAT** pursuant to the provisions of Sections 196, 197, read with Schedule V and other applicable provisions if any, of the Companies Act, 2013 including any statutory modification(s) or re-enactment thereof for the time being in force and Articles of Association of the Company, the consent of the members of the company be and is hereby accorded for reappointment of Mr. M. Rajendra Prasad (DIN: 06781058) as Whole-Time Director and CEO of the Company for a period of three years with effect from 10.04.2017 to 09.04.2020 and to pay a remuneration of Rs.4,50,000/- p.m. with effect from 01-04-2018.”

“**RESOLVED FURTHER THAT** in terms of Schedule V of the Companies Act, 2013, as amended from time to time, the Board of Directors be and is hereby authorized to vary or increase the remuneration, perquisites, and allowances etc. within such prescribed limits”.

“**RESOLVED FURTHER THAT** in the event of losses or inadequacy of profits in any financial year during his tenure the Company shall pay to Mr. M. Rajendra Prasad, remuneration by way of salaries and allowances as specified above as minimum remuneration and in accordance with the limits specified under the Companies Act, 2013 read with Schedule V to the Companies Act 2013, or such other limit as may be prescribed by the Government from time to time”.

“**RESOLVED FURTHER THAT** Mr. K.Krishna Kishore, Vice Chairman and Managing Director be and is hereby authorized to do all such deeds necessary and incidental there to including filing of requisite forms with Registrar of Companies, Telangana and Andhra Pradesh. Hyderabad.”

For and on behalf of the Board
Jeevan Scientific Technology Limited

Sd/-

K. Krishna Kishore

Vice Chairman & Managing Director

(DIN : 00876539)

Place : Hyderabad

Date : 14.08.2018

Twentieth Annual Report 2017-2018

NOTES:

1. **A MEMBER ENTITLED TO ATTEND AND VOTE IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF/HERSELF AND A PROXY NEED NOT BE A MEMBER OF THE COMPANY.** The instrument of Proxy in order to be effective shall be deposited at the Registered Office of the Company by not less than 48 hours before the commencement of the Meeting.

Pursuant to the provisions of Section 105 of the Companies Act, 2013, a person can act as a proxy on behalf of not more than fifty (50) members and holding in aggregate not more than 10% of the total share capital of the Company carrying voting rights. A member holding more than 10% of the total share capital of the Company carrying voting rights may appoint a single person as proxy, who shall not act as a proxy for any other person or shareholder. The appointment of proxy shall be in the Form No. MGT.11 annexed herewith.

2. Attendance slip, proxy form and the route map giving directions to reach the venue of the 20th Annual General Meeting is given at the end of the Notice.
3. Corporate members intending to send their authorised representative(s) to attend the Meeting are requested to send to the Company/ Registrar and Share Transfer Agent, a certified true copy of the relevant Board Resolution together with the specimen signature(s) of the representative(s) authorised under the said Board Resolution to attend and vote on their behalf at the Meeting.
4. The requirement to place the matter relating to appointment of Auditors for ratification by members at every Annual General Meeting is done away with vide notification dated May 7, 2018 issued by the Ministry of Corporate Affairs, New Delhi. Accordingly, no resolution is proposed for ratification of appointment of Auditors, who were appointed in the Annual General Meeting held on September 27, 2017.
5. The Register of Members and Share Transfer Books of the Company will remain closed from 22nd September, 2018 to 28th September, 2018 (Both days inclusive) for the purpose of AGM.
6. Members holding shares in the electronic form are requested to inform any changes in address/bank mandate directly to their respective Depository Participants.
7. Members/ Proxies/ Authorised Representatives are requested to hand over the enclosed Attendance Slip, duly signed in accordance with their specimen signature(s) registered with the Company for admission to the meeting hall. Members who hold shares in dematerialised form are requested to bring their Client ID and DP ID Numbers for identification.
8. In case of joint holders attending the Meeting, only such joint holders who are higher in the order of names will be entitled to vote.
9. The Company or its Registrar and Share Transfer Agent cannot act on any request received directly from the members holding shares in electronic form for any change of bank particulars or bank mandates. Such changes are to be advised only to the Depository Participant of the members.
10. The Securities and Exchange Board of India has mandated submission of Permanent Account Number (PAN) by every participant in securities market. Members holding shares in demat form are, therefore, requested to submit PAN details to the Depository Participants

Jeevan Scientific Technology Limited

with whom they have demat accounts. Members holding shares in physical form can submit their PAN details to the Company/ Registrar and Share Transfer Agents (M/s. CIL Securities Limited.)

11. As a measure of austerity, copies of the annual report will not be distributed at the Annual General Meeting. Members are therefore, requested to bring their copies of the Annual Report to the Meeting.
12. Members holding shares in the same name under different ledger folios are requested to apply for Consolidation of such folios and send the relevant share certificates to **M/s. CIL Securities Limited**, Share Transfer Agents of the Company for their doing the needful.
13. Members are requested to send their queries at least 10 days before the date of meeting so that information can be made available at the meeting.
14. In respect of shares held in physical mode, all shareholders are requested to intimate changes, if any, in their registered address immediately to the registrar and share transfer agent of the company and correspond with them directly regarding share transfer/transmission/transposition, Demat / Remat, change of address, issue of duplicate shares certificates, ECS and nomination facility.
15. SEBI has decided that securities of the listed companies can be transferred only in dematerialized form w.e.f cut off date being 05.12.2018. In view of the above and to avail various benefits of dematerialization, members are advised to dematerialize shares held by them in physical form.
16. In terms of Section 72 of the Companies Act, 2013, a member of the company may nominate a person on whom the shares held by him/her shall vest in the event of his/her death. Members desirous of availing this facility may submit nomination in prescribed Form-SH-13 to the company/RTA in case shares are held in physical form, and to their respective depository participant, if held in electronic form.
17. Electronic copy of the Annual Report for 2017-2018 is being sent to all the members whose email IDs are registered with the Company/Depository Participants(s) for communication purposes unless any member has requested for a hard copy of the same. For members who have not registered their email address, physical copies of the Annual Report for 2017-2018 is being sent in the permitted mode.
18. Members may also note that the Notice of the 20th Annual General Meeting and the Annual Report for 2017-2018 will also be available on the Company's website www.jeevanscientific.com for their download. The physical copies of the aforesaid documents will also be available at the Company's Registered Office for inspection during normal business hours on working days. Even after registering for e-communication, members are entitled to receive such communication in physical form, upon making a request for the same, by post free of cost. For any communication, the shareholders may also send requests to the Company's investor email id: shareholders@jeevanscientific.com.
19. Voting through electronic means
Pursuant to Section 108 of the Companies Act, 2013, a read with the relevant Rules of the Act and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 the Company is pleased to provide the facility to Members to exercise

Twentieth Annual Report 2017-2018

their right to vote by electronic means. The Members, whose names appear in the Register of Members / list of Beneficial Owners as on 21st September, 2018, i.e. the dates prior to the commencement of book closure date are entitled to vote on the Resolutions set forth in this Notice. The remote e-voting period will commence at 9.00 a.m. on 25th September, 2018 and will end at 5.00 p.m. on 27th September, 2018. The Company has appointed Mrs. D. Renuka (C.P. No. 3460), Practicing Company Secretary, to act as the Scrutinizer, to scrutinize remote e-voting and physical voting process in a fair and transparent manner. The Members desiring to vote through remote e-voting refer to the detailed procedure given hereinafter.

Procedure for remote e-voting

- i. The voting period begins at 9.00 A.M. on 25th September, 2018 and will end at 5.00 P.M. on 27th September, 2018. During this period shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (21st September, 2018) may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- ii. The shareholders should log on to the e-voting website www.evotingindia.com.
- iii. Click on Shareholders.
- iv. Now Enter your User ID
 - a) For CDSL: 16 digits beneficiary ID,
 - b) For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c) Members holding shares in Physical Form should enter Folio Number registered with the Company.
- v. Next enter the Image Verification as displayed and Click on Login.
- vi. If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier
- vii. If you are a first time user follow the steps below:

	For Members holding shares in Demat Form and Physical Form
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) <ul style="list-style-type: none"> • Members who have not updated their PAN with the Company/Depository Participant are requested to use the first two letters of their name and the 8 digits of the sequence number in the PAN field. • In case the sequence number is less than 8 digits enter the applicable number of 0's before the number after the first two characters of the name in CAPITAL letters. Eg. If your name is Ramesh Kumar with sequence number 1 then enter RA00000001 in the PAN field.
DOB	Enter the Date of Birth as recorded in your demat account or in the company records for the said demat account or folio in dd/mm/yyyy format.
Dividend Bank Details	Enter the Dividend Bank Details as recorded in your demat account or in the company records for the said demat account or folio. <ul style="list-style-type: none"> • Please enter the DOB or Dividend Bank Details in order to login. If the details are not recorded with the depository or company please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (iv).

Jeevan Scientific Technology Limited

- viii. After entering these details appropriately, click on "SUBMIT" tab.
- ix. Members holding shares in physical form will then directly reach the Company selection screen. However, members holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- x. For Members holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- xi. Click on the EVSN Jeevan Scientific Technology Limited.
- xii. On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- xiii. Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.
- xiv. After selecting the resolution you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.
- xv. Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.
- xvi. You can also take out print of the voting done by you by clicking on "Click here to print" option on the Voting page.
- xvii. If Demat account holder has forgotten the same password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.

(II) In case of members receiving the Physical copy of Notice of AGM [for members whose e-mail IDs are not registered with the company/ depository participant(s) or requesting physical copy]:

- A. Please follow all steps from sl. no. (ii) to sl. no. (xvii) above, to cast vote.
 - Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodian are required to log on to www.evotingindia.com and register themselves as Corporate.
 - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
 - After receiving the login details a compliance user should be created using the admin login and password. The Compliance user would be able to link the account(s) for which they wish to vote on.
 - The list of accounts should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
 - A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.

Twentieth Annual Report 2017-2018

- B. The voting period begins at 9.00 A.M. on 25th September, 2018 and will end at 5.00 p.m. on 27th September, 2018. During this period shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on 21st September, 2018 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter. Once the vote on a resolution is cast by the shareholder, the shareholder shall not be allowed to change it subsequently.

In case you have any queries or issues regarding e-voting, you may refer the Frequently Asked Questions ("FAQs") and e-voting manual available at www.evotingindia.com under help section or write an email to helpdesk.evoting@cdslindia.com.

20. The voting rights of shareholders shall be in proportion to their shares of the paid up equity share capital of the Company as on the cut-off date (record date) of 21st September, 2018.
21. Shareholders can also cast their vote using CDSL's mobile app m-Voting available for android based mobiles. The m-Voting app can be downloaded from Google Play Store. iPhone and Windows phone users can download the app from the App Store and the Windows Phone Store respectively . Please follow the instructions as prompted by the mobile app while voting on your mobile.
22. Mrs. D. Renuka, Practicing Company Secretary, bearing C.P. Number 3460 has been appointed as the Scrutinizer to scrutinize the e-voting process.
23. The Scrutinizer shall within a period not exceeding three (3) days from the conclusion of the e-voting period unblock the votes in the presence of at least two (2) witnesses not in the employment of the Company and make a Scrutinizer's Report of the votes cast in favour or against, if any, forthwith to the Chairman of the Company.
24. The Results shall be declared on or after the AGM of the Company. The Results declared along with the Scrutinizer's Report shall be placed on the Company's website www.jeevanscientific.com and on the website of CDSL immediately after declaration of result by chairman and communicated to the BSE Limited.
25. The Ministry of Corporate Affairs (vide circular nos. 17/2011 and 18/2011 dated April 21 and April 29, 2011 respectively), has undertaken a 'Green Initiative in Corporate Governance' and allowed companies to share documents with its shareholders through an electronic mode. Members are requested to support this green initiative by registering/uploading their email addresses, in respect of shares held in dematerialized form with their respective Depository Participant and in respect of shares held in physical form with the Company's Registrar and Share Transfer Agents.

For and on behalf of the Board
Jeevan Scientific Technology Limited

Sd/-

K. Krishna Kishore

Vice Chairman & Managing Director
(DIN : 00876539)

Place : Hyderabad
Date : 14.08.2018

Jeevan Scientific Technology Limited

EXPLANATORY STATEMENT

[Pursuant to Section 102 of the Companies Act, 2013]

ITEM NO. 3:

The Board in its meeting held on 26.05.2018 has revised the remuneration of Mr. K. Krishna Kishore to Rs. 4,50,000/- p.m who was appointed as Managing Director of the Company for a period of 5 years with effect from 01.04.2018 subject to approval of the shareholders based on the recommendations of the Nomination and Remuneration Committee.

The Board of Directors recommends the passing of the above resolution as an Ordinary Resolution set out in the item no. 3.

Save and except Mr. K. Krishna Kishore (DIN: [00876539](#)) Managing Director and Mrs. K. Vanaja (DIN: 01030437) being his relative, none of the other Directors/Key Managerial Personnel and their relatives is in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

Information in accordance with Schedule V of Companies Act, 2013

I. GENERAL INFORMATION

1. Nature of Industry : Clinical Research
2. Date or expected date of commencement of commercial: The Company started its commercial operations in the year 02.02.1999
3. In case of new companies, expected date of commencement of business activities as per project approved by financial institutions appearing in the prospects: Not Applicable
4. Financial performance based on given indications

Particulars	2017-18 (Rs. in lakhs)	2016-17 (Rs. in lakhs)	2015-16 (Rs. in lakhs)
Turnover	2,016.91	1,803.05	1,774.01
Net Profit after Tax	30.54	88.60	41.94

5. Foreign investments or collaborations, if any: Not Applicable

II. INFORMATION ABOUT THE APPOINTEE:

1. Background Details: Mr. K. Krishna Kishore, a Postgraduate from Andhra University, he is the Chief architect of Jeevan Mitra Chit Fund Private Limited, Hyderabad. Under his aegis and stewardship as Chairman and Managing Director, the Company has grown impressively in size and stature to become a leading chit fund concern in the erstwhile State of Andhra Pradesh.
2. Past Remuneration: The remuneration drawn by Mr. K. Krishna Kishore (DIN: 00876539) Managing Director is Rs.3,00,000 /- per month.
3. Recognition or awards : Not Applicable
4. Job Profile and his suitability: Mr. K. Krishna Kishore has been heading the organisation since 1999. Ever since his association with the company, the company's performance has only shown an upward graph. It is thereby proposed that Mr. K. Krishna Kishore continues heading the company.

Twentieth Annual Report 2017-2018

5. Remuneration proposed:
As set out in the Explanatory statement of resolution No.3, the remuneration to Mr. K. Krishna Kishore, Managing Director has the approval of the Nomination and Remuneration Committee and Board of Directors.
6. Comparative remuneration profile with respect to industry, size of the company profile of the position and person (in case of expatriates the relevant details would be w.r.t. the country of his origin):
Taking into consideration of the size of the Company, the profile of Mr. K. Krishna Kishore and the responsibilities shouldered on him, the aforesaid remuneration package is commensurate with the remuneration package paid to managerial positions in other companies.
7. Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any:
Besides the remuneration proposed, he is holding 19,93,391 Equity Shares of the Company.

III. OTHER INFORMATION:

1. Reasons for inadequate profits: The Company is in the mode of expansion of the business which generally requires spending lot of money upfront leading to minimal profits in the initial years. All this expenditure will result in to revenues over a period of next two to three years.
2. Steps taken or proposed to be taken for improvement: Necessary efforts are being made to increase the clientele who in turn contribute for the growth of the business as well as the profitability.
3. Expected increase in productivity and profit in measurable terms: The company is committed to build the business operations within budget and considering that the business operates on a going concern basis, it is believed that financial position of the company will improve considerably in the coming years.

ITEM NO. 4:

Mr. S.S.R Koteswara Rao is a Member of the Institute of Chartered Accountants of India and the Senior Partner of Brahmayya & Co., Chartered Accountants. Mr. S.S.R Koteswara Rao was Regional Council Member of SIRC of ICAI during 1985-1992 and was its Chairman during 1990-1992. Mr. S.S.R Koteswara Rao was the President of Federation of Andhra Pradesh Chamber of Commerce & Industry, director of Andhra Pradesh State Financial Corporation and member of Tirumala Tirupati Devasthanams Trust Board. Mr. S.S.R. Koteswara Rao is presently a Director in Sanzyme Ltd., Kakatiya Textiles Ltd., Deccan Auto Ltd., Tera Software Limited and Corona Bus Manufactures Pvt. Ltd., and Treasurer in Vignana Jyothi - a non-profitable organisation working in the field of education. Mr. S.S.R Koteswara Rao (DIN NO.00964290), is an Independent Director of the Company who retires at the ensuing 20th Annual General Meeting. It is proposed to re-appoint Mr. S.S.R Koteswara Rao (DIN NO.00964290) as an Independent Director of the Company under Section 149 and other applicable provisions of the Companies Act, 2013 to hold office for five (5) consecutive years till the conclusion of 25th Annual General Meeting to be held in the calendar year 2023 or till 30.09.2023, whichever is earlier.

In the opinion of the Board, Mr. S.S.R Koteswara Rao fulfils the conditions specified in the Companies Act, 2013 and rules made thereunder for his appointment as an Independent Director of the Company and is independent of the management.

Jeevan Scientific Technology Limited

The Board considers that his continued association would be of immense benefit to the Company and it is desirable to continue to avail services of Mr. S.S.R Koteswara Rao as an Independent Director. Accordingly, the Board recommends the resolution in relation to appointment of Mr. S.S.R Koteswara Rao as an Independent Director, for the approval by the shareholders of the Company.

Except Mr. S.S.R Koteswara Rao, being an appointee, none of the Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the resolution set out at Item No. 4.

ITEM NO. 5:

Mr. M. Rajendra Prasad (DIN: 06781058) was appointed as Whole-Time Director and CEO of the Company for a period of 3 years from 10.04.2017 .

Now, based on the recommendations of the Nomination and Remuneration Committee, the Board of Directors of the Company at their meeting held on 26th May, 2018, approved the re-appointment of Mr. M. Rajendra Prasad (DIN: 06781058) as Whole-Time Director and CEO of the Company for a period of three years from 10.04.2017 to 09.04.2020. Also, the Board revised his remuneration to Rs. 4,50,000/- p.m with effect from 01.04.2018 which is in accordance with the limits specified under the Companies Act, 2013 read with Schedule V to the Companies Act 2013 subject to the recommendation of Nomination and Remuneration Committee.

The Board of Directors recommends the passing of the above resolution as an Ordinary Resolution.

Save and except M. Rajendra Prasad (DIN: 06781058), Whole-Time Director and CEO none of the other Directors/Key Managerial Personnel and their relatives is in any way interested or concerned financially or otherwise, in the Resolution set out in the notice except to the extent of their shareholding.

Information in accordance with Schedule V of Companies Act, 2013

I. GENERAL INFORMATION

1. Nature of Industry : Clinical Research
2. Date or expected date of commencement of commercial: The Company started its commercial operations in the year 02.02.1999
3. In case of new companies, expected date of commencement of business activities as per project approved by financial institutions appearing in the prospects: Not Applicable
4. Financial performance based on given indications

Particulars	2017-18 (Rs. in lakhs)	2016-17 (Rs. in lakhs)	2015-16 (Rs. in lakhs)
Turnover	2,016.91	1,803.05	1,774.01
Net Profit after Tax	30.54	88.60	41.94

5. Foreign investments or collaborations, if any: Not Applicable

II. INFORMATION ABOUT THE APPOINTEE:

1. Background Details: Mr. Rajendra Prasad, has the vision of developing Jeevan as a fully functional CRO. Mr. Prasad is an excellent strategist, and a prudent decision maker with insightful and articulate vision. Mr. Prasad has been an exemplary leader in establishing

Twentieth Annual Report 2017-2018

and maintaining long-term business relationships. Before joining with Jeevan, Mr. Prasad was associated with M/s. Veeda Clinical Research as Chief Business Officer. He had been associated with M/s. Veeda Clinical Research, since its inception in 2004, in various leadership roles and had contributed immensely in the growth of Veeda both in "Technical" and "Business" fronts. He has a diversified experience and knowledge of various functional domains in the CRO industry including clinical operations, BA/BE studies, data management and bioanalytical. Mr. Prasad has lead the team in research and development and has hands on experience in developing and validating various bioanalytical methods. Mr. Prasad has a rich experience of more than 20 years in pharmaceutical and CRO industry and has worked in several leading names in the industry including GVK Bio, Aurobindo Pharma, Cadila Pharma, Lambda Therapeutics, Sun Pharma and Vimta Labs. He is a well-known "team builder" in CRO industry. Mr. Prasad holds a Master's Degree in Pharmacy. Mr. Rajendra Prasad delivered training to drug control authorities in CDSCO office in Delhi.

2. Past Remuneration: The remuneration drawn by Mr. M. Rajendra Prasad (DIN: 06781058), Whole-Time Director and CEO is Rs. 2,58,333 /- per month.
3. Recognition or awards : Not Applicable
4. Job Profile and his suitability: Keeping in mind the background details, past record and proficiency of Mr. M. Rajendra Prasad, the Board is of the view that he is the most suitable person for the job.
5. Remuneration proposed As set out in the Explanatory statement of resolution No.5 the remuneration to Mr. M. Rajendra Prasad as Whole-Time Director and CEO has the approval of the Nomination and Remuneration Committee and Board of Directors.
6. Comparative remuneration profile with respect to industry, size of the company profile of the position and person (in case of expatriates the relevant details would be w.r.t. the country of his origin) Taking into consideration of the size of the Company, the profile of Mr. M. Rajendra Prasad and the responsibilities shouldered on him, the aforesaid remuneration package is commensurate with the remuneration package paid to managerial positions in other companies.
7. Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any Besides the remuneration proposed, he is holding 8,96,250 Equity Shares of the Company.

III. OTHER INFORMATION:

1. Reasons for inadequate profits: The Company is in the mode of expansion of the business which generally requires spending lot of money upfront leading to minimal profits in the initial years. All this expenditure will result in to revenues over a period of next two to three years.
2. Steps taken or proposed to be taken for improvement: Necessary efforts are being made to increase the clientele who in turn contribute for the growth of the business as well as the profitability.
3. Expected increase in productivity and profit in measurable terms: The company is committed to build the business operations within budget and considering that the business operates on a going concern basis, it is believed that financial position of the company will improve further in near future.

Jeevan Scientific Technology Limited

DIRECTOR'S REPORT

To the Members,

The Directors have pleasure in presenting before you the 20th Director's Report of the Company together with the Audited Statements of Accounts for the year ended 31st March, 2018.

FINANCIAL SUMMARY/HIGHLIGHTS, OPERATIONS, STATE OF AFFAIRS:

The performance during the period ended 31st March, 2018 has been as under:

(Rs. In Lakhs)

Particulars	Standalone		Consolidated	
	2017-2018	2016-2017	2017-2018	2016-2017
Total Income	2,016.91	1,803.05	2,132.04	1,878.89
Total Expenditure	1,968.42	1,690.22	2,095.84	1,777.82
Profit Before Tax	48.49	112.83	36.20	101.07
Provision for Tax	23.79	9.63	25.02	10.74
Profit before Other Comprehensive Income	24.70	103.20	11.18	90.33
Other Comprehensive Income	5.84	(14.60)	5.84	(14.60)
Profit after Tax	30.54	88.60	17.02	75.73

REVIEW OF OPERATIONS:

During the year under review, your company recorded a turnover of Rs. 2,016.91 Lakhs as against Rs. 1,803.05 Lakhs in the previous financial year. The turnover includes revenue from the Clinical Research services, Information Technology Services and Data Management Service charges.

MATERIAL CHANGES AND COMMITMENTS:

There were no material changes and commitments affecting financial position of the company between 31st March and the date of Board's Report. (i.e. 14.08.2018)

CHANGE IN THE NATURE OF BUSINESS, IF ANY:

During the period under review and the date of Board's Report there was no change in the nature of Business.

TRANSFER TO RESERVES:

On allotment of 21,80,000 equity pursuant to conversion of 21,80,000 warrants on 06.03.2018, an amount of Rs. 4,41,45,000 was transferred to reserves.

FAMILIARISATION PROGRAMMES:

The Company familiarises its Independent Directors on their appointment as such on the Board with the Company, their roles, rights, responsibilities in the Company, nature of the industry in which the Company operates, etc. through familiarisation programme. The Company also conducts orientation programme upon induction of new Directors, as well as other initiatives to update the Directors on a continuing basis. The familiarisation programme for Independent Directors is disclosed on the Company's website www.bnrsecurities.com

Twentieth Annual Report 2017-2018

CORPORATE GOVERNANCE:

A separate section titled "Report on Corporate Governance" along with the Auditors' Certificate on Corporate Governance as stipulated under Regulation 34 read with Schedule V of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 forms part of this Annual Report.

REVISION OF FINANCIAL STATEMENTS:

There was no revision of the financial statements for the year under review.

EXTRACT OF ANNUAL RETURN:

Extract of Annual Return is Annexed as Annexure no.II of this Annual Report.

SHARE CAPITAL:

The authorised capital of the company is Rs. 21,00,00,000/- consisting of 2,10,00,000 equity shares of Rs. 10/- each and the paid up share capital of the Company is Rs. 15,30,14,650/- consisting of 1,53,01,465 equity shares of Rs. 10/- each.

In the Board Meeting held on 06.03.2018, 21,80,000 warrants were converted into 21,80,000 equity shares of Rs. 10/- each at an issue price of Rs. 30.25 per share.

Further, in the Board Meeting held on 12.06.2018, 38,42,000 warrants were converted into 38,42,000 equity shares of Rs. 10/- each at an issue price of Rs. 30.25 per share.

As a result, the paid up capital of the company increased from Rs. 9,27,94,650/- consisting of 92,79,465 equity shares of Rs. 10/- each to Rs. 15,30,14,650/- consisting of 1,53,01,465 equity shares of Rs. 10/- each as on the date of Board's Report (14.08.2018).

DIVIDEND:

As the profits are inadequate, the Directors do not propose any dividend for the year under review.

BOARD MEETINGS:

The Board of Directors duly met 7 (seven) times on 10-04-2017, 30-05-2017, 14-08-2017, 27-09-2017, 14-12-2017, 12-02-2018 and 06-03-2018 and in respect of which meetings, proper notices are given and the proceedings are properly recorded and signed in the Minutes Book maintained for the purpose.

DIRECTORS AND KEY MANAGERIAL PERSONNEL: The following Directors/ KMPs are appointed or resigned during the year 2017-18 and upto the date of Board's Report as on 14.08.2018:

- i. Mr. Raghav Beeram resigned as Director of the Company w.e.f 11.10.2017.
- ii. Mr. A. Vijay Kumar resigned as Director of the Company w.e.f 01.04.2018.
- iii. Mr. K. Krishna Kishore was appointed as Managing Director w.e.f 10.04.2017
- iv. Mr. G. Ravi kumar was appointed as CFO of the Company w.e.f 03.05.2018.
- v. Mrs. G. Krishna Sowjanya, Company Secretary cum Compliance officer resigned w.e.f 28.04.2018

The Board places its sincere appreciation for the services rendered by Mr. Raghav Beeram and Mr. A. Vijay Kumar and Mrs. G. Krishna Sowjanya during their period of service in the Company.

As required under regulation 36 (3) of the SEBI (LODR), Regulations, 2015, brief particulars of the Directors or Key Managerial Personnels who are appointed during the year and upto the date of Board's Report or seeking appointment/re-appointment are given as under:-

Jeevan Scientific Technology Limited

Name of the Director/ KMP	S.S.R. Koteswara Rao	M. Rajendra Prasad	K. Vanaja	G. Ravi Kumar	K. Krishna Kishore
Appointment/ Reappointment	Re-appointment	Appointed as CEO (w.e.f 10.04.2017)	Re-appointment	Appointed as CFO	Re-appointment
Date of Birth	25/03/1943	05/07/1973	14/06/1967	30/06/1955	29/07/1960
Qualification	Chartered Accountant	Master's Degree in Pharmacy	Graduate Diploma in Pharmacy	Master's Degrees in Business & Financial Management from Osmania University and in Social work from Andhra University. He is also certified by the Indian Institute of Banking and Finance.	Postgraduate from Andhra University
Address	Plot No.1303a Road No.65, Jubilee Hills Hyderabad 500033	109, Bhavyas Majestic Enclave, Miyapur, Hyderabad, Telangana – 500049, India.	Plot no. 72, Flat no. 101 Padmaja Courts - II, Srinagar Colony Hyderabad 500072	Flat no. 1101, Avani Block, Green Grace Apartments Khajaguda Hyderabad 500008	Plot no. 72, Flat no. 101, Padmaja Courts - II, Srinagar Colony Hyderabad 500072
Names of listed entities in which the person also holds the directorship and the membership of Committees of the board No. of Shares held in the	Director in 1 Company: 1. Tera Software Limited	Director in 1 Company: 1. Jeevan Scientific Technology Limited	Director in 1 Company: 1. Jeevan Scientific Technology Limited	Nil	Director in 1 Company: 1. Jeevan Scientific Technology Limited
Company	Nil	8,96,250	15,73,800	Nil	19,93,391
Inter se relationship with any Director	NA	NA	Wife of Mr. K. Krishna Kishore	NA	Husband of Mrs. K. Vanaja

Twentieth Annual Report 2017-2018

DIRECTOR'S RESPONSIBILITY STATEMENT:

In pursuance of section 134 (5) of the Companies Act, 2013, the Directors hereby confirm that:

- (a) In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- (b) The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;
- (c) The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- (d) The Directors had prepared the annual accounts on a going concern basis; and
- (e) The Directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
- (f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

DECLARATION FROM INDEPENDENT DIRECTORS ON ANNUAL BASIS:

The Company has received a declarations from Independent directors of the company, Mr. G. Bhanu Prakash, Mr. S.S.R Koteswara, Mr. K. Rama Krishna Prasad and Mr. T. Ravi Babu, to the effect that they are meeting the criteria of independence as provided in Sub-section (6) of Section 149 of the Companies Act, 2013 and Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 annexed to the Annual Report as Annexure –III.

STATUTORY COMPLIANCE:

The Company has complied with the required provisions relating to statutory compliance with regard to the affairs of the Company in all respects.

INFORMATION ABOUT THE FINANCIAL PERFORMANCE / FINANCIAL POSITION OF THE SUBSIDIARIES / ASSOCIATES / JOINT VENTURES:

In accordance with Section 129(3) of the Companies Act, 2013, a statement containing salient features of the financial statements of the subsidiary companies in Form AOC 1 is as an attachment herewith forming part of the Annual Report. In accordance with third provision to Section 136(1) of the Companies Act, 2013, the Annual Report of your Company, containing therein its audited standalone and the consolidated financial statements has been placed on the website of the Company at www.jeevanscientific.com. Further, audited financial statements together with related information and other reports of each of the subsidiary companies, have also been placed on the website of the Company at www.jeevanscientific.com.

THE NAMES OF COMPANIES WHICH HAVE BECOME OR CEASED TO BE ITS SUBSIDIARIES, JOINT VENTURES OR ASSOCIATE COMPANIES DURING THE YEAR.

No companies have become or ceased to be the subsidiaries, joint ventures or associate companies of the company.

Jeevan Scientific Technology Limited

DETAILS IN REPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB-SECTION (12) OF SECTION 143 OTHER THAN THOSE WHICH ARE REPORTABLE TO CENTRAL GOVERNMENT.

There were no frauds reported by the auditors as per section 143 (12).

AUDITORS:

STATUTORY AUDITORS:

M/s. Pavuluri & Co, were appointed as Statutory Auditors for a period of 5 years in the previous Annual General Meeting held on 27th September, 2017.

The requirement to place the matter relating to appointment of Auditors for ratification by members at every Annual General Meeting is done away with vide notification dated May 7, 2018 issued by the Ministry of Corporate Affairs, New Delhi. Accordingly, no resolution is proposed for ratification of appointment of Auditors, who were appointed in the Annual General Meeting held on September 27, 2017.

INTERNAL AUDITORS:

M/s. K P & Associates, Chartered Accountants, Hyderabad are the internal Auditors of the Company for the financial year 2017-18

SECRETARIAL AUDITORS:

Pursuant to the provisions of Section 134(3)(f) & Section 204 of the Companies Act, 2013, Secretarial audit report as provided by M/s. S.S. Reddy & Associates., Practicing Company Secretaries is annexed to this Report as Annexure - IV.

INDIAN ACCOUNTING STANDARDS

The implementation of Indian Accounting Standards (IAS) was a major change process which the company has implemented with effect from 1st April 2017 onwards.

Twentieth Annual Report 2017-2018

QUALIFICATIONS IN AUDIT REPORTS:

(a) Statutory Auditors Report:

The Board has duly reviewed the Statutory Auditor's Report on the Accounts for the year ended March 31, 2018 and has noted that the same does not have any reservation, qualification or adverse remarks. However, the Board decided to further strengthen the existing system and procedures to meet all kinds of challenges and growth in the market expected in view of the robust growth in the industry.

(b) Secretarial Audit Report:

The Board has duly reviewed the Secretarial Audit Report on the Compliances according to the provisions of section 204 of the Companies Act 2013 and has noted that the same does not have any reservations qualifications, or adverse remarks. The Secretarial Audit Report in Form MR-3 is annexed to the Annual Report as Annexure - IV.

CONSOLIDATED FINANCIAL STATEMENTS:

In compliance with the provisions of the Companies Act, 2013 and the Accounting Standards AS-21 and AS-27 on consolidated financial statements, the Directors have provided the consolidated financial statements for the financial year ended March 31, 2018 which forms part of the Annual Report.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE OUTGO:

The required information as per Sec.134(3)(m) of the Companies Act 2013 is provided hereunder:

A. Conservation of Energy:

The Company's operations are not energy intensive. Adequate measures have been taken to conserve energy wherever possible by using energy efficient computers and purchase of energy efficient equipment.

B. Technology Absorption:

i. Research and Development (R&D): The company has started a Bioanalytical Lab in the new premises. Bioanalytical research laboratory is designed with state of the art facility equipped with advanced analytical instrumentation having 2 processing labs and 4 LC-MS/MS labs, which can accommodate up to 12 LCMS/ MS. Jeevan Scientific offers a unique combination of highly trained workforce enabled with well-equipped bio analytical research and development (R&D) laboratory.

ii. Technology absorption, adoption and innovation: There was considerable technology absorption, adoption and innovation with the addition of the above equipment in the new facility the results of which can be seen in the years to come.

C. Foreign Exchange Earnings and Out-Go: The foreign exchange earned in terms of actual inflows during the year and the foreign exchange outgoduring the year in terms of actual outflow: Please refer to note no.1(xiv) of notes to accounts.

DETAILS RELATING TO DEPOSITS, COVERING THE FOLLOWING:

The Company has not accepted any deposits falling within the meaning of Sec.73, 74 & 76 of

Jeevan Scientific Technology Limited

the Companies Act, 2013 read with the Rule 8(v) of Companies (Accounts) Rules 2014, during the financial year under review.

DETAILS OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS:

The Internal Financial Controls with reference to financial statements as designed and implemented by the Company are adequate. During the year under review, no material or serious observation has been received from the Internal Auditors of the Company for inefficiency or inadequacy of such controls. The Company maintains appropriate system of internal control, including monitoring procedures, to ensure that all assets are safeguarded against loss from unauthorized use or disposition. Company policies, guidelines and procedures provide for adequate checks and balances, and are meant to ensure that all transactions are authorized, recorded and reported correctly.

DISCLOSURE OF ORDERS PASSED BY REGULATORS OR COURTS OR TRIBUNAL

No orders have been passed by any Regulator or Court or Tribunal which can have impact on the going concern status and the Company's operations in future.

INSURANCE:

The properties and assets of your Company are adequately insured.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:

The company has not given any Loans, Guarantees or Investments during the year under review.

CREDIT & GUARANTEE FACILITIES:

The Company has been availing facilities of Credit and Guarantee as and when required, for the business of the Company, from The Karur Vysya Bank Ltd. and Personal Guarantees were given by Mr. K. Krishna Kishore, Vice Chairman & Managing Director, Smt. K. Vanaja, Director & Shri. M. Rajendra Prasad Whole Time Director & CEO without any consideration for obtaining Bank Guarantees.

RISK MANAGEMENT POLICY:

The Company follows a comprehensive system of Risk Management. The Company has adopted a procedure for assessment and minimization of probable risks. It ensures that all the risks are timely defined and mitigated in accordance with the well structured risk management process.

CORPORATE SOCIAL RESPONSIBILITY POLICY:

Since the Company does not have net worth of Rs. 500 Crore or more, or turnover of Rs. 1000 Crore or more, or a net profit of Rs. 5 Crore or more during the financial year, section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility is not applicable and hence the Company need not adopt any Corporate Social Responsibility Policy.

RELATED PARTY TRANSACTIONS:

All contracts/arrangements/transactions entered into by the Company during the financial year with related parties were in the ordinary course of business and on arm's length basis. During the year, the Company had not entered into any contract/arrangement/transaction

Twentieth Annual Report 2017-2018

with related parties which could be considered material in accordance with the policy of the company on materiality of related party transactions.

The Policy on materiality of related party transactions and dealing with related party transactions as approved by the Board may be accessed on the Company's website at www.jeevanscientific.com.

The Directors draw attention of the members to Note no.31 in notes to accounts which sets out related party disclosures.

DISCLOSURE ABOUT COST AUDIT:

Cost Audit is not applicable to the Company.

STATEMENT SHOWING THE NAMES OF THE TOP TEN EMPLOYEES IN TERMS OF REMUNERATION DRAWN AND THE NAME OF EVERY EMPLOYEE:

A statement showing the names of the top ten employees in terms of remuneration drawn and the name of every employee is annexed to this Annual report as Annexure A

RATIO OF REMUNERATION TO EACH DIRECTOR:

Under section 197(12) of the Companies Act, 2013, and Rule 5(1)(2) & (3) of the Companies(Appointment & Remuneration) Rules, 2014 read with Schedule V of the Companies Act, 2013 a remuneration to Mr. K. Krishna Kishore, Vice-Chairman and Managing Director of the Company is 14:1 and to Mr. Rajendra Prasad, Whole-Time director and CEO of the Company is 12:1.

NON-EXECUTIVE DIRECTORS' COMPENSATION AND DISCLOSURES

None of the Independent / Non-Executive Directors has any pecuniary relationship or transactions with the Company which in the Judgment of the Board may affect the independence of the Directors.

CEO/ CFO Certification

The Managing Director and CEO/ CFO certification of the financial statements for the year 2017-18 is provided elsewhere in this Annual Report.

BOARD EVALUATION:

Pursuant to the applicable provisions of the Companies Act, 2013 and SEBI Listing Regulations, the Board has carried out an Annual Evaluation of its own performance, performance of the Directors and the working of its Committees. The Board's functioning was evaluated on various aspects, including inter alia degree of fulfilment of key responsibilities, Board structure and composition, establishment and delineation of responsibilities to various Committees, effectiveness of Board processes, information and functioning.

Evaluation of the Committees performance was based on the criteria like composition, its terms of the reference and effectiveness of committee meetings, etc., Individual Director's performance evaluation is based on their preparedness on the issues to be discussed, meaningful and constructive discussions and their contribution to the Board and Committee meetings. The Chairperson was evaluated mainly on key aspects of his role. These performance exercises were conducted seeking inputs from all the Directors / Committee Members wherever applicable.

Jeevan Scientific Technology Limited

The evaluation procedure followed by the company is as mentioned below:

- i) Feedback is sought from each Director about their views on the performance of the Board, covering various criteria such as degree of fulfilment of key responsibilities, Board structure and composition, establishment and delineation of responsibilities to various Committees, effectiveness of Board processes, information and functioning, Board culture and dynamics, quality of relationship between the Board and the Management and efficacy of communication with external stakeholders. Feedback was also taken from every Director on his assessment of the performance of each of the other Directors.
- ii) The Nomination and Remuneration Committee (NRC) then discusses the above feedback received from all the Directors.
- iii) Based on the inputs received, the Chairman of the NRC also makes a presentation to the Independent Directors at their meeting, summarising the inputs received from the Directors as regards Board performance as a whole and of the Chairman. The performance of the Non-Independent Non-Executive Directors and Board Chairman is also reviewed by them.
- iv) Post the meeting of the Independent Directors, their collective feedback on the performance of the Board (as a whole) is discussed by the Chairman of the NRC with the Chairman of the Board. It is also presented to the Board and a plan for improvement is agreed upon and is pursued.
- v) Every statutorily mandated Committee of the Board conducts a self-assessment of its performance and these assessments are presented to the Board for consideration. Areas on which the Committees of the Board are assessed include degree of fulfilment of key responsibilities, adequacy of Committee composition and effectiveness of meetings.
- vi) Feedback is provided to the Directors, as appropriate. Significant highlights, learning and action points arising out of the evaluation are presented to the Board and action plans are drawn up. During the year under report, the recommendations made in the previous year were satisfactorily implemented.

The peer rating on certain parameters, positive attributes and improvement areas for each Board member are also provided to them in a confidential manner. The feedback obtained from the interventions is discussed in detail and, where required, independent and collective action points for improvement are put in place.

LISTING WITH STOCK EXCHANGES:

The Company confirms that it has paid the Annual Listing Fees for the year 2017-2018 to Bombay Stock Exchange where the Company's Shares are listed.

MANAGEMENT DISCUSSION AND ANALYSIS:

Management discussion and analysis report for the year under review as stipulated under Regulation 4(3) read with schedule V , Part B of SEBI(Listing Obligations and Disclosure Requirements), Regulations 2015 with the stock exchange in India is presented in a separate section forming part of the annual report.

INDUSTRY BASED DISCLOSURES AS MANDATED BY THE RESPECTIVE LAWS GOVERNING THE COMPANY

The Company is not a NBFC, Housing Companies etc., and hence Industry based disclosures

Twentieth Annual Report 2017-2018

is not required.

SECRETARIAL STANDARDS

The company is in compliance with Secretarial Standards issued by The Institute of Company Secretaries of India on Meetings of the Board of Directors and General Meetings.

EVENT BASED DISCLOSURES

During the year under review, the Company has not taken up any of the following activities:

1. **Issue of sweat equity share:** The Company has not issued any sweat equity shares during the year under review and hence no information as per provisions of Section 54(1)(d) of the Act read with Rule 8(13) of the Companies (Share Capital and Debenture) Rules, 2014.
2. **Issue of shares with differential rights:** The Company has not issued any shares with differential rights and hence no information as per provisions of Section 43(a)(ii) of the Act read with Rule 4(4) of the Companies (Share Capital and Debenture) Rules, 2014.
3. **Issue of shares under employee's stock option scheme:** The Company has not issued any equity shares under Employees Stock Option Scheme during the year under review and hence no information as per provisions of Section 62(1)(b) of the Act read with Rule 12(9) of the Companies (Share Capital and Debenture) Rules, 2014
4. **Non- Exercising of voting rights :** During the year under review, there were no instances of non-exercising of voting rights in respect of shares purchased directly by employees under a scheme pursuant to Section 67(3) of the Act read with Rule 16(4) of Companies (Share Capital and Debentures) Rules, 2014.
5. **Disclosure on purchase by company or giving of loans by it for purchase of its shares:** The company did not purchase or give any loans for purchase of its shares.
6. **Buy back shares:** The company did not buy-back any shares during the period under review.
7. **Disclosure about revision:** Since the company did not undergo any revision, this clause is Not Applicable to the company for the period under review.
8. **Preferential Allotment of Shares:**
 - (i) 21,80,000 warrants were converted into 21,80,000 equity shares of Rs. 10/- each at an issue price of Rs. 30.25/- per share on preferential basis on 06.03.2018
 - (ii) 38,42,000 warrants were converted into 38,42,000 equity shares of Rs. 10/- each at an issue price of Rs. 30.25/- per share on preferential basis on 12.06.2018

The proceeds of the preferential issues was spent/ utilized towards intended objects and as mentioned in the explanatory statement of the notice of the AGM dated 30th Day of August, 2016.

EMPLOYEE RELATIONS:

The Directors are pleased to record their sincere appreciation of the contribution by the staff at all levels in the improved performance of the Company.

None of the employees is drawing Rs. 8,50,000/- and above per month or Rs.1,02,00,000/-

Jeevan Scientific Technology Limited

and above in aggregate per annum, the limits prescribed under Section 197(12) of Companies Act 2013 read with Rule 5 of Companies(Appointment & Remuneration Of Managerial Personnel) Rules, 2014.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has in place an Anti Sexual Harassment Policy in line with the requirements of The Sexual Harassment of Women at workplace (Prevention, Prohibition and Redressal) Act, 2013. Internal Complaint Committee (ICC) has been set up to redress complaints received regarding sexual harassment. All employees are covered under this policy.

The following is the summary of sexual harassment complaints received and disposed during the calendar year.

- No. of complaints received: Nil
- No. of complaints disposed off: Nil

The directors further state that during the year under review, there were no cases filed pursuant to the Sexual Harassment of Women at Work Place. (Prevention, Prohibition and Redressal Act, 2013)

ACKNOWLEDGEMENTS:

The Directors wish to place on record their appreciation of the contribution made by the employees at all levels, to the continued growth and prosperity of your Company.

The Directors also wish to place on record their appreciation of business constituents, banks and other financial institutions and shareholders of the Company like SEBI, BSE, NSE, MCX, NSDL, CDSL, The Karur Vysya Bank, Oriental Bank of Commerce, Andhra Bank and State Bank of India etc. for their continued support for the growth of the Company.

For and on behalf of the Board
Jeevan Scientific Technology Limited

Place : Hyderabad
Date : 14.08.2018

Sd/-
K. Krishna Kishore
Vice Chairman &
Managing Director
(DIN : 00876539)

Sd/-
M. Rajendra Prasad
Whole-Time Director
and CEO
(DIN : 02376561)

Twentieth Annual Report 2017-2018

CODE OF CONDUCT

DECLARATION BY DIRECTOR OF AFFIRMATION BY DIRECTORS AND SENIOR MANAGEMENT PERSONNEL OF COMPLIANCE WITH THE CODE OF CONDUCT:

The shareholders

M/s. Jeevan Scientific Technology Limited

Pursuant to Reg. 17(5) read with Reg. 34(3), Schedule V, part D of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 I, K. Krishna Kishore, Managing Director of the Company do hereby declare that the directors and senior management of the Company have exercised their authority and powers and discharged their duties and functions in accordance with the requirements of the code of conduct as prescribed by the company and have adhered to the provisions of the same.

For and on behalf of the Board
Jeevan Scientific Technology Limited

Sd/-

K. Krishna Kishore

Vice Chairman & Managing Director

(DIN : 00876539)

Place : Hyderabad

Date : 14.08.2018

Jeevan Scientific Technology Limited

CERTIFICATE BY THE MANAGING DIRECTOR OF THE COMPANY

To
The Board of Directors
Jeevan Scientific Technology Limited

Dear Sirs,

As required under Regulation 17(8) read with Part B, Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we state that:

1. We have reviewed the financial statements and the cash flow statement for the year ended 31st March 2018 and to the best of our knowledge and belief;
 - a) These statements do not contain any materially untrue statement nor omit any material fact nor contain statements that might be misleading, and
 - b) These statements present a true and fair view of the company's affairs and are in compliance with the existing accounting standards, applicable laws and regulations.
2. There are, to the best of my knowledge and belief, no transactions entered into by the company during the year, which are fraudulent, illegal or violative of the company's code of conduct.
3. We accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the company and I have disclosed to the auditors and the audit committee, deficiencies in the design or the operation of internal controls, if any, of which I was aware and the steps that I have taken or propose to take and rectify the identified deficiencies and,
4. That we have informed the auditors and the audit committee of:
 - a) Significant changes in the internal control during the year;
 - b) Significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and

Instances of significant fraud of which we have become aware and the involvement of any employee having a significant role in the company's internal control system.

For and on behalf of the Board
Jeevan Scientific Technology Limited

Sd/-

K. Krishna Kishore

Vice Chairman & Managing Director
(DIN : 00876539)

Place : Hyderabad
Date : 14.08.2018

MANAGEMENT DISCUSSIONS & ANALYSIS REPORT

This report contains financial review, opportunities, challenge, outlook etc.

i) **FINANCIAL REVIEW:**

Income earned to the extent of **Rs. 2,016.91** lakhs as against Rs. **1,803.05** lakhs of previous year and earned a profit of Rs. **30.54** lakhs as against Rs. **88.60** lakhs compared to last year.

ii) **PERFORMANCE:**

During the year under review your company recorded a turnover of Rs. **1,926.43** Lakhs against Rs. **1,746.06** Lakhs for the previous financial year. The turnover includes the Data Management Services, Information Technology Services and Clinical Research Services. The Business plan is to ensure at least two fold growth in business in the coming year(s) with the stable business. During the Financial Year under report, **Clinical Research Services** division has expanded into offering the complete portfolio of services as explained below:

Jeevan has the advantage of fully integrated scientific expertise team in Clinical research functions. Jeevan started offering a varied range of clinical research services like Bioavailability/Bioequivalence studies and Phase I to Phase IV services to pharmaceutical and biotechnology industries. The technical team at Jeevan has immense experience in handling various projects in diverse therapeutic areas for different regulatory authorities. The leadership team at Jeevan has over 150 years of cumulative experience in this arena, which comprises successful execution of more than 2000 clinical research projects for several pharmaceutical clients across the globe.

a. **Bioanalytical Research:**

Bioanalytical research laboratory is designed with state of the art facility equipped with advanced analytical instrumentation having 2 processing labs and 4 LC-MS/MS labs, which can accommodate up to 12 LC-MS/MS. Jeevan Scientific offers a unique combination of highly trained workforce enabled with well-equipped bioanalytical research and development (R&D) laboratory. Your bioanalytical laboratory located at Hyderabad is performing well and faced several successful regulatory and client audits.

b. **Clinical Operations:**

Being BA/BE studies are prime focused JSTL offering services, JSTL built a facility for executing the clinical phase of the BA/BE studies. In this regard, Jeevan established its clinical pharmacology centre in Hyderabad at B-17, TIE, Phase II, Balanagar, , Hyderabad, Telangana – 500037. This facility is spread over 20,000 sft and distributed in the 2nd, 3rd and 4th floors of the building. This facility accommodate a total of 132 beds distributed in to 4 clinical pharmacology units with bed capacity of 42(Clinic 1), 24(Clinic 2), 42(Clinic 3) and 24(Clinic 4). This facility also consists of special care areas (3+3 beds), emergency lift, tie-up with tertiary care hospital and a dedicated ambulance to handle emergencies. This facility is capable of carrying out approximately 200 studies per year at a peak capacity. Experienced, trained medical and paramedical staff conducts all these studies at this facility as per GCP and applicable regulations.

Jeevan Scientific Technology Limited

The facility is in compliance with all the statutory requirements and also the applicable regulatory requirements like Drug Control General of India (DCGI). This facility being used to carry out the BA/BE studies for pharmaceutical companies who are developing molecules for global market.

c. Clinical Trials and Trial Management:

Jeevan's Clinical operation team has a vast experience in executing clinical projects of different therapeutic areas across the globe. Jeevan has rich pool of clinical investigators experienced in handling various phases of clinical projects including Pharmacokinetic and Pharmacodynamic studies. The Project management team oversee the technical and administrative aspects of the study. The team is committed to ensure timely update of project status, and meeting the client requirements in agreed timelines.

d. Regulatory Services:

Jeevan's Scientific Medical Writing team is structured with a team of competent writers, with diverse portfolios. The team is currently supporting major pharma clients across the globe, to achieve their objectives in Regulatory & technical documents writing. Jeevan provide expert services for the management of concerns with regulatory authorities and fulfill client expectations in a realistic and transparent manner.

e. Clinical Data Management and Statistical Analysis Services:

The Data Management team has hands on experience in handling clinical data, and the team ensures efficient and reliable management of the data in compliance with industry standards and regulatory requirements.

f. Pharmacovigilance Services:

Jeevan scientific offers a wide range of comprehensive pharmacovigilance and safety monitoring services. Jeevan's aim at a rapid pace growth, and retains an experienced vigilance team, thus being able to provide a wide range Pharmacovigilance services for different regulatory bodies. Currently your company is woring with a about eight clients in this area.

A. AN IMPORTANT MILESTONE:

USFDA conducted an un-announced audit of our clinical pharmacology centre. The purpose of this audit was to review the BA/BE studies. The auditors audited our facilities for 4 days. We are pleased to inform you that the auditors were satisfied with our procedures and processes which resulted with only one study specific 483 Observation. We submitted response to the same and strengthened the procedures and process in order to comply with the regulatory requirements,

B. OPPORTUNITIES:

Your Company could visualize increasing opportunities in exploring new avenues in Clinical Research Services. The marketing efforts of the company received an encouraging response. Today there is an ample business for Clinical Research Services in India and abroad. The quality based infrastructure and manpower are not easily available in the market. Due to these strengths with Jeevan we are able to see lot of opportunities coming to Jeevan. Further your company successfully completed stringent regulatory inspections like USFDA and we are expecting to have more and more opportunities in the area of

clinical research services.

C. CHALLENGES:

Your Company faces normal market competition in all its business from domestic and overseas companies. However, our business strategies and global competitive cost position have enabling us to retain the market position and maintain operating margin and enhance long term, even under difficult operating conditions for the IT industry, Pharmaceutical Sector is going to play a vital role in c=increasing the revenues of the organization. We endeavor to enhance its competitive advantage through a process of continuous improvements and by implementing appropriate business strategies.

D. Advantages of CROs in India

None of the following advents of India changed drastically to have a competetive edge over other organizations located outside India and India is considered as the hub for the clinical trial industry and where in we provide the Clinical Research Services.

- India offers a set of advantages that are so unique and strong vis-a-vis other regions of the world that no major drug research company can afford to ignore India in the medium to long term.
- Ability to conduct a trial faster than most of the major locations in the world in most of the significant therapeutic segments. In this industry, time is money in true sense. In a study by Ernst & Young, it was concluded that in most cases there is a 20%-30% time advantage of carrying out a Phase III study in India compared to undertaking it in North America or in Western Europe.
- India has a huge pool of subjects/ patients (many of them are treatment- naïve) with wide spectrum of diseases that is willing to participate in clinical studies. The past experience has shown that in most of the multi country trials, patient enrolment is rapid in India, thereby speeding up the drug development process. The 20-year clock on drug patent starts ticking when a new compound is discovered, not when it is approved. An early completion of drug testing results in the reduction in cost incurred on its development and provides more time for selling it as a monopoly product enabling better recovery of costs incurred as well as earning good profits. Diseases like multi drug resistant pneumonia, hepatitis B, diabetes, cardiovascular diseases and some cancers are more prevalent in India than in the West. Also, testing a drug on different ethnic groups can determine how drugs work differently in various racial groups and among other things, whether different dosages are required in different ethnic populations.
- English is the main language of communications in the hospitals in all major cities.
- Carrying out a study in India in strict accordance with global guidelines results in cost saving of between 25-40% when compared to the regions mentioned above.
- India has a talented pool of Clinical Research Professionals (highly trained medical professionals) and infrastructure, which includes all super specialties of Medicine.
- Importing clinical supplies has become easier. An import license is granted with the clinical trial permission.
- Apart from cost advantage, the more promising and long-standing advantage is the speed of recruitment/completion of trial that enables the drug developer to have longer time in the market before expiry of the patent to fetch the obvious benefits.

Jeevan Scientific Technology Limited

- IT enabled infrastructure at a lower cost.
- In the recent past, the efficient regulatory system in the country, enabling to attract more business from abroad in the area of clinical research.

E. OUTLOOK:

The outlook for margins in current scenario will depend upon global demand and supply trends in the pharmaceutical industry. We intend to extend our client base and explore the new avenues and opportunities by entering in to tie-up arrangements with more national and International pharmaceutical companies.

F. ADEQUACY OF INTERNAL CONTROL:

Your company has internal auditors to ensure that internal control systems are in place and all assets are safeguarded and protected against loss. An extensive program of Internal Audit and reviews supplement the internal control systems by management & documented policy guidelines and procedures. The internal control systems are designed to ensure that the financial records are available for preparing financial statements and other data and maintaining accountability of assets.

G. QUALITY:

The QA team is focused on continual improvement of Quality Management System and reports directly to management. QA auditors are armed with knowledge on national, international regulations and guidelines. The QA team audits quality systems and studies, carried out by Jeevan, in accordance with set procedures and applicable regulatory guidelines, to ensure fulfillment of quality requirements. Our Motto is to ensure total Customer Satisfaction. Proactive efforts are directed towards determining customers' requirements and achieving all round customer satisfaction. This is primarily achieved through automated systems, high attention to complaint resolution online communication and information exchange, quality circles and adoption of programs.

H. HUMAN RESOURCES DEVELOPMENT (HRD):

Yours is a young Company, with human resources of an average age of 30 years for its employees as on March 31, 2018. Right from the beginning the company got good HR policies for retaining manpower. Your company employs a total of 200 people with high good qualifications and high technical background and experienced in the area of work where they are in.

I. LEARNING & TRAINING:

Training programs have been devised to develop cross-functional skills and is a continuous process across functions and throughout the organization.

ENHOPS:

Enhops Solutions Pvt. Ltd. in India and ENHOPS, Inc., USA are fully owned subsidiary companies of Jeevan Scientific Technology Limited, Hyderabad.

Enhops is an independent testing services organization, which provides services in the areas of Test Assessment, Test Center of Excellence, Process Establishment, Functional and Non-functional testing. Enhops has a dedicated team working on tools and accelerators to speed up testing and extending the benefits to its customers

Test Advisory Services: Today's digital business world demands high-quality products and

Twentieth Annual Report 2017-2018

services. Organizations should invest in innovation and quality assurance for their software and applications to stay ahead of their competition. They need a reliable software-testing partner who can assess their testing requirements, refine QA practice and advise on a QA roadmap in line with their business needs.

Test Automation: Ever-changing market demands make it challenging for enterprises to deliver high quality software at high speed. Enterprises are increasingly adopting alternate software development approaches such as Agile and DevOps to deliver effective software and applications. Traditional software testing approaches, including manual testing, are not enough to rapidly deliver software with impeccable quality. Hence, test automation has gained lot of prominence in the recent times. Also, agile-driven software development and test practices have made test automation as an integral component of continuous integration and testing for continuous delivery.

Performance Testing: Today's hyper-connected world across mobile phones, smart devices, diverse media channels, and business applications demand enterprises to offer seamless end user experience so as to achieve competitive advantage. Enterprises need their applications and websites to be up and running 24/7 to facilitate enormous number of real-time transactions. The slightest application downtime can put the reputation of an enterprise at stake and cause substantial revenue loss. Hence, testing of such business-critical applications/software requires a different perception entirely by putting customer experience at the centre.

Security Testing: Data security is becoming extremely critical with more and more technological innovations happening in the industry. Security breach can happen at network level, system software level, client-side or server-side. Enhops Security Testing Services helps our customer to develop and secure their web or mobile applications as well as meet applicable regulatory and compliance requirements.

Mobile testing: Usage of mobile devices and applications has seen tremendous growth in the recent past. They are considerably enabling businesses and customers to interact in a whole new format. This exponential growth in the mobile market is bringing in new testing challenges with variant platforms, OS versions, screen sizes and networks. Enhops offers the following Mobile testing services:

Test Centre of Excellence: Some of the common testing challenges we see in an organization are – ambiguous requirements, aggressive schedules, limited budgets for testing, complex environments, high operations costs and so on. Test Centre of Excellence (TCoE) is a centralized testing function established to address these challenges effectively and meet testing needs of all business units successfully.

DevOps: Industry recognizes the need for continuous integration and deployment. Without bringing testing into the mainstream development lifecycle, DevOps is incomplete, leading to quality issues.

Organizations are looking to adopt DevOps to reduce Build to Deploy time. DevOps framework integrates development and operations with focus on continuous integration and testing to cut down the cycle time. The framework encompasses testing at various levels such as ambiguity reviews of individual user stories, testing at individual sprint level and complete end-to-end testing at the release level.

Jeevan Scientific Technology Limited

Enhops DevOps framework focuses on minimizing challenges in–

- Integration between development and operations
- Introducing change
- Continuous monitoring in production
- Automating tests for agility and scalability
- Quality deployments through minimal human intervention
- Parallel user tests

Functional Manual Testing: Early testing brings lot of benefits in terms of quality, time and cost. Static and dynamic testing goes hand in hand to make this happen. Involving testing teams in requirement workshops helps in understanding the expectations and build required tests soon.

Process Framework Establishment: Enhops brings its vast experience and expertise to establish a robust test methodology that will offer benefits through unified test governance, standardization and reusability. Our proprietary Global Delivery Methodology is used as basis to establish process framework at our client locations. handled as change requests and are addressed based on the priority assigned.

Our Differentiators:

CORE: CORE is a homegrown methodology to establish and maintain Test Center of Excellence (TCoE).

QuesT: QuesT is an online questionnaire management tool, which is used for Test Advisory Services.

EstiMate: EstiMate tool uses the industry standard PERT three-point estimation and test point analysis technique to understand the complexity and estimate effort.

KnoRA: Enhops KnoRA tool helps in managing requirements ambiguity analysis and reporting ambiguous requirements.

OptiTest: OptiTest is Enhops' proprietary tool that supports test data generation for Orthogonal array testing.

QGuage: QGuage is Enhops' dashboard management tool that helps in generating customized metric reports and dashboards as per the requirement.

PrediQT: PrediQT is Enhops' statistical prediction model that helps in predicting defects based on historical data.

CalRol: Enhops Automation ROI analyzer is an effective and simple way to understand the benefits derived automation at defines intervals.

Global Delivery Methodology:

Enhops global delivery methodology is common across all functional and non-functional testing types. It uses a proven approach that integrates industry standards, innovation and our experience and expertise to deliver consistent, efficient and high quality services to our customer. The methodology has a set of repeatable processes and techniques for analyzing business situation and developing an optimal solution.

REPORT ON CORPORATE GOVERNANCE

In accordance with Regulation 34 (3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the report containing the details of Corporate Governance systems and processes at Jeevan Scientific Technology Limited as follows:

COMPANY'S PHILOSOPHY ON CORPORATE GOVERNANCE:

The Company is in full compliance with the requirements of Regulation 34 (3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

BOARD DIVERSITY:

The Company recognizes and embraces the importance of a diverse board in its success. We believe that a truly diverse board will leverage differences in thought, perspective, knowledge, skill, regional and industry experience, cultural and geographical background, age, ethnicity, race and gender, which will help us, retain our competitive advantage. The Board has adopted the Board Diversity Policy which sets out the approach to diversity of the Board of Directors. The Board Diversity Policy is available on our website, www.jeevanscientific.com

FAMILIARIZATION PROGRAM FOR INDEPENDENT DIRECTORS:

All new independent directors inducted into the Board attend an orientation program. The details of training and familiarization program are provided in the corporate governance report. Further, at the time of the appointment of an independent director, the Company issues a formal letter of appointment outlining his / her role, function, duties and responsibilities.

COMPANY'S CODE OF CONDUCT FOR THE PREVENTION OF INSIDER TRADING:

The Board of Directors has adopted the Insider Trading Laws in accordance with the requirements of the SEBI (Prohibition of Insider Trading) Regulation, 2015. The Insider Trading Laws of the Company lays down guidelines and procedures to be followed, and disclosures to be made while dealing with shares of the Company. The policy has been formulated to regulate, monitor and ensure reporting of deals by employees and to maintain the highest ethical standards of dealing in Company securities.

The Insider Trading Laws of the Company covering code of practices and procedures for fair disclosure of unpublished price sensitive information and code of conduct for the prevention of insider trading, is available on our website www.jeevanscientific.com

Jeevan Scientific Technology Limited

The Composition of the Board, attendance at board meetings (BM) held during the financial year under review and at the last Annual General Meeting (AGM), number of Directorships and memberships / chairmanships in public companies (including the Company) are given below.

S.No.	Name of the Director	Category	Attendance at Board Meeting	Whether Attended AGM Held on 27-09-2017	No. of Director Ships in Other Public Companies	No. of Other Board Committees in which he is Member	No. of Other Board Committees in which he is a Chairman
1.	Mr. A. Vijay Kumar*	Non-Executive Independent Director	4	No	-nil-	1	1
2.	Mr. K. Krishna Kishore, Vice Chairman & Managing Director	Executive Promoter	7	Yes	-nil-	1	-nil-
3.	Ms. K. Vanaja	Non-Executive Promoter	6	Yes	-nil-	-nil-	-nil-
4.	Mr. T. Ravi Babu	Non-Executive Independent Director	2	No	-nil-	-nil-	-nil-
5.	Mr. G. Bhanu Prakash	Non-Executive Independent Director	2	No	-nil-	-nil-	-nil-
6.	Mr. M. Rajendra Prasad, Executive Director	Executive Director & CEO	5	Yes	-nil-	-nil-	-nil-
7.	Mr. K. Rama Krishna Prasad	Non-Executive Independent Director	4	Yes	-nil-	-nil-	-nil-
8 .	Mr. SSR Koteswara Rao, Chairman	Non-Executive Independent Director	6	Yes	2	-nil-	-nil-
9.	Mr. Raghav Beeram**	Non-Executive Director	1	No	-nil-	-nil-	-nil-

* Resigned w.e.f 01.04.2018

** Resigned w.e.f. 11.10.2017

Alternate Directorships, Directorships in Private Bodies and Membership in governing councils, chambers and other bodies were not considered.

As seen from the above, the Non-Executive Directors constitute more than half of the total number of Directors. The Company has a Non-Executive Chairman and one third of the total strength of the Board comprises of Independent Directors. Managing Director is overseeing the day-to-day operations of the Company.

Twentieth Annual Report 2017-2018

DISCLOSURE OF RELATIONSHIPS BETWEEN DIRECTORS INTER-SE

Mr. K. Krishna Kishore and Mrs. K. Vanaja are inter-se related as Husband and Wife.

NUMBER OF SHARES AND CONVERTIBLE INSTRUMENTS HELD BY NON-EXECUTIVE DIRECTORS:

None of the non-Executive Directors of the company except as mentioned below hold any shares and Convertible Instruments in their name.

- i. Thammareddy Ravi (2500 equity shares)
- ii. Bhanu prakash Gali (3000 equity shares)
- iii. K Vanaja (12,57,800 equity shares)
- iv. K R K Prasad (3,00,000 equity shares)

COMPOSITION OF AUDIT COMMITTEE:

- I. The Audit Committee of the Company is constituted in line with the provisions of Regulation 18 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Section 177 of the Companies Act, 2013.
- II. The terms of reference of the Audit Committee include a review of the following:
 1. Overview of the Company's financial reporting process and disclosure of its financial information to ensure that the financial statements reflect a true and fair position and that sufficient and credible information is disclosed.
 2. Recommending the appointment and removal of external auditors, fixation of audit fee and also approval for payment for any other services.
 3. Discussion with external auditors before the audit commences, of the nature and scope of audit as well as post-audit discussion to ascertain any area of concern.
 4. Reviewing the financial statements and draft audit report including quarterly / half yearly financial information.
 5. Reviewing with management the annual financial statements before submission to the Board, focusing on:
 - a) Any changes in accounting policies and practices;
 - b) Qualification in draft audit report;
 - c) Significant adjustments arising out of audit;
 - d) The going concern concept;
 - e) Compliance with accounting standards;
 - f) Compliance with stock exchange and legal requirements concerning financial statements;
 - g) Any related party transactions
 - h) Reviewing the company's financial and risk management's policies.
 - i) Disclosure of contingent liabilities.
 - j) Reviewing with management, external and internal auditors, the adequacy of internal control systems.
 - k) Reviewing the adequacy of internal audit function, including the audit character, the structure of the internal audit department, approval of the audit plan and its

Jeevan Scientific Technology Limited

execution, staffing and seniority of the official heading the department, reporting structure, coverage and frequency of internal audit.

- l) Discussion with internal auditors of any significant findings and follow-up thereon.
- m) Reviewing the findings of any internal investigations by the internal auditors into the matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board.
- n) Looking into the reasons for substantial defaults in payments to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors.
- o) Reviewing compliances as regards the Company's Whistle Blower Policy.

III. The previous Annual General Meeting of the Company was held on 27-Sep-2017 and Chairman of the Audit Committee attended previous AGM.

IV. The composition of the Audit Committee and the attendance of each member of the Audit Committee are given below:

The Company has complied with all the requirements of Regulation 18 of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 relating to the composition of the Audit Committee. During the financial year 2017-2018, (4) four meetings of the Audit Committee were held on the 30.05.2017, 14.08.2017, 14.12.2017 and 12.02.2018.

The details of the composition of the Committee and attendance of the members at the meetings are given below:

Name	Designation	Category	No of Meetings held	No of Meetings attended
Mr. A. Vijay Kumar	Chairman	NED(I)	4	3
Mr. K. Krishna Kishore	Member	ED	4	4
Mr. S.S.R Koteswara Rao	Member	NED(I)	4	4
Mr. K. Rama Krishna Prasad	Member	NED(I)	4	1

NED (I) : Non Executive Independent Director

ED : Executive Director

V. NOMINATION & REMUNERATION COMMITTEE

The details of composition of the Committee are given below:

Name	Designation	Category	No of Meetings held	No of Meetings attended
Mr. A. Vijay Kumar	Chairman	NED(I)	1	1
Mr. Kuchipudi Krishna Kishore	Member	ED	1	1
Mrs. K. Vanaja	Member	NED	1	1
Mr. S.S.R Koteswara Rao	Member	NED(I)	1	1

NED (I) : Non Executive Independent Director

NED : Non Executive Director

ED : Executive Director

Twentieth Annual Report 2017-2018

Terms of reference:

The main term of reference of the Committee is to approve the fixation/revision of remuneration of the Managing Director/Whole Time Director of the Company and while approving:

- To take into account the financial position of the Company, trend in the industry, appointee's qualification, experience, past performance, past remuneration etc.
- To bring out objectivity in determining the remuneration package while striking a balance between the interest of the Company and the Shareholders.

Remuneration Policy:

The objectives of the remuneration policy are to motivate Directors to excel in their performance, recognize their contribution and retain talent in the organization and reward merit.

The remuneration levels are governed by industry pattern, qualifications and experience of the Directors, responsibilities shouldered, individual performance etc.

The details of remuneration paid to the Executive and Non Executive Directors per annum for the financial year 2017-2018 are given below:

Amount in Rs.(p.a)

Name of the Director	Remuneration/Sitting Fees
Mr. K. Krishna Kishore	36,00,000 (Remuneration)
Mr. M. Rajendra Prasad	30,99,996 (Remuneration)
Mr. Raghav Beeram*	10,000 (sitting fees)
Mrs. K. Vanaja	60,000 (Sitting fees)
Mr. A. Vijay Kumar**	70,000 (Sitting fees)
Mr. SSR Koteswara Rao	1,00,000 (Sitting fees)
Mr. T. Ravi Babu	20,000 (Sitting fees)
Mr. G. Bhanu Prakash	20,000 (Sitting fees)
Mr. K. Rama Krishna Prasad	50,000(Sitting fees)

* Resigned w.e.f 11-Oct-2017

** Resigned w.e.f 01-Apr-2018

None of the Directors is drawing any Commission, Perquisites, Retirement benefits etc.

PERFORMANCE EVALUATION CRITERIA FOR INDEPENDENT DIRECTORS:

The Performance evaluation criteria for Independent Directors is already mentioned under the head 'Board Evaluation' in Directors' Report.

POLICY FOR SELECTION OF DIRECTORS AND DETERMINING DIRECTORS' INDEPENDENCE

1. Scope:

This policy sets out the guiding principles for the Nomination & Remuneration Committee for identifying persons who are qualified to become Directors and to determine the independence of Directors, in case of their appointment as independent Directors of the Company.

Jeevan Scientific Technology Limited

2. Terms and References:

2.1 “**Director**” means a director appointed to the Board of a Company.

2.2 “**Nomination and Remuneration Committee**” means the committee constituted in accordance with the provisions of Section 178 of the Companies Act, 2013 and Reg. 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2.3 “**Independent Director**” means a director referred to in sub-section (6) of Section 149 of the Companies Act, 2013 and Regulation 16(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3. Policy:

Qualifications and criteria

3.1.1 The Nomination and Remuneration Committee, and the Board, shall review on annual basis, appropriate skills, knowledge and experience required of the Board as a whole and its individual members. The objective is to have a board with diverse background and experience that are relevant for the Company’s operations.

3.1.2 In evaluating the suitability of individual Board member the NR Committee may take into account factors, such as:

- General understanding of the company’s business dynamics, global business and social perspective;
- Educational and professional background
- Standing in the profession;
- Personal and professional ethics, integrity and values;
- Willingness to devote sufficient time and energy in carrying out their duties and responsibilities effectively.

3.1.3 The proposed appointee shall also fulfil the following requirements:

- shall possess a Director Identification Number;
- shall not be disqualified under the companies Act, 2013;
- shall Endeavour to attend all Board Meeting and Wherever he is appointed as a Committee Member, the Committee Meeting;
- shall abide by the code of Conduct established by the company for Directors and senior Management personnel;
- shall disclose his concern or interest in any company or companies or bodies corporate, firms, or other association of individuals including his shareholding at the first meeting of the Board in every financial year and thereafter whenever there is a change in the disclosures already made;
- Such other requirements as any be prescribed, from time to time, under the companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other relevant laws.

3.1.4 The Nomination & Remuneration Committee shall evaluate each individual with the objective of having a group that best enables the success of the company’s business.

3.2 **Criteria of Independence**

3.2.1 The Nomination & Remuneration Committee shall assess the independence of Directors at the time of appointment/ re-appointment and the Board shall assess the same annually. The Board shall re-assess determinations of independence when any new interest or relationships are disclosed by a Director.

3.2.2 The criteria of independence, as laid down in companies Act, 2013 and Regulation 16(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is as below:

An independent director in relation to a company, means a director other than a managing director or a whole-time director or a nominee director-

- a. Who, in the opinion of the Board, is a person of integrity and possesses relevant expertise and experience;
 - b. (i) who is or was not a promoters of the company or its holding, subsidiary or associate company;
 - (ii) Who is not related to promoters or directors of the company its holding, subsidiary or associate company
 - c. Who has or had no pecuniary relationship with the company, its holding, subsidiary or associate company, or their promoters, or director, during the two immediately preceding financial year or during the current financial year;
 - d. None of whose relative has or had pecuniary relationship or transaction with the company, its holding, subsidiary or associate company, or their promoters, or directors, amounting to two per cent or more of its gross turnover or total income or fifty lakh rupees or such higher amount as may be prescribed, whichever is lower, during the two immediately preceding financial year or during the current finance year;
 - e. Who, neither himself nor any of his relative-
 - (i) Holds or has held the position of a key managerial personnel or is or has been employee of the or associate company in any of the three finance years immediately preceding the finance year in which he is proposed to be appointed;
 - (ii) Is or has been an employee or proprietor or a partner, in any of the three finance year immediately preceding the finance year in which he is proposed to be appointed of-
- (A) a firm of auditors or company secretaries in practice or cost auditors of the company or its holding, subsidiary or associate company; or
- (B) any legal or a consulting firm that has or had any transaction with the company, its holding subsidiary or associate company amounting to ten per cent or more of the gross turnover of more of the gross turnover of such firm;
- (iii) holds together with his relatives two per cent or more of the total voting power of the company; or
 - (iv) is a chief Executive or director, by whatever name called, of any non-profit organization that receives twenty-five per cent or more of its receipt from the company any of its promoters , directors or its holding subsidiary or associate

Jeevan Scientific Technology Limited

company or that holds two per cent or more of the total voting power of the company; or

- (v) is a material supplier, service provider or customer or a lessor or lessee of the company.
- f. Shall possess appropriate skills experience and knowledge in one or more field of finance , law management, sales, marketing administration, research, corporate governance, technical operations, corporate social responsibility or this disciplines related to the company's business.
- g. Shall possess such other qualifications as may be prescribed from time to time, under the companies Act, 2013.
- h. Who is not less than 21 years of age

3.2.3 The independent Director shall abide by the "code for independent Directors "as specified in Schedule IV to the companies A ct, 2013.

3.3 other directorships/ committee memberships

3.3.1 The Board members are expected to have adequate time and expertise and experience to contribute to effective Board performance Accordingly, members should voluntarily limit their directorships in other listed public limited companies in such a way that it does not interfere with their role as director of the company. The NR Committee shall take into account the nature of, and the time involved in a director service on other Boards, in evaluating the suitability of the individual Director and making its recommendations to the Board.

3.3.2 A Director shall not serve as director in more than 20 companies of which not more than 10 shall be public limited companies.

3.3.3 A Director shall not serve an independent Director in more than 7 listed companies and not more than 3 listed companies in case he is serving as a whole-time Director in any listed company.

3.3.4 A Director shall not be a member in more than 10 committee or act chairman of more than 5 committee across all companies in which he holds directorships.

For the purpose of considering the limit of the committee, Audit committee and stakeholder's relationship committee of all public limited companies, whether listed or not, shall be included and all other companies including private limited companies, foreign companies and companies under section 8 of the companies Act, 2013 shall be excluded.

Remuneration policy for Directors, key managerial personnel and other employees:

1. Scope:

1.1 This policy sets out the guiding principles for the Nomination and Remuneration committee for recommending to the Board the remuneration of the directors, key managerial personnel and other employees of the company.

2. Terms and Reference:

In this policy the following terms shall have the following meanings:

Twentieth Annual Report 2017-2018

- 2.1 **“Director”** means directors appointed to the Board of the company.
- 2.2 **“Key Managerial Personnel”** means
- (i) The Chief Executive Officer or the managing director or the manager;
 - (ii) The company secretary;
 - (iii) The whole-time director;
 - (iv) The chief finance Officer; and
 - (v) Such other office as may be prescribed under the companies Act, 2013
- 2.3 **“Nomination and Remuneration committee”** means the committee constituted by Board in accordance with the provisions of section 178 of the companies Act, 2013 and Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3. Policy:

- 3.1 Remuneration to Executive Director and key managerial personnel
- 3.1.1 The Board on the recommendation of the Nomination and Remuneration (NR) committee shall review and approve the remuneration payable to the Executive Director of the company within the overall approved by the shareholders.
- 3.1.2 The Board on the recommendation of the NR committee shall also review and approve the remuneration payable to the key managerial personnel of the company.
- 3.1.3 The remuneration structure to the Executive Director and key managerial personnel shall include the following components:
- (i) Basic pay
 - (ii) Perquisites and Allowances
 - (iii) Stock Options
 - (iv) Commission (Applicable in case of Executive Directors)
 - (v) Retrial benefits
 - (vi) Annual performance Bonus
- 3.1.4 The Annual plan and Objectives for Executive committee) shall be reviewed by the NR committee and Annual performance Bonus will be approved by the committee based on the achievement against the Annual plan and Objectives.
- 3.2 **Remuneration to Non – Executive Directors**
- 3.2.1 The Board, on the recommendation of the NR Committee, shall review and approve the remuneration payable to the Non – Executive Directors of the Company within the overall limits approved by the shareholders.
- 3.2.2 Non – Executive Directors shall be entitled to sitting fees attending the meetings of the Board and the Committees thereof. The Non- Executive Directors shall also be entitled to profit related commission in addition to the sitting fees.
- 3.3. **Remuneration to other employees**
- 3.3.1. Employees shall be assigned grades according to their qualifications and work experience, competencies as well as their roles and responsibilities in the organization. Individual remuneration shall be determined within the appropriate grade and shall be based on various factors such as job profile skill sets, seniority, experience and prevailing remuneration levels for equivalent jobs.

Jeevan Scientific Technology Limited

VI. STAKEHOLDERS RELATIONSHIP COMMITTEE

A.) Composition:

The Details of composition of the Committee are given below:

Name	Designation	Category
Mr. A. Vijay Kumar	Chairperson	NED(I)
Mr. K. Krishna Kishore	Member	ED
Mr. SSR Koteswara Rao	Member	NED(I)

NED (I) : Non Executive Independent Director

ED : Executive Director

B) Powers:

The Committee has been delegated with the following powers:

- To redress shareholder and investor complaints relating to transfer of shares, Dematerialization of Shares, non-receipt of Annual Reports, non-receipt of declared dividend and other allied complaints.
- To approve, transfer, transmission, and issue of duplicate / fresh share certificate(s)
- Consolidate and sub-division of share certificates etc.
- To redress, approve and dispose off any, other complaints, transactions and requests etc., received from any shareholder of the company and investor in general.

The Board has delegated the power to process the transfer and transmission of shares to the Registrar and Share Transfer Agents, who process share transfers within a week of lodgement in the case of shares held in physical form.

The Company has designated an exclusive e-mail ID called shareholders@jeevanscientific.com

C.) NAME AND DESIGNATION OF COMPLIANCE OFFICER

Ms. G. Krishna Sowjanya , Company Secretary of the company, is the compliance officer of the Company.

D.) DETAILS OF COMPLAINTS/REQUESTS RECEIVED, RESOLVED AND PENDING DURING THE YEAR 2017-18

INVESTOR COMPLAINTS

Particulars	Year ended 31-Mar-2018
Pending at the beginning of the year	—
Received during the year	—
Disposed of during the year	—
Remaining unresolved at the end of the year	—

Twentieth Annual Report 2017-2018

VII. RISK MANAGEMENT COMMITTEE

A.) Composition:

The Details of composition of the Committee are given below:

Name	Designation	Category
Mr. K.Rama Krishna Prasad	Chairperson	NED(I)
Mr. A. Vijay Kumar	Member	NED(I)
Mr. K. Krishna Kishore	Member	ED
Mr. SSR Koteswara Rao	Member	NED(I)

NED (I) : Non Executive Independent Director

ED : Executive Director

Role and Responsibilities of the Committee includes the following:

- Framing of Risk Management Plan and Policy
- Overseeing implementation of Risk Management Plan and Policy
- Monitoring of Risk Management Plan and Policy
- Validating the process of risk management
- Validating the procedure for Risk minimisation.
- Periodically reviewing and evaluating the Risk Management Policy and practices with respect to risk assessment and risk management processes.
- Continually obtaining reasonable assurance from management that all known and emerging risks have been identified and mitigated or managed.

Annual General Body Meetings:

Location and time of last three Annual General Meetings are as under:

Year	Location	Date	Time	Spl resolutions.
2017	III Floor, R.R. Towers	27-Sep-2017	09.30 A.M	No
2016	III Floor, R.R. Towers	30-Sep-2016	09.00 A.M	Yes
2015	III Floor, R.R. Towers	30-Sep-2015	09.00 A.M	No

During the year 2015-16 under review following resolutions were put to vote and were passed by Special Resolution :-

1. Alteration of Articles of Association of the Company.
2. Issue of Equity Shares and Convertible Equity Warrants on Preferential Basis to the Promoters and the Others.
3. Jeevan Scientific Technology Limited Employee (JSTL) Stock Option Scheme-2016.
4. Jeevan Employee Stock Option (Jstl) Scheme-2016 to the Employees of Subsidiary Companies.
5. Increase In Authorised Capital of the Company from Rs. 9,99,00,000/- to Rs. 21,00,00,000/-

Jeevan Scientific Technology Limited

During the last year under review no resolution was put to vote and was passed by Postal Ballot.

- A. PECUNIARY RELATIONSHIP OR TRANSACTIONS OF THE NON-EXECUTIVE DIRECTORS VIS-À-VIS THE LISTED COMPANY:** The Non- Executive Directors have no pecuniary relationship or transactions.
- B. CRITERIA FOR MAKING PAYMENTS TO NON-EXECUTIVE DIRECTORS:** As per the remuneration policy of the company.
- C. REMUNERATION TO DIRECTORS PAID DURING THE FINANCIAL YEAR 2017-18 AND OTHER DISCLOSURES**

Name of the Director	Salary (Rs) (p.a)	Sitting fees (Rs)(p.a)	Number of shares held	Service Contracts	Stock Option Details	Fixed Component	Performance Based Incentive
Mr. K. Krishna Kishore	36,00,000	—	19,93,391	-	-	-	-
Mr. M. Rajendra Prasad	30,99,996	—	8,96,250	-	-	-	-
Mr. Raghav Beeram*	—	10,000	1,42,390	-	-	-	-
Mr. SSR Koteswara Rao	—	1,00,000	-	-	—	—	-
Mr. A. Vijay Kumar **	—	70,000	-	-	-	-	-
Ms. K. Vanaja	—	60,000	15,73,800	-	-	-	-
Mr. T. Ravi Babu	—	20,000	2,500	-	-	-	-
Mr. G. Bhanu Prakash	—	20,000	3,000	-	-	-	-
Mr. K. Rama Krishna Prasad	—	50,000	3,00,000	-	-	-	-

* Resigned w.e.f 11-Oct-2017

** Resigned w.e.f 01-Apr-2018

D. INDEPENDENT DIRECTORS' MEETING:

As per clause 7 of the schedule IV of the Companies Act (Code for Independent Directors), a separate meeting of the Independent Directors of the Company (without the attendance of Non-Independent directors) was held on 06-Mar-2018, and discussed the following:

1. Evaluation of the performance of Non Independent Directors and the Board of Directors as whole;
2. Evaluation of the quality, content and timelines of flow of information between the management and the Board that is necessary for the Board to effectively and reasonably perform its duties.

All the Independent Directors of the Company were present at the meeting.

As required under Regulation 34(3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the company regularly familiarizes Independent Directors with the Company, their roles, rights, responsibilities in the company, nature of the industry in which the company operates, business model of the company etc.

Twentieth Annual Report 2017-2018

FORMAL ANNUAL EVALUATION:

As per section 149 of the Companies Act, 2013 read with clause VII (1) of the schedule IV and rules made there under, the independent directors of the company had a meeting on 06th day of March, 2018 without attendance of non-independent directors and members of management. In the meeting the following issues were taken up:

- (a) Review of the performance of non-independent directors and the Board as a whole;
- (b) Review of the performance of the Chairperson of the company, taking into account the views of executive directors and non-executive directors;
- (c) Assessing the quality, quantity and timeliness of flow of information between the company management and the Board that is necessary for the Board to effectively and reasonably perform their duties.

The meeting also reviewed and evaluated the performance of non-independent directors. The company has 5 (Five) non-independent directors namely: i.) Mr. K. Krishna Kishore – Vice chairman & Managing Director ii) Mr. M. Rajendra Prasad - Whole time director & CEO and iii.) Mrs. K. Vanaja – Non Executive Director. The meeting recognized the significant contribution made by non-independent directors in the shaping up of the company and putting the company on accelerated growth path. They devoted more time and attention to bring up the company to the present level.

The meeting also reviewed and evaluated the performance of the Board as whole in terms of the following aspects:

- Preparedness for Board/Committee meetings
- Attendance at the Board/Committee meetings
- Guidance on corporate strategy, risk policy, corporate performance and overseeing acquisitions and disinvestments.
- Monitoring the effectiveness of the company's governance practices
- Ensuring a transparent board nomination process with the diversity of experience, knowledge, perspective in the Board.
- Ensuring the integrity of the company's accounting and financial reporting systems, including the independent audit, and that appropriate systems of control are in place, in particular, systems for financial and operational control and compliance with the law and relevant standards.

It was noted that the Board Meetings have been conducted with the issuance of proper notice and circulation of the agenda of the meeting with the relevant notes thereon.

VIII. OTHER DISCLOSURES

A. MATERIALLY SIGNIFICANT RELATED PARTY TRANSACTIONS

During the year under review, the Company had not entered in to any materially significant transaction with any related party. Remuneration paid to directors is well within the limits of Section 197 read with Schedule V of Companies Act, 2013. During the year, the Company had not entered into any other contract/arrangement/transaction with related parties which could be considered material in accordance with the policy of the company on materiality of related party transactions that may have potential conflict with the interests of the Company at large. All the related party transactions during the year are in the ordinary course of business and on arm's length basis.

Jeevan Scientific Technology Limited

B. COMPLIANCES:

There are no penalties imposed on the Company by the Stock Exchanges or SEBI or any other statutory authority on any matter related to capital markets, during the last three years.

C. WHISTLE BLOWER POLICY

With a view to adopt the highest ethical standards in the course of business, the Company has a whistle blower policy in place for reporting the instances of conduct, which are not in conformity with the policy. Directors, employees, vendors or any person having dealings with the Company may report non-compliance to the Chairman of the Audit Committee, who reviews the report. Confidentiality is maintained of such reporting and it is ensured that the whistle blowers are not subjected to any discrimination. No person was denied access to the Audit Committee.

D. COMPLIANCE WITH THE MANDATORY REQUIREMENTS AND ADOPTION OF THE NON-MANDATORY REQUIREMENTS OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.

All mandatory requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 have been appropriately complied with and the status of non-mandatory requirements is given below:

The Board & Separate posts of Chairman and CEO: The positions of the Chairman and the CEO are separate of the company. All other requirements of the Board during the year have been complied with.

- Shareholders' rights: The quarterly results are uploaded on the website of the Company www.jeevanscientific.com. The soft copy of the quarterly results is also sent to the shareholders who have registered their e-mail addresses.
- Audit qualifications: Company's financial statements are unqualified.
- Reporting of Internal Auditor: The Internal Auditor of the Company directly reports to the Audit Committee on functional matters.
- Modified opinion in Audit Report: The audit report does not contain any qualification.

E. WEBLINK FOR POLICIES ADOPTED BY THE COMPANY :

Different policies adopted by the company are available for reference at http://www.jeevanscientific.com/policies_documents.html

ACCOUNTING STANDARDS AND TREATMENT:

The Accounting Treatment, as prescribed in the Accounting Standards has been followed in the preparation of financial statements.

MEANS OF COMMUNICATION:

The Quarterly, Half-Yearly and Annual Accounts are normally published by the Company in the newspapers in English version circulating in the whole of India in Business Standard and in Newspapers in the language of Region in Andhra Prabha. Official news items are sent to the Bombay Stock Exchange, where shares of the Company are listed.

Twentieth Annual Report 2017-2018

DISCLOSURE OF ACCOUNTING TREATMENT

The Company has complied with the appropriate accounting policies and has ensured that they have been applied consistently. There have been no deviations from the treatment prescribed in the Accounting Standards notified under Section 129 of the Companies Act, 2013.

SHARE HOLDERS INFORMATION:

Annual General Meeting:

Day, Date & Time : 28TH day, September, 2018 9.30 A.M
Venue : III Floor, R.R. Towers, C.A. Lane, Abids, Hyderabad 500001.

FINANCIAL CALENDAR:

Un-Audited results for Quarter ending Jun 30 2018	- on or before 14-Aug-2018
Un-Audited results for Quarter ending Sep 30 2018	- on or before 14-Nov-2018
Un-Audited results for Quarter ending Dec 31 2018	- on or before 14-Feb-2019
Audited results for Quarter & Year ending Mar 31 2019	- on or before 30-May-2019

Book closure Dates: 22-Sep-2018 to 28-Sep-2018 (Both days inclusive)

Listing of Equity Shares	:	Bombay Stock Exchange.
Code	:	538837
ISIN	:	INE237B01018
Address	:	Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001

LISTING ON STOCK EXCHANGES:

The equity shares of the Company are listed on BSE Ltd. The Company has paid the listing fees for the year 2017-18 to BSE limited.

A) ELECTRONIC CONNECTIVITY:

Demat ISIN Number: INE237B01018

B) NATIONAL SECURITIES DEPOSITORY LIMITED

Trade World, Kamala Mills Compound
Senapati Bapat Marg, Lower Parel
Mumbai – 400 013.

C) CENTRAL DEPOSITORY SERVICES (INDIA) LIMITED

PhirozeJeejeebhoy Towers, 28th Floor
Dalal Street, Mumbai – 400 023.

Jeevan Scientific Technology Limited

REGISTRAR AND TRANSFER AGENTS:

Physical & Demat
CIL Securities Ltd
214, R.R. Towers, C.A. Lane
Abids, Hyderabad –500001.
Vide SEBI Regn. No. INR 000002276

LOCATION & ADDRESS FOR CORRESPONDENCE:

Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir,
Near Lanco Hills, Golconda Post, Hyderabad 500008 .

MARKET DATA:

Month	High	Low
April'17	46.65	36.00
May'17	45.45	33.15
June'17	47.00	33.00
July'17	54.00	41.55
Aug'17	47.50	33.55
Sept'17	46.40	35.00
Oct'17	47.00	37.90
Nov'17	56.00	37.00
Dec'17	69.00	41.05
Jan'18	63.00	47.25
Feb'18	53.80	42.25
Mar'18	46.05	38.00

Disclosure:

- a) Materially significant related party transactions of the Company of material nature with its promoters, the directors or the Management their subsidiaries or relatives if that may have potential conflict with the interests of the Company at large:

The transactions with the related parties were mentioned in Notes on Accounts as accounting standard 18 (note no. 24) in the schedules forming part of the balance sheet.

- b) Details of Non Compliance by the Company, penalties imposed on the Company by Stock Exchanges, SEBI or any other statutory authority on any matter related to capital markets during the last three years:

Twentieth Annual Report 2017-2018

The Company has complied with all the requirements of regulatory authorities on capital markets and no penalties have been imposed against it.

SHARE TRANSFER SYSTEM:

Securities lodged for transfer at the Registrar's address are normally processed within 15 days from the date of lodgment, if the documents are clear in all respects. All requests for dematerialization of shares are processed and the confirmation is given to the depositories within 15 days. Senior executives of the Company are empowered to approve transfer of shares. Grievances received from investors and other miscellaneous correspondence on change of address etc., are processed by the Registrars within 30 days. The Company extends the facility of simultaneous transfer and dematerialization of shares to the shareholders.

Pursuant to clause 47(c) of the listing agreement and Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with the Stock Exchanges, certificates on half yearly basis have been issued by a Company secretary in practice for due compliance of share transfer formalities by the Company. Pursuant to SEBI (depositories and participants) regulations, 1966, certificates have also been received from a Company secretary in practice for timely dematerialization of the shares of the Company and for conducting a Secretarial Audit on a quarterly basis for reconciliation of the Share Capital of the Company.

DEMATERIALIZATION & LIQUIDITY:

The paid-up share capital of the Company consists of 1,14,59,465 equity shares of Rs. 10/- each and out of the same physical share holding consists of 27,65,933 (24.14%) equity shares, through National Securities Depository Limited (NSDL) 51,01,313 (44.51%) equity shares and through Central Depository Services (India) Limited (CDSL) 35,92,219 (31.35%) equity shares as on 31st March 2018.

DISTRIBUTION OF SHAREHOLDING-AS ON: 31-Mar-2018.

No. of Shares	Share Holders		No. of Shares	
	Number	%	No's.	% to Total
Upto - 5,000	1952	69.67	4267140	3.72
5,001 - 10,000	335	11.96	2911200	2.54
10,001 - 20,000	178	6.35	2807340	2.45
20,001 - 30,000	99	3.53	2526700	2.20
30,001 - 40,000	39	1.39	1458380	1.27
40,001 - 50,000	51	1.82	2444460	2.13
50,001 - 1,00,000	62	2.21	5100070	4.45
1,00,001 and above	86	3.07	93079360	81.22
TOTAL	2802	100.00	114594650	100.00

Jeevan Scientific Technology Limited

SHAREHOLDING PATTERN AS ON 31ST MARCH,2018:

S. No	Category	No. of shares held	Percentage of shareholding
A Shareholding of Promoter and Promoter group			
1.	Indian		
	Individual	43,32,891	37.81
2.	Foreign		
	Individual	-	-
	Sub-Total A	43,32,891	37.81
B Public Shareholding			
1.	Institutions	-	-
2.	Non Institutions	71,26,574	62.19
	Sub Total B	71,26,574	62.19
	Grand Total (A+B)	1,14,59,465	100.00

Pursuant to first proviso to sub-section (3) of section 129 of Companies Act, 2013, read with rule 5 of Companies (Accounts) Rules, 2014 - AOC-1, the Company is presenting summarised financial information about individual subsidiaries as at March 31, 2018.

Information relating to Subsidiaries as at March 31, 2018.

Sl. No.	Name of the Subsidiary	Reporting Currency	Exchange rate as on 31-Mar-2018	Share Capital	Reserves and Surpluses	Total Assets	Investments	% of holding	Sales and Other Income	Profit before taxation	Provision for Taxation	Profit after taxation	Proposed Dividend
1.	Enhops Solutions Private Limited	INR	—	100 00,000				99. 99%					
2.	Enhops, Inc.(U.S.A)	INR	—	269070				100%	—				

Notes: The following information shall be furnished at the end of the statement:

- Names of subsidiaries which are yet to commence operations- None
- Names of subsidiaries which have been liquidated or sold during the year- None

STATEMENT SHOWING THE NAMES OF TOP TEN EMPLOYEES PURSUANT TO SEC. 197 READ WITH RULE 5 (1) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

Rule 5 (1) Of The Companies (Appointment And Remuneration Of Managerial Personnel) Rules, 2014

- 1 The ratio of remuneration to each director to the median remuneration of the employees of the company for the financial year.

Director	Total Remuneration	Ratio to median remuneration
K. Krishna Kishore	36,00,000	14:01
M. Rajendra Prasad	30,99,996	12:01

- 2 The percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year

Name	Designation	Remuneration		Increase/ (Decrease)%
		FY 2017-18	FY 2016-17	
K. Krishna Kishore Managing Director	Vice Chairman &	36,00,000	26,12,903	37.78%
M. Rajendra Prasad	Executive Director & CEO	30,99,996	30,99,996	0.00%
G. Krishna Sowjanya	Company Secretary	1,80,000	1,80,000	0.00%

- 3 The percentage increase in the median remuneration of employees in the financial year

Particulars	Remuneration		Increase/ (Decrease)%
	FY 2017-18	FY 2016-17	
Median Remuneration of all the employees per annum*	2,65,259	2,49,678	6.24%

*Employees who have served for whole of the respective financial years have been considered.

Particulars	Number
The number of employees on the rolls of the company as on March 31, 2018	170

Jeevan Scientific Technology Limited

- 5 Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and details if there are any exceptional circumstances for increase in the managerial remuneration**

Particulars		Increase/ (Decrease)%
Average percentage increase in the remuneration of all Employees* (Other than Key Managerial Personnel)		39.39%
Average Percentage increase in the Remuneration of Key Managerial Personnel		
K. Krishna Kishore	Vice Chairman & Managing Director	37.78%
M. Rajendra Prasad	Executive Director & CEO	0.00%
G. Krishna Sowjanya	Company Secretary	0.00%

**Employees who have served for whole of the respective financial years have been considered.*

- 6 Affirmation that the remuneration is as per the remuneration policy of the company.**
The Company is in compliance with its remuneration policy.

AUDITOR'S CERTIFICATE ON CORPORATE GOVERNANCE

To
The Members of
Jeevan Scientific Technology Limited

We have examined the Compliance with conditions of Corporate Governance of M/s. Jeevan Scientific Technology Limited for the year ended 31st March, 2018 as stipulated in Regulation 34(3) read with Para E Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Compliance with the conditions of Corporate Governance is the responsibility of the Management. Our examination has been limited to review the procedures and implementations thereof adopted by the Company for ensuring the compliance with the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statement of the Company.

In our opinion and to the best of our information and according to the explanations given to us and representations made by the Directors and the Management's, we certify that the company has complied with conditions of the Corporate Governance as stipulated in Regulation 34 (3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

As required by the guidance note issued by the institute of Chartered Accountants of India, we have to state that no grievances of investors are pending for a period exceeding one month against the Company as per the records maintained by the Company.

We further state that such compliance is neither an assurance as to future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the company.

For PAVULURI&Co.
Chartered Accountants
Firm Reg. No:012194S

Sd/-
(CA KANTHI SREE KOLLI)
PARTNER
M.No : 224434

Place : Hyderabad
Date : 26.05.2018

Jeevan Scientific Technology Limited

UN PAID / UN CLAIMED DIVIDEND:

DISCLOSURE WITH RESPECT TO DEMAT SUSPENSE ACCOUNT/ UNCLAIMED SUSPENSE ACCOUNT

As per Regulation 34(3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company hereby discloses the details of unpaid/unclaimed dividend and the respective share thereof as follows:

**

Aggregate No. of Shareholders and the outstanding shares in the suspense account at the beginning of the year	No. of shareholders who approached the company for transfer of shares from suspense account during the year	No. of shareholders to whom shares were transferred from suspense account during the year	Aggregate No. of Shareholders and the outstanding shares in the suspense account at the end of the year
NIL	NIL	NIL	NIL

**** *Voting Right on these shares shall remain frozen till the rightful owner of such shares claims the shares.***

In terms of the provisions of the Companies Act, the Company is obliged to transfer dividends, which remain unpaid or unclaimed for a period of seven years from the declaration to the credit of the Investor education and Protection Fund established by the Central Government. The Company has not declared any dividend since its inception and hence the transfer of any unpaid /unclaimed dividend to the credit of the Investor education and Protection Fund does not arise.

Twentieth Annual Report 2017-2018

Annexure II

MGT 9

Extract of Annual Return

As on the Financial Year 31-Mar-2017

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:	
i. CIN	L72200TG1999PLC031016
ii. Registration Date	02/02/1999
iii. Name of the Company	Jeevan Scientific Technology Limited
iv. Category / Sub-Category of the Company	Company limited by shares / Non-Government Company
v. Address of the Registered office and contact details	Plot No. 1&2, Sai Krupa Enclave, contact details Manikonda, Near Lanco Hills, Golconda Post, Hyderabad- 500008, Telangana, India. Phone No: +91-40-67364700 Fax No: +91-40-67364707
vi. Whether listed company Yes / No	Yes
vii. Name, Address and Contact details of Registrar and Transfer Agent, if any	M/s. CIL Securities Limited 214, Raghava Ratna Towers, Chairag Ali Lane, Abids, Hyderabad- 500001 Ph: +91-40-23203155, Fax: +91-40-23203028

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

Sl. No.	Name and Description of main products /services	NIC Code of the Product / service	% to total turnover of the company
1	Research and experimental development services in medical sciences	99811301	95.00

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:-

Sl. No.	Name and Address of the Company	CIN/GIN	Holding/ Subsidiary/ Associate	%of Shares held	Applicable Section
1	Enhops Solutions Pvt. Ltd.	U72300TG2015PTC100314	Subsidiary	100%	2(87)(ii)
2	Enhops, Inc. (U.S.A)	n/a	Subsidiary	100%	2(87)(ii)

Jeevan Scientific Technology Limited

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i) Category-wise Share Holding:-

Category of Share holders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
Individual/ HUF	16,39,691	8,15,000	24,54,691	26.45	33,04,691	—	33,04,691	28.84	8.63
Central Govt	—	—	—	—	—	—	—	—	—
State Govt (s)	—	—	—	—	—	—	—	—	—
Bodies Corp.	85,200	—	85,200	0.92	85,200	—	85,200	0.74	0.31
Banks / FI	—	—	—	—	—	—	—	—	—
Any Other....	7,43,000	—	7,43,000	8.01	9,43,000	—	9,43,000	8.23	0.92
Sub-total(A) (1) :-	24,67,891	8,15,000	32,82,891	35.38	43,32,891	—	43,32,891	37.81	9.86
(2) Foreign									
a) NRIs -Individuals	—	—	—	—	—	—	—	—	—
b) Other –Individuals	—	—	—	—	—	—	—	—	—
c) Bodies Corp.	—	—	—	—	—	—	—	—	—
d) Banks / FI	—	—	—	—	—	—	—	—	—
e) AnyOther....	—	—	—	—	—	—	—	—	—
Sub-total(A) (2):-	—	—	—	—	—	—	—	—	—
Total share holding of Promoter (A) =(A)(1)+(A)(2)	24,67,891	8,15,000	32,82,891	35.38	43,32,891	—	43,32,891	37.81	9.86
B. Public Shareholding									
1.Institutions									
a) Mutual Funds	—	—	—	—	—	—	—	—	—
b) Banks / FI	—	—	—	—	—	—	—	—	—
c) Central Govt	—	—	—	—	—	—	—	—	—
d) State Govt(s)	—	—	—	—	—	—	—	—	—
e) Venture Capital Funds	—	—	—	—	—	—	—	—	—
f) Insurance Companies	—	—	—	—	—	—	—	—	—
g) FIs	—	—	—	—	—	—	—	—	—
h) Foreign Venture Capital Fund	—	—	—	—	—	—	—	—	—
i) Others(specify)	—	—	—	—	—	—	—	—	—

Twentieth Annual Report 2017-2018

Category of Share holders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
2. Non Institutions									
a) Bodies Corp.	1,56,375	—	1,56,375	1.69	1,33,102	—	1,33,102	1.16	0.77
i) Indian	1,56,375	—	1,56,375	1.69	1,33,102	—	1,33,102	1.16	0.77
ii) Overseas	—	—	—	—	—	—	—	—	—
b) Individuals	42,28,805	4,58,038	46,86,843	50.5	43,48,961	10,80,933	54,29,894	47.38	10.38
i) Individual share holders holding nominal share capital up to Rs. 2 lakh	19,34,316	4,10,038	23,44,354	25.26	18,58,910	4,32,933	22,91,843	20.00	8.89
ii) Individual share holders holding nominal share capital in excess of Rs 2lakh	22,94,489	48,000	23,42,489	25.24	24,90,051	6,48,000	31,38,051	27.38	1.49
c) Others (specify)									
1. NRI	5,81,469	5,45,000	11,26,469	12.14	9,22,600	6,35,000	15,57,600	13.59	4.02
2. Clearing Members	26,887	—	26,887	0.29	5,978	—	5,978	0.05	0.28
Sub-total (B)(2):- Total Public Shareholding(B)= (B)(1)+(B)(2)	49,93,536	10,03,038	59,96,574	64.62	54,10,641	17,15,933	71,26,574	62.19	0.4
C. Shares held by Custodian for GDRs & ADRs	—	—	—	—	—	—	—	—	—
Grand Total(A+B+C)	74,61,427	18,18,038	92,79,465	100.0	97,43,532	17,15,933	1,14,59,465	100.00	—

Jeevan Scientific Technology Limited

(ii) Shareholding of Promoters

Share Holder's Name	No. of Shares held at the beginning of the year			No. of Shares held at the end of the year			% Change during the year
	No. of Shares	% of Total Shares	% of Shares pledged/ encumbered to total Shares	No. of Shares	% of Total Shares	% of Shares pledged/ encumbered to total Shares	
1. K. Krishna Kishore(HUF)	2,00,000	2.16	—	2,00,000	1.75	—	0.41
2. T. Chalapathi Rao	3,84,700	4.15	—	3,84,700	3.36	—	0.79
3. K. Vanaja	8,57,800	9.24	—	12,57,800	10.98	—	1.74
4. K. Gopi Krishna	2,70,000	2.91	—	2,70,000	2.36	—	0.55
5. Jeevan Krishna Kuchipudi	2,24,300	2.42	—	4,24,300	3.70	—	1.28
6. T. Sridevi	1,34,000	1.44	—	1,34,000	1.17	—	0.27
7. Jeevana Mitra Chit Fund Private Limited	85,200	0.92	—	85,200	0.74	—	0.18
8. T. Ravi	2,500	0.03	—	2,500	0.02	—	0.01
9. Krishna Kishore Kuchipudi	11,24,391	12.12	—	15,74,391	13.74	—	1.62

(iii) Change in Promoters' Shareholding (please specify, if there is no change):

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1.	K. Vanaja				
	At the beginning of the year	8,57,800	9.24	12,57,800	10.98
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	Conversion of 4,00,000 convertible warrants into 4,00,000 equity shares on 06.03.2017.			
	At the End of the year	12,57,800	10.98	12,57,800	10.98

Twentieth Annual Report 2017-2018

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1.	Jeevan Krishna Kuchipudi				
	At the beginning of the year	2,24,300	2.42	4,24,300	3.70
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	Conversion of 2,00,000 convertible warrants into 2,00,000 equity shares on 06.03.2017			
	At the End of the year	4,24,300	3.70	4,24,300	3.70

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1.	Kuchipudi Krishna Kishore				
	At the beginning of the year	11,24,391	12.12	15,74,391	13.74
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	Conversion of 4,50,000 convertible warrants into 4,50,000 equity shares on 06.03.2017			
	At the End of the year	15,74,391	13.74	15,74,391	13.74

Jeevan Scientific Technology Limited

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1.	Durisala Desaiiah				
	At the beginning of the year	8,30,000	8.94	8,30,000	8.94
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	There was no change in the shareholding during the Financial Year 2017-18			
	At the End of the year	8,30,000	8.94	8,30,000	8.94

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
2.	Sridevi Nutakki				
	At the beginning of the year	2,30,000	2.48	2,30,000	2.48
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	There was no change in the shareholding during the Financial Year 2017-18			
	At the End of the year	2,30,000	2.48	2,30,000	2.48

Twentieth Annual Report 2017-2018

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
3.	Akhila Kakarla				
	At the beginning of the year	2,00,000	2.16	2,00,000	2.16
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	There was no change in the shareholding during the Financial Year 2017-18			
	At the End of the year	2,00,000	2.16	2,00,000	2.16

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
4.	Sesha Ratnam Bathineni				
	At the beginning of the year	1,08,232	1.17	1,08,232	1.17
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	There was no change in the shareholding during the Financial Year 2017-18			
	At the End of the year	1,08,232	1.17	1,08,232	1.17

Jeevan Scientific Technology Limited

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
5.	Jigisha Jayesh Dabhi				
	At the beginning of the year	1,01,700	1.10	1,01,700	1.10
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	There was no change in the shareholding during the Financial Year 2017-18			
	At the End of the year	1,01,700	1.10	1,01,700	1.10

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
6.	Naga Kishore Nutakki				
	At the beginning of the year	1,00,000	1.08	1,00,000	1.08
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	There was no change in the shareholding during the Financial Year 2017-18			
	At the End of the year	1,00,000	1.08	1,00,000	1.08

Twentieth Annual Report 2017-2018

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
7.	Jammula Narendra Babu				
	At the beginning of the year	1,00,000	1.08	1,00,000	1.08
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	There was no change in the shareholding during the Financial Year 2017-18			
	At the End of the year	1,00,000	1.08	1,00,000	1.08

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
8.	Nutakki Geethika Sai				
	At the beginning of the year	1,00,000	1.08	1,00,000	1.08
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	There was no change in the shareholding during the Financial Year 2017-18			
	At the End of the year	1,00,000	1.08	1,00,000	1.08

Jeevan Scientific Technology Limited

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
9.	Sirisha Gali				
	At the beginning of the year	83,000	0.89	83,000	0.89
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	There was no change in the shareholding during the Financial Year 2017-18			
	At the End of the year	83,000	0.89	83,000	0.89

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
10.	Bobba Govardhan Rao				
	At the beginning of the year	75,000	0.81	75,000	0.81
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	There was no change in the shareholding during the Financial Year 2017-18			
	At the End of the year	75,000	0.81	75,000	0.81

Twentieth Annual Report 2017-2018

V. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

Sl.No.	Particulars of Remuneration	Name of MD/WTD/ Manager:		Total Amount
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income tax Act, 1961	Remuneration to managing Director Mr. K. Krishna Kishore Rs.36,00,000/- Per Annum.	Remuneration to Whole time Director(s): Mr. M. Rajender Prasad = Rs. 30,99,996/- Per Annum.	---
2.	Stock Option	—	—	—
3.	Sweat Equity	—	—	—
4.	Commission - as % of profit - Others, specify...	—	—	—
5.	Others, please specify	—	—	—
6.	Total (A)	36,00,000	30,99,996	66,99,996
7.	Ceiling as per the Act	—	—	—

B. Remuneration to other directors:

Particulars of Remuneration	Name of Director				Amount
	Mr. A. Vijay Kumar	Mr. SSR Koteswara Rao	Mr. K. Rama Krishna Prasad	Mr. G. Bhanu Prakash	
Independent Directors - Fee for attending board / committee meetings - Commission - Others, please specify					---
Total (1)	70,000	1,00,000	50,000	20,000	2,40,000
Other Directors - Fee for attending board / committee meetings - commission - Others, please specify	Ms. K. Vanaja	Mr. T. Ravi Babu	Mr. Raghav Beeram	—	—
Total (2)	60,000	20,000	10,000		90,000
Total (B)=(1+2)	1,30,000	1,20,000	60,000	20,000	3,30,000
Total Managerial Remuneration (A+B)					70,29,996
Overall Ceiling as per the Act					

Jeevan Scientific Technology Limited

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD

Particulars of Remuneration	Key Managerial Personnel	
	Company Secretary (Y.K. Sowjanya Guntaka)	Total
1. Gross salary(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	Rs.15,000*12 months=1,80,000/-	Rs.1,80,000/-
2. Stock Option	—	—
3. Sweat Equity	—	—
4. Commission- as % of profit- others, specify...	—	—
5. Others, please Specify	—	—
6. Total	Rs. 1,80,000/-	Rs. 1,80,000/-

VI. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)
A. COMPANY					
Penalty	—	—	—	—	—
Punishment	—	—	—	—	—
Compounding	—	—	—	—	—
B. DIRECTORS					
Penalty	—	—	—	—	—
Punishment	—	—	—	—	—
Compounding	—	—	—	—	—
C. OTHER OFFICERS IN DEFAULT					
Penalty	—	—	—	—	—
Punishment	—	—	—	—	—
Compounding	—	—	—	—	—

ANNEXURE III

DECLARATION FROM INDEPENDENT DIRECTORS ON ANNUAL BASIS

The Board of Directors

Jeevan Scientific Technology Limited

Dear Sir,

I undertake to comply with the conditions laid down in Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with section 149 and Schedule IV of the Companies Act, 2013 in relation to conditions of independence and in particular:

- (a) I declare that up to the date of this certificate, apart from receiving director's remuneration, I did not have any material pecuniary relationship or transactions with the Company, its promoter, its directors, senior management or its holding Company, its subsidiary and associates as named in the Annexure thereto which may affect my independence as director on the Board of the Company. I further declare that I will not enter into any such relationship/transactions. However, if and when I intend to enter into such relationships/transactions, whether material or non-material I shall keep prior approval of the Board. I agree that I shall cease to be an independent director from the date of entering into such relationship/transaction.
- (b) I declare that I am not related to promoters or persons occupying management positions at the Board level or at one level below the board and also have not been executive of the Company in the immediately preceding three financial years.
- (c) I was not a partner or an executive or was also not partner or executive during the preceding three years, of any of the following:
 - (i) the statutory audit firm or the internal audit firm that is associated with the Company and
 - (ii) the legal firm(s) and consulting firm(s) that have a material association with the company
- (d) I have not been a material supplier, service provider or customer or lessor or lessee of the company, which may affect independence of the director, and was not a substantial shareholder of the Company i.e., owning two percent or more of the block of voting shares.

Thanking You,

Yours Faithfully,

Date: 01.04.2017
Place: Hyderabad

(G. Bhanu Prakash)

Jeevan Scientific Technology Limited

ANNEXURE III

DECLARATION FROM INDEPENDENT DIRECTORS ON ANNUAL BASIS

The Board of Directors

Jeevan Scientific Technology Limited

Dear Sir,

I undertake to comply with the conditions laid down in Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with section 149 and Schedule IV of the Companies Act, 2013 in relation to conditions of independence and in particular:

- (a) I declare that up to the date of this certificate, apart from receiving director's remuneration, I did not have any material pecuniary relationship or transactions with the Company, its promoter, its directors, senior management or its holding Company, its subsidiary and associates as named in the Annexure thereto which may affect my independence as director on the Board of the Company. I further declare that I will not enter into any such relationship/transactions. However, if and when I intend to enter into such relationships/transactions, whether material or non-material I shall keep prior approval of the Board. I agree that I shall cease to be an independent director from the date of entering into such relationship/transaction.
- (b) I declare that I am not related to promoters or persons occupying management positions at the Board level or at one level below the board and also have not been executive of the Company in the immediately preceding three financial years.
- (c) I was not a partner or an executive or was also not partner or executive during the preceding three years, of any of the following:
 - (i) the statutory audit firm or the internal audit firm that is associated with the Company and
 - (ii) the legal firm(s) and consulting firm(s) that have a material association with the company
- (d) I have not been a material supplier, service provider or customer or lessor or lessee of the company, which may affect independence of the director, and was not a substantial shareholder of the Company i.e., owning two percent or more of the block of voting shares.

Thanking You,

Yours Faithfully,

Date: 01.04.2017

Place: Hyderabad

(SSR Koteswara Rao)

ANNEXURE III

DECLARATION FROM INDEPENDENT DIRECTORS ON ANNUAL BASIS

The Board of Directors

Jeevan Scientific Technology Limited

Dear Sir,

I undertake to comply with the conditions laid down in Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with section 149 and Schedule IV of the Companies Act, 2013 in relation to conditions of independence and in particular:

- (a) I declare that up to the date of this certificate, apart from receiving director's remuneration, I did not have any material pecuniary relationship or transactions with the Company, its promoter, its directors, senior management or its holding Company, its subsidiary and associates as named in the Annexure thereto which may affect my independence as director on the Board of the Company. I further declare that I will not enter into any such relationship/transactions. However, if and when I intend to enter into such relationships/transactions, whether material or non-material I shall keep prior approval of the Board. I agree that I shall cease to be an independent director from the date of entering into such relationship/transaction.
- (b) I declare that I am not related to promoters or persons occupying management positions at the Board level or at one level below the board and also have not been executive of the Company in the immediately preceding three financial years.
- (c) I was not a partner or an executive or was also not partner or executive during the preceding three years, of any of the following:
 - (i) the statutory audit firm or the internal audit firm that is associated with the Company and
 - (ii) the legal firm(s) and consulting firm(s) that have a material association with the company
- (d) I have not been a material supplier, service provider or customer or lessor or lessee of the company, which may affect independence of the director, and was not a substantial shareholder of the Company i.e., owning two percent or more of the block of voting shares.

Thanking You,

Yours Faithfully,

Date: 01.04.2017

Place: Hyderabad

(K. Rama Krishna Prasad)

Jeevan Scientific Technology Limited

ANNEXURE III

DECLARATION FROM INDEPENDENT DIRECTORS ON ANNUAL BASIS

The Board of Directors

Jeevan Scientific Technology Limited

Dear Sir,

I undertake to comply with the conditions laid down in Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with section 149 and Schedule IV of the Companies Act, 2013 in relation to conditions of independence and in particular:

- (a) I declare that up to the date of this certificate, apart from receiving director's remuneration, I did not have any material pecuniary relationship or transactions with the Company, its promoter, its directors, senior management or its holding Company, its subsidiary and associates as named in the Annexure thereto which may affect my independence as director on the Board of the Company. I further declare that I will not enter into any such relationship/transactions. However, if and when I intend to enter into such relationships/transactions, whether material or non-material I shall keep prior approval of the Board. I agree that I shall cease to be an independent director from the date of entering into such relationship/transaction.
- (b) I declare that I am not related to promoters or persons occupying management positions at the Board level or at one level below the board and also have not been executive of the Company in the immediately preceding three financial years.
- (c) I was not a partner or an executive or was also not partner or executive during the preceding three years, of any of the following:
 - (i) the statutory audit firm or the internal audit firm that is associated with the Company and
 - (ii) the legal firm(s) and consulting firm(s) that have a material association with the company
- (d) I have not been a material supplier, service provider or customer or lessor or lessee of the company, which may affect independence of the director, and was not a substantial shareholder of the Company i.e., owning two percent or more of the block of voting shares.

Thanking You,

Yours Faithfully,

Date: 01.04.2017
Place: Hyderabad

(T. Ravi Babu)

FORM MR-3

SECRETARIAL AUDIT REPORT

(Pursuant to section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014
FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2018

To
The Members of
M/s Jeevan Scientific Technology Limited

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by M/s Jeevan Scientific Technology Limited (hereinafter called "the Company"). Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's Books, Papers, Minute Books, Forms and Returns filed and other Records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the company has, during the audit period covering the financial year ended on 31st March, 2018, complied with the statutory provisions listed hereunder and also that the Company has proper Board process and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

1. We have examined the books, papers, minute books, forms and returns filed and other records maintained by M/s Jeevan Scientific Technology Limited ("The Company") for the financial year ended on 31st March, 2018, according to the provisions of:
 - i. The Companies Act, 2013 (the Act) and the rules made there under ;
 - ii. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under;
 - iii. The Depositories Act, 1996 and the Regulations and Bye-laws framed there under.
 - iv. Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of Foreign Direct Investment (FDI) and Overseas Direct Investment and External Commercial Borrowings;
2. Compliance status in respect of the provisions of the following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 (SEBI Act) is furnished hereunder for the financial year 2017-18.
 - i. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; **Complied with yearly and event based disclosures.**
 - ii. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 Insider Trading Regulations; **The Company has framed code of conduct for regulating & reporting trading by insiders and for fair disclosure and displayed the same on the Company's website i.e. <http://www.jeevanscientific.com/>**
 - iii. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009; **Not Applicable as the company has not issued any shares during the year under review.**

Jeevan Scientific Technology Limited

- iv. The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999; **Not Applicable as the Company has not issued any Employee Stock Options during the year under review.**
- v. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008. **Not Applicable as the Company has not issued any debt securities during the year under review.**
- vi. The Securities and Exchange Board of India (Registrars to an issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client; **Not Applicable as the Company is not registered as Registrar to an Issue and Share Transfer Agent during the year under review. However the company has M/s. CIL Securities Limited, as its Share Transfer Agent.**
- vii. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; **Not Applicable as the company has not delisted/ proposed to delist its equity shares during the year under review.**
- viii. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998; **Not Applicable as the Company has not bought back/ proposed to buy-back any of its securities during the year under review.**
- ix. Other applicable laws include the following:
 - The Payment of Gratuity Act, 1972
 - Employees Provident Fund and Miscellaneous Provisions Act, 1952
 - Employees State Insurance Act, 1948
 - The Information Technology Act, 2000
 - Income Tax Act, 1961
 - Indian Stamp Act, 1899
 - Minimum Wages Act, 1948
 - Payment of Bonus Act, 1965
 - Payment of Wages Act, 1936
 - Shops and Establishments Act, 1948

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (ii) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 were complied with to the extent applicable.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above subject to the following **observations**:

- a) During the year the Company has conducted 6 meetings of the Board of Directors, 4 meetings of the Audit committee, 1 Meeting of Stakeholder Relationship Committee and 1 meeting of Independent Directors. We have also examined compliance with the applicable clauses of the Secretarial Standards issued by the Institute of Company secretaries of India.
- b) As per the information and explanations provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, **we report that**

Twentieth Annual Report 2017-2018

- (i) the provisions of the Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of:
- External Commercial Borrowings were not attracted to the Company under the financial year under report;
 - Foreign Direct Investment (FDI) was not attracted to the company under the financial year under report;
 - Overseas Direct Investment by Residents in Joint Venture/Wholly Owned Subsidiary abroad was not attracted to the company under the financial year under report.
- (ii) As per the information and explanations provided by the company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we report that the Company has not made any GDRs/ADRs or any Commercial Instrument under the financial year under report.

We further report that:

- i. The Company has Internal Auditors namely M/s. K P & Associates, Chartered Accountants, Hyderabad.
- ii. The website of the company contains several policies as specified by SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 and the provisions of Companies Act, 2013.
- iii. The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.
- iv. Adequate notice of board meeting is given to all the directors along with agenda and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and meaningful participation at the meeting.
- v. Minutes of the meeting duly recorded and signed by the Chairman.
- vi. We, further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable Laws, rules, regulations and guidelines.
- vii. We, further report that there was a conversion of 21,80,000 warrants into 21,80,000 equity shares of Rs. 10/- each at an issue price of Rs. 30.25/- per share.
- viii. The compliance by the Company of applicable financial laws like Direct and Indirect tax laws has not been reviewed thoroughly in this audit since the same have been subject to review by statutory financial audit and other designated professionals.

For **S.S. Reddy & Associates**

Sd/-

S.Sarveswar Reddy

Proprietor

C.P.No: 7478

Place: Hyderabad

Date : 14.08.2018

Jeevan Scientific Technology Limited

Annexure A

To
The Members of
M/s Jeevan Scientific Technology Limited

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have relied on the reports given by the concerned professionals in verifying the correctness and appropriateness of financial records and books of accounts of the company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The secretarial Audit report is neither an assurance as to future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

For **S.S. Reddy & Associates**

Sd/-

S.Sarveswar Reddy

Proprietor

C.P.No: 7478

Place: Hyderabad

Date : 14.08.2018

INDEPENDENT AUDITOR'S REPORT

To the members of,

M/s. JEEVAN SCIENTIFIC TECHNOLOGY LIMITED,

Report on the Standalone Financial Statements:

We have audited the accompanying Standalone financial statements of M/s. JEEVAN SCIENTIFIC TECHNOLOGY LIMITED, which comprise the Balance Sheet as at March 31, 2018, the Statement of Profit and Loss (including Other Comprehensive Income), the statement of changes in equity and the statement of Cash Flows for the year ended 31st March, 2018 and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these standalone financial statements based on our audit. In conducting our audit, we have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder and the Order issued under section 143(11) of the Act.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Ind AS financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Ind AS financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Standalone financial statements, whether due to fraud or error. In making those risk assessments, the

Jeevan Scientific Technology Limited

auditor considers internal financial control relevant to the Company's preparation of the Ind AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the Ind AS financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, Ind AS Financial Statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including the Ind AS, of the state of affairs of the Company as at March 31, 2018, its financial performance including other comprehensive income, its cash flows and the statement of changes in equity for the year ended on that date.

Report on Other Legal and Regulatory Requirements:

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure A, a statement on the matters specified in paragraphs 3 and 4 of the said Order.
2. As required by section 143(3) of the Act, we further report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - b) In our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;
 - c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the books of account.
 - d) In our opinion, the aforesaid financial statements comply with the applicable accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;
 - e) On the basis of written representations received from the directors as on March 31, 2018, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2018, from being appointed as a director in terms of Section 164(2) of the Act;
 - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B". Our report expresses an unmodified opinion on the adequacy

Twentieth Annual Report 2017-2018

and operating effectiveness of the Company's internal financial controls over financial reporting.

- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us
- i. The Company doesn't have pending litigations which will have an impact on its financial position in the Standalone financial statements.
 - ii. The Company did not have any long-term contracts including derivative contracts; as such the question of commenting on any material foreseeable losses thereon does not arise.
 - iii. There have been no occasions in case of the company during the year under report to transfer any sums to the Investor Education and Protection Fund.

For PAVULURI&Co.
Chartered Accountants
Firm Reg. No:012194S

Sd/-
(CA KANTHI SREE KOLLI)
PARTNER
M.No : 224434

Place : Hyderabad
Date : 26.05.2018

Jeevan Scientific Technology Limited

“Annexure A” to the Independent Auditors’ Report

Referred to in paragraph 1 under the heading ‘Report on Other Legal & Regulatory Requirement’ of our report of even date to the Standalone financial statements of the Company for the year ended March 31, 2018:

- 1) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets;
(b) The Fixed Assets have been physically verified by the management in a phased manner, designed to cover all the items over a period of three years, which in our opinion, is reasonable having regard to the size of the company and nature of its business. Pursuant to the program, a portion of the fixed asset has been physically verified by the management during the year and no material discrepancies between the books records and the physical fixed assets have been noticed.
(c) The title deeds of immovable properties are held in the name of the company.
- 2) (a) The management has conducted the physical verification of inventory at reasonable intervals.
b) The discrepancies noticed on physical verification of the inventory as compared to books records which has been properly dealt with in the books of account were not material.
- 3) The Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability partnerships or other parties covered in the Register maintained under section 189 of the Act. Accordingly, the provisions of clause 3 (iii) (a) to (c) of the Order are not applicable to the Company and hence not commented upon.
- 4) In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the Companies Act, 2013 in respect of loans, investments, guarantees, and security.
- 5) The Company has not accepted any deposits from the public and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.
- 6) As informed to us, the maintenance of Cost Records has not been specified by the Central Government under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the company.
- 7) (a) According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income-Tax, Sales tax, Service Tax, Duty of Customs, Duty of Excise, Value added Tax, Cess and any other statutory dues with the appropriate authorities though there has been slight delay in few cases.

Twentieth Annual Report 2017-2018

- (b) According to the information and explanations given to us, no undisputed amounts payable in respect of the above were in arrears as at March 31, 2018 for a period of more than six months from the date on when they become payable.
- 8) In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of dues to banks.
 - 9) Based upon the audit procedures performed and the information and explanations given by the management, the company has not raised moneys by way of initial public offer or further public offer including debt instruments and term Loans. Accordingly, the provisions of clause 3 (ix) of the Order are not applicable to the Company and hence not commented upon.
 - 10) Based upon the audit procedures performed and the information and explanations given by the management, we report that no fraud by the Company or on the company by its officers or employees has been noticed or reported during the year.
 - 11) Based upon the audit procedures performed and the information and explanations given by the management, the managerial remuneration has been paid or provided in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act;
 - 12) In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause 4 (xii) of the Order are not applicable to the Company.
 - 13) All transactions with the related parties are in compliance with sections 177 and 188 of the Companies Act, 2013 in so far as our examination of the proceedings of the meetings of the Audit Committee and Board of Directors are concerned. The details of related party transactions have been disclosed in the Standalone Ind AS Financial Statements as required by the applicable Accounting Standard.
 - 14) The Company has made preferential allotment of shares during the year under review. The requirement specified under section 42 of the companies act 2013 has been complied.
 - 15) Based upon the audit procedures performed and the information and explanations given by the management, the company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, the provisions of clause 3 (xv) of the Order are not applicable to the Company and hence not commented upon.

In our opinion, the company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of clause 3 (xvi) of the Order are not applicable to the Company and hence not commented upon.

For PAVULURI&Co.
Chartered Accountants
Firm Reg. No:012194S

Sd/-
(CA KANTHI SREE KOLLI)
PARTNER
M.No : 224434

Place : Hyderabad
Date : 26.05.2018

Jeevan Scientific Technology Limited

“Annexure B” to the Independent Auditor’s Report of even date on the Standalone Financial Statements of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED (“the Company”) as of March 31, 2018 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on “the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India”. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the Standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Twentieth Annual Report 2017-2018

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Standalone financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Standalone financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the Standalone financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2018, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For PAVULURI&Co.
Chartered Accountants
Firm Reg. No:012194S

Sd/-
(CA KANTHI SREE KOLLI)
PARTNER
M.No : 224434

Place : Hyderabad
Date : 26.05.2018

Jeevan Scientific Technology Limited

Stand Alone Balance Sheet as at 31st March, 2018

(In Rupees)

Particulars	Note No.	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Assets				
(1) Non-current Assets				
a) Property, Plant and Equipment	2	179,976,619	105,229,694	81,022,897
b) Other Intangible Assets	2	6,749,558	4,659,090	1,945,212
c) Intangible Assets Process	2	51,203,910	28,411,859	3,042,333
d) Financial Assets				
i) Investments	3	10,269,070	5,269,070	5,269,070
ii) Loans	4	35,226,109	24,326,338	46,691
iii) Advances	5	5,034,310	4,559,785	5,254,906
c) Deferred tax asset (net)	6	0	1,281,864	2,244,508
(2) Current Assets				
a) Inventories	7	989,587	4,741,677	742,572
b) Financial Assets				
i) Trade receivables	8	161,238,640	111,069,188	72,264,103
ii) Cash and cash equivalents	9	6,712,313	689,254	465,336
iii) Bank balances other than (ii) above	10	7,016,821	1,279,642	1,192,436
iv) Loans	11	4,339,757	4,769,825	384,670
v) Other Financial Assets	12	2,702,750	1,533,733	-
c) Current Tax Assets (Net)	13	19,879,838	11,146,259	7,666,722
d) Other Current Assets	14	1,607,918	872,023	2,153,511
Total		<u>492,947,200</u>	<u>309,839,301</u>	<u>183,694,967</u>
Equity and Liabilities				
Equity				
a) Equity Share Capital	A	114,594,650	92,794,650	60,416,000
b) Other Equity	B	112,446,768	81,525,738	-40,505,738
Liabilities				
(1) Non-current Liabilities				
a) Financial liabilities				
Borrowings	15	98,372,835	47,475,165	83,193,804
b) Provisions	16	968,587	746,915	271,264
c) Deferred tax Liability (net)	6	1,158,997	0	0
(2) Current Liabilities				
a) Financial Liabilities				
i) Borrowings	17	70,414,014	24,621,966	24,479,407
ii) Trade Payables	18	20,562,838	22,436,046	33,347,137
iii) Other Financial liabilities	19	25,839,766	15,570,174	5,493,360
iv) Other Financial Creditors	20	25,545,192	4,586,303	831,188
b) Other current liabilities	21	22,818,054	17,593,736	14,944,588
c) Provisions	22	225,498	2,488,608	1,223,957
Total		<u>492,947,200</u>	<u>309,839,301</u>	<u>183,694,967</u>

Summary of significant accounting policies & Notes 1

Per our report of even Date

for PAVULURI & Co.

Chartered Accountants

Firm Regn No: 012194S

for and on behalf of the Board of Directors

Jeevan Scientific Technology Limited

Sd/-

CA Kanthi Sree Kolli

Partner

Membership No:224434

Place : Hyderabad

Date : 26.05.2018

Sd/-

K.Krishna Kishore

Vice Chairman & Managing Director

DIN: 00876539

Sd/-

M. Rajendra Prasad

Executive Director & CEO

DIN: 06781058

Sd/-

G. Ravi Kumar

Chief Financial Officer

Twentieth Annual Report 2017-2018

Stand Alone Statement of Profit and Loss for the Period ended 31st March, 2018

(In Rupees)

Particulars	Note No.	For the Year 2017-2018	For the Year 2016-2017	For the Year 2015-2016
Continuing Operations				
Income				
I. Revenue from operations	23	192,643,389	174,605,246	173,368,735
II. Other Income	24	9,047,831	5,699,635	4,032,315
III. Total revenue(I+II)		201,691,220	180,304,881	177,401,050
IV. Expenses				
Cost of Material consumed	25	12,987,432	1,585,147	1,509,833
Employee benefits expenses	26	49,851,992	18,427,564	32,492,236
Finance costs	27	16,631,043	13,635,437	12,759,026
Depreciation	2	16,588,890	11,809,207	6,714,335
Amortisation on Process	2	4,058,837	-	-
Other expenses	28	96,723,499	123,564,404	117,502,335
Total expenses		196,841,693	169,021,759	170,977,765
V. Profit/ (Loss) before tax (III)-(IV)		4,849,527	11,283,122	6,423,285
Tax expenses				
Current Tax		924,077	2,488,608	1,223,957
Less: Mat Credit Entitlement		(985,600)	(2,488,608)	(1,223,957)
Deferred Tax		2,440,861	962,644	2,229,313
Total tax expenses		2,379,338	962,644	2,229,313
Profit / (Loss) for the period from continuing operations		2,470,189	10,320,478	4,193,972
Profit / (Loss) from discontinuing operations		-	-	-
Tax expense from discontinuing operations		-	-	-
Profit / (Loss) from discontinuing operations (After tax)		-	-	-
Profit / (loss) for the Period		2,470,189	10,320,478	4,193,972
Other Comprehensive Income				
A (i) Items that will not be reclassified to profit and loss Re-measurements of post-employment benefit obligations)		645,160	(1,460,270)	-
(ii) Income tax relating to items that will not be reclassified to profit and loss		61,523	-	-
B (i) Items that will be reclassified to profit and loss		-	-	-
(ii) Income tax relating to items that will be reclassified to profit and loss		-	-	-
Total Comprehensive Income		3,053,827	8,860,208	4,193,972
Earning per equity share				
(Face value of Rs.10/- each)				
Basic		0.27	0.95	0.69
Diluted		0.32	1.33	0.69

Per our report of even Date
for **PAVULURI & Co.**
Chartered Accountants
Firm Regn No: 012194S

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
CA Kanthi Sree Kolli
Partner
Membership No:224434
Place : Hyderabad
Date : 26.05.2018

Sd/-
K.Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M. Rajendra Prasad
Executive Director & CEO
DIN: 06781058

Sd/-
G. Ravi Kumar
Chief Financial Officer

Jeevan Scientific Technology Limited

Stand Alone Cash Flow statement for the year ended 31st March, 2018

(In Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
A. Cash flow from operating activities			
Net Profit before tax and extraordinary items	4,849,527	11,076,861	6,423,285
Adjustments for:			
Depreciation	24,711,388	11,809,207	6,714,335
Loss on Sale of Assets	3,995	0	278,285
Interest	15,274,436	12,853,448	11,768,653
Operating profit before working capital changes	44,839,346	35,739,516	25,184,558
Adjustments for:			
Inventories	3,752,091	-3,999,105	-147,577
Trade and other receivables	-76,752,171	-71,760,557	-3,465,113
Trade and other Paybles	-80,771,063	28,408,351	29,717,777
Cash generated from operations	52,610,328	-68,428,497	51,289,645
Taxes Provision		0	0
Interest paid	15,274,436	12,853,448	11,768,653
Net cash from operating activity	37,335,892	-81,281,945	39,520,992
B. Cash flow from investing activities			
Purchase of fixed assets	124,353,827	64,099,409	36,178,304
Investments	0	0	5,269,070
Sale/ Transfer of fixed assets	9,000	0	697,966
Net cash used in investing activity	-124,344,827	-64,099,409	-40,749,408
C. Cash flow from financing activity			
Proceeds from loans	50,897,670	142,559	2304543
Increase in Capital	21,800,000	32,378,650	0
Increase in Other Equity	26,071,504	113,171,268	0
Net cash generated in financing activity	98,769,174	145,692,477	2,304,543
Net increase in cash and cash equivalents (A+B+C)	11,760,239	311,123	1,076,127
Cash and cash equivalents as at 31.03.2017	1,968,895	1,657,772	581,645
Cash and cash equivalents as at 31.03.2018	13,729,134	1,968,895	1,657,772

Per our report of even Date
for PAVULURI & Co.
Chartered Accountants
Firm Regn No: 012194S

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
CA Kanthi Sree Kolli
Partner
Membership No:224434

Sd/-
K.Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M. Rajendra Prasad
Executive Director & CEO
DIN: 06781058

Sd/-
G. Ravi Kumar
Chief Financial Officer

Place : Hyderabad
Date : 26.05.2018

Significant Accounting Policies and Notes on Accounts

Company Information

The Company was incorporated on 2nd February, 1999 to carry on the business Clinical research, Data management services.

Transition to Ind AS

The Company's standalone financial statements for the quarter ended June 30, 2017 are the first interim standalone financial statements prepared in accordance with Ind AS.

The adoption of Ind AS was carried out in accordance with Ind AS 101, using April 1, 2016 as the transition date. Ind AS 101 requires that all Ind AS standards and interpretations that are effective for the first Ind AS Standalone Financial Statements for the quarter ended June 30, 2017, be applied consistently and retrospectively for all fiscal years presented.

All applicable Ind AS have been applied consistently and retrospectively wherever required. The resulting difference between the carrying amounts of the assets and liabilities in the standalone financial statements under both Ind AS and Indian GAAP as of the transition date have been recognized directly in equity at the transition date.

1. Significant Accounting Policies

1.1 Basis of Preparation

a) Statement of Compliance

The standalone financial statements have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016 and other relevant provisions of the Act.

For all the periods up to and including the year ended March 31, 2017 the Company prepared its financial statements in accordance with accounting standards notified under the section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (Indian GAAP). These financial statements are the first, the Company has prepared in accordance with Ind AS. Refer to note on transition to Ind AS for information on how the Company adopted Ind AS.

b) Basis of measurement

The standalone financial statements have been prepared on a historical cost convention and on an accrual basis, except for the following material items that have been measured at fair value as required by relevant Ind AS:

- i. Certain financial assets and liabilities measured at fair value (refer accounting policy on financial instruments);
- ii. Defined benefit and other long-term employee benefits.

c) Functional and presentation currency

The standalone financial statements are presented in Indian rupees, which is the functional currency of the Company and the currency of the primary economic

Jeevan Scientific Technology Limited

environment in which the entity operates. All financial information presented in Indian rupees.

d) Use of estimates and judgment

The preparation of standalone financial statements in conformity with Ind AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on a periodic basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

1.2 Summary of significant accounting policies

i. Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which these entities operate (i.e. the “functional currency”). The standalone financial statements are presented in Indian Rupee, the national currency of India, which is the functional currency of the Company.

ii. Foreign currency transactions and balances

Transactions in foreign currency are translated into the respective functional currencies using the exchange rates prevailing at the dates of the respective transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at the exchange rates prevailing at reporting date of monetary assets and liabilities denominated in foreign currencies are recognized in the statement of profit and loss and reported within foreign exchange gains / (losses).

Non-monetary assets and liabilities denominated in a foreign currency and measured at historical cost are translated at the exchange rate prevalent at the date of transaction.

iii. Investment in subsidiaries

Investment in subsidiaries is measured at cost. Dividend income from subsidiaries is recognized when its right to receive the dividend is established.

iv. Financial instruments

All financial instruments are recognized initially at fair value. Transaction costs that are attributable to the acquisition of the financial asset (other than financial assets recorded at fair value through profit or loss) are included in the fair value of the financial assets. Purchase or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trade) are recognized on trade date. While, loans and borrowings and payable are recognized net of directly attributable transactions costs.

For the purpose of subsequent measurement, financial instruments of the Company are classified in the following categories: non-derivative financial assets comprising

Twentieth Annual Report 2017-2018

amortized cost; non derivative financial liabilities at amortized cost.

The classification of financial instruments depends on the objective of the business model for which it is held. Management determines the classification of its financial instruments at initial recognition.

Financial instrument is derecognized only when the Company has transferred its right to receive/ extinguish its obligation to pay cash flow from such financial instruments.

a) **Non-derivative financial assets**

Financial assets at amortized cost

A financial asset shall be measured at amortized cost if both of the following conditions are met:

- the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

They are presented as current assets, except for those maturing later than 12 months after the reporting date which are presented as non-current assets. Financial assets are measured initially at fair value plus transaction costs and subsequently carried at amortized cost using the effective interest method, less any impairment loss.

Amortized cost is represented by security deposits, cash and cash equivalents, employee and other advances and eligible current and non-current assets.

Cash and cash equivalents comprise cash on hand and in banks and demand deposits with banks which can be withdrawn at any time without prior notice or penalty on the principal.

For the purposes of the cash flow statement, cash and cash equivalents include cash on hand, in banks and demand deposits with banks, net of outstanding bank overdrafts that are repayable on demand and are considered part of the Company's cash management system.

b) **Non-derivative financial liabilities**

Financial liabilities at amortized cost

Financial liabilities at amortized cost represented by trade and other payables are initially recognized at fair value, and subsequently carried at amortized cost using the effective interest method.

v. **Property, plant and equipment:**

Recognition and measurement: Normally Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Cost includes expenditures directly attributable to the acquisition of the asset. The Company has elected to apply the optional exemption to use this previous GAAP value as deemed cost at 1 April 2015, the date of transition.

Jeevan Scientific Technology Limited

Depreciation: Normally the Company depreciates property, plant and equipment over the estimated useful life of the assets as prescribed in Schedule II of the Companies Act 2013 on a straight-line basis from the date the assets are ready for intended use. Wherever the useful life is determined by technical assessment for certain assets, such assets are depreciated as per their assessed life. Assets acquired under finance lease and leasehold improvements are amortized over the lower of estimated useful life and related term. Depreciation methods, useful lives and residual values are reviewed at each reporting date.

When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Subsequent expenditure relating to property, plant and equipment is capitalized only when it is probable that future economic benefits associated with these will flow to the Company and the cost of the item can be measured reliably. Repairs and maintenance costs are recognized in the statement of profit and loss when incurred. The cost and related accumulated depreciation are eliminated from the standalone financial statements upon sale or disposition of the asset and the resultant gains or losses are recognized in the statement of profit and loss.

The management estimates the useful lives for the following class of assets, based on internal assessment and independent technical evaluation carried out by external valuers, the management believes that useful lives as given below best represents the period over which the management expects to use these assets. Hence the useful lives for these assets is different from the useful lives as prescribed under Part - C of schedule II of the companies act 2013.

Plant and machinery	21 years
Electrical Installations	21 years
Computers	6 years
Vehicles- Motor car	10 years
Furniture and Fixtures	15 years
Office Equipment	21 years

Fixed Assets costing Rs.5,000/- or less are fully depreciated in the year of purchase

vi. Intangible assets

Intangible assets are stated at cost less accumulated amortization and impairment. Intangible assets are amortized over their respective estimated useful lives on a straight-line basis, from the date that they are available for use. The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition and other economic factors (such as the stability of the industry and known technological advances) and the level of maintenance expenditures required to obtain the expected future cash flows from the asset.

Twentieth Annual Report 2017-2018

Policy for accounting of expenses of Research & Development:

Clinical Research is a specified job and the ready availability of newly developed methods for BA/BE Analysis of drug samples is required to get the business from various Pharmaceutical Clients. JSTL has been in the process of developing process and new methods. Equipment, Machines, Manpower and consumables are used for development of new methods.

Investment in development method is calculated on the basis of proportionate of time spent by manpower, machines and also consumable for developing that particular method and the relative expenditure is capitalised as intangible asset. Each method will be of useful for a minimum period of 10-12 years. It is also decided by the Board that the amortisation of the investment in process for developing methods should take place in a period 7 years from the date of the method put to use on quarterly basis in straight line method.

vii. Inventory

- a) Raw materials, Stores and Consumables, work in process and finished products are valued at lower of cost and net realizable value of the respective units.
- b) The basis of determining the cost is
- | | | |
|------------------------------------|---|--|
| Raw materials | : | Weighted average cost |
| Stores and Consumables | : | Weighted average cost |
| Work in process and finished goods | : | valued at lower of cost and net realizable value |
- c) In case of identified Obsolete/Surplus/Non-moving items necessary provision is made and charged to revenue.

viii. Impairment

a) Financial assets

In accordance with Ind AS 109, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss.

- i. The Company follows 'simplified approach' for recognition of impairment loss allowance on trade receivable.

The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

For recognition of impairment loss on other financial assets and risk exposure, the Company determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If in subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognising impairment loss allowance based on 12 month ECL.

Jeevan Scientific Technology Limited

Lifetime ECLs are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12 month ECL is a portion of the lifetime ECL which results from default events that are possible within 12 months after the reporting date.

ECL is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the entity expects to receive (i.e. all shortfalls), discounted at the original EIR. When estimating the cash flows, an entity is required to consider:

- ii. All contractual terms of the financial instrument (including prepayment, extension etc.) over the expected life of the financial instrument. However, in rare cases when the expected life of the financial instrument cannot be estimated reliably, then the entity is required to use the remaining contractual term of the financial instrument.
- iii. Cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECL impairment loss allowance (or reversal) recognised during the period is recognised as income/ expense in the statement of profit and loss. The balance sheet presentation for various financial instruments is described below:

Financial assets measured at amortised cost, contractual revenue receivable: ECL is presented as an allowance, i.e. as an integral part of the measurement of those assets in the balance sheet. The allowance reduces the net carrying amount. Until the asset meets write off criteria, the Company does not reduce impairment allowance from the gross carrying amount.

b) Non-financial assets

The Company assesses at each reporting date whether there is any objective evidence that a non financial asset or a group of non financial assets is impaired. If any such indication exists, the Company estimates the amount of impairment loss.

An impairment loss is calculated as the difference between an asset's carrying amount and recoverable amount. Losses are recognised in profit or loss and reflected in an allowance account. When the Company considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, then the previously recognised impairment loss is reversed through profit or loss.

The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the "cash-generating unit").

ix. Employee benefits

a) Gratuity & Provident Fund:

The Company's liability towards retirement benefits in the form of gratuity is provided in accordance with the payment of Gratuity Act, 1972 to all the employees other than the whole time Directors which is made on the basis of actuarial valuation.

b) The Company's contribution to the provident fund is remitted to Government based on the percentage of the eligible employees' salary as per Provident Fund act.

c) Accrued Leave Salary:

Liability towards Accrued Leave Salary, as at the end of the year is recognized on the basis of valuation made on basic salary. The balance PL's earned by every employee in the previous year, a maximum of 8 days will be paid out during the month of January. These 8 days will be paid as per the last drawn basic salary and taxes will be applicable as per law

x. Provisions

All the provision are recognized as per Ind AS 37. Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation.

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset, if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Provisions for onerous contracts are recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable costs of meeting the future obligations under the contract. Provisions for onerous contracts are measured at the present value of lower of the expected net cost of fulfilling the contract and the expected cost of terminating the contract.

xi. Revenue recognition:

Revenue is recognised when the significant risks and rewards of ownership have been transferred to the customer, recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, there is no continuing management involvement with the goods, and the amount of revenue can be measured reliably. Revenue is measured net of returns, trade discounts and volume rebates. The timing of the transfer of risks and rewards varies depending on the individual terms of the sales agreement. Revenue is recognized only when there is no significant uncertainty as to the measurability / collectability of the amounts.

Jeevan Scientific Technology Limited

Export Services:

Revenue from Export services are recognized on the date of Invoicing and is accounted for at the exchange rate prevailing at the time of sale or service. Gain/Loss arising out of variances in the exchange rates is recognized as income / expenditure of the year.

- a) **Domestic Services:** Domestic services are accounted on the date of Invoicing on recognized as per the terms of agreement on the basis of work completion stage.
- b) **Obsolete Stores & Scrap:** Income is accounted on realization basis in respect of used / surplus / obsolete / unserviceable materials / waste products and scrap.

xii. Finance income and expense

Finance income consists of interest income on funds invested, dividend income and gains on the disposal of Fair value through profit and loss account financial assets. Interest income is recognized as it accrues in the statement of profit and loss, using the effective interest method.

Dividend income is recognized in the statement of profit and loss on the date that the Company's right to receive payment is established.

Finance expenses consist of interest expense on loans and borrowings. Borrowing costs are recognized in the statement of profit and loss using the effective interest method.

Foreign currency gains and losses are reported on a net basis. This includes changes in the fair value of foreign exchange derivative instruments, which are accounted at fair value through profit or loss.

xiii. Income tax

Income tax comprises current and deferred tax. Income tax expense is recognized in the statement of profit and loss except to the extent it relates to items directly recognized in equity or in other comprehensive income.

a) Current income tax

Current income tax for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities based on the taxable income for the period. The tax rates and tax laws used to compute the current tax amount are those that are enacted or substantively enacted by the reporting date and applicable for the period. The Company offsets current tax assets and current tax liabilities, where it has a legally enforceable right to set off the recognized amounts and where it intends either to settle on a net basis or to realize the asset and liability simultaneously.

b) MAT credit

Minimum Alternate Tax (MAT) credit is recognized as an asset only when and to the extent there is convincing evidence that the Company will pay normal income tax during the specified period. In the year in which the MAT credit becomes eligible to be recognized as an asset, in accordance with the provisions contained in the Guidance Note on Accounting for Credit Available under Minimum Alternative Tax, issued by

Twentieth Annual Report 2017-2018

the ICAI, the said asset is created by way of a credit to the Profit and Loss account and shown as "MAT Credit Entitlement". The Company reviews the same at each Balance Sheet date and writes down the carrying amount of MAT Credit Entitlement to the extent there is no longer convincing evidence to the effect that the Company will pay normal income tax during the specified period.

c) Deferred income tax

Deferred income tax is recognized using the balance sheet approach. Deferred income tax assets and liabilities are recognized for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount in financial statements, except when the deferred income tax arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profits or loss at the time of the transaction. Deferred income tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized. Deferred income tax liabilities are recognized for all taxable temporary differences. The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized. Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

xiv. Foreign currency transaction

i. Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

ii. Conversion

Foreign currency monetary items denominated in foreign currencies at the yearend are restated at year end rates. In case of monetary items which are covered by foreign exchange contracts, the difference between the original entry dates to forward contract date is recognized as an exchange difference.

iii. Exchange differences

Exchange differences arising on the settlement of monetary items, or on reporting such monetary items of company at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognized as income or as expenses in the year in which they arise.

Jeevan Scientific Technology Limited

iv. Foreign currency Transactions.

(in lakhs)

Particulars	Current Year	Previous Year
Earnings in Foreign exchange	497.08	263.61
Expenditure in Foreign exchange	NIL	NIL

xv. Earnings per share

Basic earnings per share is computed using the weighted average number of equity shares outstanding during the year.

Diluted EPS is computed by dividing the net profit after tax by the weighted average number of equity shares considered for deriving basic EPS and also weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the year, unless issued at a later date. Dilutive potential equity shares are determined independently for each year presented. The number of equity shares and potentially dilutive equity shares are adjusted for bonus shares, as appropriate.

xvi. Borrowing costs

Borrowings costs directly attributable to acquisition or construction of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which it occurs. Borrowing costs consist of interest and other costs that the entity incurs in connection with the borrowing of funds.

xvii. Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence of non-occurrence of one or more uncertain future events beyond the control of the company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The company does not recognize a contingent liability but discloses its existence in the financial statements.

The contingent liability is Rs. 4.13 Lakhs during the financial year.

10. Property, Plant and Equipment

(in Rupees)

S. No.		GROSS BLOCK				DEPRECIATION				NET BLOCK					
		As at 01.04.2016	Additions	Deletions	As at 31.03.2017	As at 01.04.2016	Additions	Deletions	As at 31.03.2017	For the year 31.03.2017	Up to 31.03.2017	Up to 31.03.2018	As at 31.03.2018	As at 31.03.2017	As at 31.03.2016
1	LEASE HOLD BUILDINGS	8,165,864	-	-	8,165,864	6,551,976	-	-	806,940	7,358,916	8,165,864	8,165,864	-	806,948	1,613,888
2	PLANT & MACHINERY	8,165,864	-	-	8,165,864	6,551,976	-	-	806,940	7,358,916	8,165,864	8,165,864	-	806,948	1,613,888
	a. Electrical Installations	10,312,302	7,556,285	-	17,868,587	1,632,104	-	-	1,011,773	2,643,877	2,643,877	2,643,877	-	1,619,085	8,680,198
	b. Airconditioners	1,194,942	-	-	1,194,942	810,322	-	-	56,760	867,082	923,842	923,842	-	56,760	384,620
	c. I.P.S. Systems	1,048,582	-	-	1,048,582	782,802	-	-	49,808	852,610	166,764	166,764	-	49,808	265,780
	d. Inverter	275,203	-	-	275,203	162,554	-	-	13,072	175,626	112,649	112,649	-	13,072	86,505
		12,831,029	7,556,285	-	20,387,314	3,387,782	-	-	1,131,413	4,519,195	6,257,920	6,257,920	-	1,738,725	15,868,119
3	COMPUTERS	12,578,867	3,463,955	-	16,042,822	2,075,779	-	-	1,388,717	9,394,283	11,674,617	11,674,617	-	2,280,334	6,648,539
	a. Computers	12,578,867	3,463,955	-	16,042,822	2,075,779	-	-	1,388,717	9,394,283	11,674,617	11,674,617	-	2,280,334	6,648,539
4	VEHICLES	4,463,910	2,107,565	0	6,571,475	4,202,964	49,170	-	552,942	2,380,080	3,223,983	3,223,983	-	843,903	7,550,456
	a. Motor Car	131,086	-	-	131,086	93,185	49,170	-	12,453	105,638	81,916	81,916	-	12,453	25,448
	b. Scooter	4,332,824	2,107,565	-	6,440,389	4,109,779	-	-	540,489	2,284,395	3,342,067	3,342,067	-	831,450	7,525,008
		4,594,996	2,107,565	-	6,702,561	4,202,964	49,170	-	565,395	2,485,718	3,305,899	3,305,899	-	856,356	7,550,456
5	FURNITURE & FIXTURES	16,842,306	11,704,970	-	28,547,276	1,037,682	-	-	1,574,571	7,499,042	10,076,026	10,076,026	-	2,576,984	19,508,932
	a. Furniture	988,151	-	-	988,151	988,151	-	-	988,151	988,151	988,151	988,151	-	988,151	10,917,835
	b. Fixtures	17,830,457	11,704,970	-	29,535,427	1,037,682	-	-	1,574,571	8,487,193	11,064,177	11,064,177	-	2,576,984	21,048,234
		826,026	489,833	-	1,315,859	366,360	-	-	82,516	418,483	624,595	624,595	-	206,112	897,376
	a. Office Equipments	53,643,983	9,769,036	-	63,413,019	85,879,213	-	-	5,303,956	7,843,319	18,274,839	18,274,839	-	10,431,520	55,569,700
	b. Laboratory Equipments	460,323	-	-	460,323	274,794	-	-	21,865	296,659	318,524	318,524	-	21,865	163,664
	c. E.P.A.B.X & Telephones	15,100	-	-	15,100	12,035	-	-	717	12,752	13,469	13,469	-	717	2,348
	d. Fax Machine	366,841	-	-	366,841	362,358	-	-	4,483	366,841	366,841	366,841	-	4,483	4,483
	e. Projector with LCD Panel	55,312,273	10,258,869	-	65,571,142	86,245,573	-	-	5,413,537	8,938,054	19,598,268	19,598,268	-	10,660,214	56,633,088
		89,983	-	-	89,983	77,786	-	-	4,274	82,060	86,334	86,334	-	4,274	7,923
	a. Books	89,983	-	-	89,983	77,786	-	-	4,274	82,060	86,334	86,334	-	4,274	7,923
		111,403,469	35,091,644	-	146,495,113	93,683,755	49,170	240,129,698	10,884,847	41,265,419	60,153,079	60,153,079	-	18,923,835	105,229,694
	Total:	34,974,781	77,542,150	1,113,462	111,403,469	35,091,644	-	-	6,221,749	30,380,572	41,265,419	41,265,419	-	10,884,847	81,022,897
	previous year														

II. Intangible Assets

(in Rupees)															
GROSS BLOCK						DEPRECIATION						NET BLOCK			
S. No.	Description	As at 01.04.2016	Additions	Deletions	As at 31.03.2017	As at 31.03.2018	Up to 01.04.2016	Deletions 31.03.2017	For the year 31.03.2017	Up to 31.03.2017	Deletions 31.03.2018	For the year 31.03.2018	Up to 31.03.2018	As at 31.03.2017	As at 31.03.2016
1	COMPUTERS Software	3,267,426	3,638,238	-	6,905,664	10,724,848	1,594,464	-	688,560	2,278,024	-	1,697,266	3,975,290	6,749,558	1,672,962
2	COPYRIGHTS	1,204,000	-	-	1,204,000	1,204,000	931,750	-	240,800	1,172,550	-	31,450	1,204,000	31,450	272,250
	Total:	4,471,426	3,638,238	-	8,109,664	11,928,848	2,526,214	-	924,360	3,450,574	-	1,728,716	5,179,290	6,749,558	1,945,212

III. Intangible Assets Process

(in Rupees)															
GROSS BLOCK						DEPRECIATION						NET BLOCK			
S. No.	Description	As at 01.04.2016	Additions	Deletions	As at 31.03.2017	As at 31.03.2018	Up to 01.04.2016	Deletions 31.03.2017	For the year 31.03.2017	Up to 31.03.2017	Deletions 31.03.2018	For the year 31.03.2018	Up to 31.03.2018	As at 31.03.2017	As at 31.03.2016
1	Process	3,042,333	25,369,526	-	28,411,859	55,262,747	-	-	-	-	-	4,058,837	4,058,837	28,411,859	3,042,333
	Total:	3,042,333	25,369,526	-	28,411,859	55,262,747	-	-	-	-	-	4,058,837	4,058,837	28,411,859	3,042,333
	previous year	2,961,261	4,552,498	-	7,513,759	29,007,764	2,033,627	-	492,586	2,526,214	-	924,360	3,450,574	4,987,545	927,634

Notes: An amount of Rs. 40,63,661/- has been transferred from depreciation to Process Knowhow since the assets are used to create process.

Twentieth Annual Report 2017-2018

Notes to financial statements for the year ended 31st March, 2018

3. Investments

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Enhops Solutions Inc.	269,070	269,070	269,070
Enhops Solutions Pvt Ltd	10,000,000	5,000,000	5,000,000
Total	10,269,070	5,269,070	5,269,070

4. Long term Loans

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
i) Loans to Subsidiaries	35,226,109	24,326,338	46,691.00
ii) Other Loans and advances	-	-	-
Total	35,226,109	24,326,338	46,691

5. Advances

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
i) Capital Advances	-	-	-
ii) Security Deposit	5,034,310	4,559,785	5,254,906
Total	5,034,310	4,559,785	5,254,906

6. Deferred Tax (Net)

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Deferred Tax Asset Opening	1,281,864	2,244,508	4,473,821
Add/Less: Deferred Tax liability	(2,440,861)	(962,644)	(2,229,313)
Total	(1,158,997)	1,281,864	2,244,508

7. Inventories

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Work in progress point of sale boxes	210,240	210,240	210,240
Consumables - R & D	779,346	4,531,437	532,332
Total	989,586	4,741,677	742,572

Jeevan Scientific Technology Limited

8. Trade receivables (Unsecured)

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Debtors outstanding for more than Six months- Considered good	79,539,482	14,355,549	5,720,444
Doubtful Debts	1,164,207	-	-
Other debts	81,699,158	96,713,639	66,543,659
	162,402,847	111,069,188	72,264,103
Less: Provision for doubtful Debts	1,164,207	-	-
Total	161,238,640	111,069,188	72,264,103

9. Cash and Cash Equivalents

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Cash and cash equivalents			
Balances with Banks in current accounts	337,273	172,347	98,918
Cash on hand	6,375,040	516,907	366,418
Total	6,712,313	689,254	465,336

10. Cash and Cash Equivalents

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Bank balances other than in fixed deposits more than 12 months	524,806	1,279,642	1,192,436
in fixed deposits Less than 12 months	6,492,015	-	-
Total	7,016,821	1,279,642	1,192,436

11. Loans (current)

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Loans	4,339,757	4,769,825	384,670
Total	4,339,757	4,769,825	384,670

Twentieth Annual Report 2017-2018

12. Other Financial Assets

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Interest Receivable	2,702,750	1,533,733	-
Total	2,702,750	1,533,733	-

13. Current Tax Assets (Net)

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Tax deducted at source	12,950,862	5,202,883	4,211,954
MAT Credit	6,928,976	5,943,376	3,454,768
Total	19,879,838	11,146,259	7,666,722

14. Other Current Assets

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
VAT input Credit	-	49,637	49,637
Prepaid Expenses	1,373,014	822,386	568,654
Hero Finance corporation	234,904	-	-
Service Tax Input Credit	-	-	1,535,220
Total	1,607,918	872,023	2,153,511

Jeevan Scientific Technology Limited

STATEMENT OF CHANGES IN EQUITY

Jeevan Scientific Technology Limited

Statement of changes in Equity for the Period ended 31st March 2018

(in Rupees)

A. Equity Share Capital	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Authorised 2,10,00,000 equity Shares of Rs.10/- each	210,000,000	210,000,000	99,900,000
Issued, subscribed and paid- up 1,14,59,465 (31st March 2018:1,14,59,465) equity Shares of Rs. 10/- each fully paid-up	114,594,650	92,794,650	60,416,000

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Issued, subscribed and paid- up			
Opening Balance	92,794,650	60,416,000	60,416,000
Add : issue of shares during the year	21,800,000	32,378,650	-
Total	114,594,650	92,794,650	60,416,000

The details of shares in the company held by each shareholder holding more than 5% shares :

Name of the Share Holder	As at 31.03.2018		As at 31.03.2017		As at 01.04.2016	
	No. of Shares	% of Share Holding	No. of Shares	% of Share Holding	No. of Shares	% of Share Holding
Sri K. Krishna Kishore	1,774,391	15.48%	1,324,391	14.28%	993,391	16.44%
Smt. K. Vanaja	1,257,800	10.98%	857,800	9.24%	373,800	6.19%
Sri. T. Chalapathi Rao	-	-	-	-	384,700	6.37%
Smt. Niramala Desaiiah Durisala	-	-	-	-	480,000	7.94%
Dr. Desaiiah Durisala	830,000	7.24%	830,000	8.94%	-	-

Twentieth Annual Report 2017-2018

B. Other Equity

Particulars	Share application money on pending allotment	Equity component of financial instruments	Reserves and Surplus				Debt instruments through other comprehensive income	Equity instruments through other comprehensive income	Effective portion of cash flow Hedges	Revaluation Surplus	Exchange differences on translating the financial statements of foreign operations	Other items of other comprehensive income	Money received against share warrants	Total
			Capital Reserve	Securities premium reserve	Other reserves	Retained Earnings								
Balance at the beginning of the reporting period i.e. 1st April 2016	-	-	-	-	(18,450,629)	-	-	-	-	-	-	-	(18,450,629)	
Ind AS Adjustment	-	-	-	-	(22,055,109)	-	-	-	-	-	-	-	(22,055,109)	
Restated balance at the beginning of the reporting period	-	-	-	-	(40,505,738)	-	-	-	-	-	-	-	(40,505,738)	
Total comprehensive Income for the year	-	-	-	-	8,860,208	-	-	-	-	-	-	-	8,860,208	
Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	
Transfer to retained earnings	-	-	-	-	-	-	-	-	-	-	-	-	-	
Issued during the Year	-	-	-	-	65,566,766	-	-	-	-	-	-	47,604,502	113,171,268	
Balance at the end of the reporting period i.e. 31st March 2017	-	-	-	-	65,566,766	-	-	-	-	-	-	47,604,502	81,525,738	

Particulars	Share application money on pending allotment	Equity component of financial instruments	Reserves and Surplus				Debt instruments through other comprehensive income	Equity instruments through other comprehensive income	Effective portion of cash flow Hedges	Revaluation Surplus	Exchange differences on translating the financial statements of foreign operations	Other items of other comprehensive income	Money received against share warrants	Total
			Capital Reserve	Securities premium reserve	Other reserves	Retained Earnings								
Balance at the beginning of the reporting period i.e. 1st April 2017	-	-	-	-	(31,645,530)	-	-	-	-	-	-	-	47,604,502	81,525,738
Changes in accounting policy or prior period errors	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restated balance at the beginning of the reporting period	-	-	-	-	(31,645,530)	-	-	-	-	-	-	-	47,604,502	81,525,738
Total comprehensive Income for the year	-	-	-	-	3,053,827	-	-	-	-	-	-	-	-	3,053,827
Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transfer to retained earnings	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issued during the Year	-	-	-	-	44,145,000	-	-	-	-	-	-	-	(16,277,796)	27,867,204
Balance at the end of the reporting period i.e. 31st March, 2018	-	-	-	-	109,711,766	-	-	-	-	-	-	-	31,326,706	112,446,768

Jeevan Scientific Technology Limited

15. Long term borrowings

(in Rupees)

Particulars	Non-Current Portion			Current Portion		
	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Term Loan- secured						
A) From Banks						
i) Car Loans- Hypothecation against the Cars	2,748,553	646,036	13,540	1,497,467	621,238	641,436
ii) Machinery loans	71,699,117	38,829,129	27,316,375	17,568,540	11,807,578	2,483,307
B) Intercorporate Loans	9,000,000	8,000,000	5,000,000	-	-	-
C) Loans and advances from related parties	14,925,165	-	50,863,889	-	-	-
Total	98,372,835	47,475,165	83,193,804	19,066,007	12,428,816	3,124,743

16. Long Term Provisions

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Gratuity Payable	968,587	746,915	271,264
Total	968,587	746,915	271,264

17. Short Term Borrowings

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Loan repayable on Demand			
i) Loan From Banks (Guaranteed by Director)	70,414,014	24,621,966	24,479,407
Total	70,414,014	24,621,966	24,479,407

18. Trade Payables

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Trade payables (for services received)	20,562,838	22,436,046	33,347,137
Total	20,562,838	22,436,046	33,347,137

There are no dues to Micro Small and Medium Enterprises as defined under the MSMED Act, 2006

Twentieth Annual Report 2017-2018

19. Other Financial liabilities

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Current maturities of Long term borrowings	19,066,007	12,428,816	3,124,743
Interest Payable	2,605,961	-	1,513,617
Rent Payable	4,167,798	3,141,358	855,000
Total	25,839,766	15,570,174	5,493,360

20. Other Financial Creditors

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Creditors for Capital Assets	25,545,192	4,586,303	831,188
Total	25,545,192	4,586,303	831,188

21. Other Current Liabilities

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
TDS Payable	3,780,619	3,125,002	1,370,497
Professional tax payable	16,550	21,050	7,250
Service tax payable	-	3,409,956	1,255,133
GST Payable	8,875,848	-	-
Provident Fund payable	261,746	442,980	80,067
ESI payable	87,025	83,720	11,869
Salaries payable	4,051,351	2,660,079	1,690,799
Directors Remuneration Payable	643,402	1,961,958	381,233
Provision for expenses	1,340,872	2,135,635	1,618,942
Advance received from Customers	3,731,250	3,731,250	8,500,000
Other Payables	29,391	22,106	28,798
Total	22,818,054	17,593,736	14,944,588

22. Short Term Provisions

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Leave Encashment Payable	93,318	-	-
Bonus Payable	116,975	-	-
Gratuity Payable	15,205	-	-
Provision for tax	-	2,488,608	1,223,957
Total	225,498	2,488,608	1,223,957

Jeevan Scientific Technology Limited

23. Revenue from operations

(in Rupees)

Particulars	For the Year 2017-2018	For the Year 2016-2017	For the Year 2015-2016
IT Consultancy Service Charges - Export	-	11,862,500	37,800,588
Clinical Research Services- Domestic	123,017,832	20,210,673	5,522,994
Clinical Research Services- Export	49,707,896	14,498,436	4,128,735
Data Management service charges	19,917,661	128,033,637	125,916,418
Total	192,643,389	174,605,246	173,368,735

24. Other non operating income

(in Rupees)

Particulars	For the Year 2017-2018	For the Year 2016-2017	For the Year 2015-2016
Interest on Income Tax Refund	166,222	80,453	2,984
Interest Received from Others	5,010,019	1,801,045	-
Interest Received from Banks	63,188	-	-
Miscellaneous Income	208,402	134,651	670,125
Exchange Variance Profit	-	83,486	2,438,755
Rent Received	3,600,000	3,600,000	900,000
Excess Gratuity Provision	-	-	20,451
Total	9,047,831	5,699,635	4,032,315

25. Cost of Material Consumed

(in Rupees)

Particulars	For the Year 2017-2018	For the Year 2016-2017	For the Year 2015-2016
Hardware			
Opening Stock	210,240	210,240	210,240
Purchases: Components & Software	-	-	-
	210,240	210,240	210,240
Less: Closing Stock	210,240	210,240	210,240
Total (A)	-	-	-
Consumables - R & D			
Opening Stock	4,531,437	532,332	384,755.00
Purchases: Consumables	13,473,286	5,584,252	3,189,910
	18,004,723	6,116,584	3,574,665
Less: Closing Stock	779,346	4,531,437	532,332
Less: Transfer to Process	4,237,945	-	1,532,500
Total (B)	12,987,432	1,585,147	1,509,833
Total (A+B)	12,987,432	1,585,147	1,509,833

Twentieth Annual Report 2017-2018

26. Employees benefit expenses

(in Rupees)

Particulars	For the Year 2017-2018	For the Year 2016-2017	For the Year 2015-2016
Salaries & Allowances	39,358,312	14,751,583	24,170,670
Contribution to Provident Fund&Others	1,785,231	680,859	520,629
Welfare Expenses	1,889,413	609,066	428,609
Gratuity	559,746	269,390	14,001
Bonus	116,975	-	-
Leave encashment	93,318	-	-
Director's Remuneration	6,048,997	2,116,666	7,358,327
Total	49,851,992	18,427,564	32,492,236

27. Finance Cost

(in Rupees)

Particulars	For the Year 2017-2018	For the Year 2016-2017	For the Year 2015-2016
Bank charges	151,677	161,214	222,486
Loan Processing Charges	1,120,090	620,775	767,887
FLC Charges	84,840	-	-
Interest expense			
on Vehicle Loans	166,041	110,204	97,991
on Bank Overdraft	3,588,051	3,631,174	3,170,071
on Term loan from Bank	7,312,323	4,529,220	2,412,165
on Customduty	40,124	-	-
on Unsecured Loans	4,167,897	4,582,850	6,088,426
Total	16,631,043	13,635,437	12,759,026

28. Other expenses

(in Rupees)

Particulars	For the Year 2017-2018	For the Year 2016-2017	For the Year 2015-2016
Rent	8,961,140	7,013,609	7,084,050
Electricity	4,691,596	3,370,755	2,941,762
Repairs & Maintenance	2,031,716	900,064	763,331
Insurance	950,218	829,608	460,255
Rates & Taxes	1,559,354	226,283	151,903
Communication Charges	2,144,274	907,759	672,213
Travelling, Conveyance	1,383,867	891,578	1,785,354
Printing & Stationery	1,447,775	605,751	373,956

Jeevan Scientific Technology Limited

Particulars	For the Year 2017-2018	For the Year 2016-2017	For the Year 2015-2016
Advertisement ,Publicity & Business Promotion	722,611	197,696	564,297
Professional Charges	11,861,294	3,478,969	3,838,763
Audit Fee: As Auditors	70,000	50,000	50,000
: For Certification	68,607	65,375	44,013
General Expenses	2,611,331	1,505,560	669,272
Office Maintenance	5,450,111	2,547,812	1,746,132
Security Service	-	283,399	577,205
Director's Sitting fees	337,000	440,500	190,000
Registrar's expenses	169,992	75,566	70,048
Web Designing Charges	8,626	8,626	64,410
Garden Maintenance	73,385	78,700	83,000
Conference Fee	17,250	-	233,683
BSE Listing Fee	287,500	201,000	200,000
ROC Filing Fee	37,200	1,040,272	-
PF Late Filing Fee	21,882	-	-
ESI Late Filing Fee	8,135	-	-
Service Tax Late Filing Fee	59,300	-	-
Service Tax Paid	144,794	-	-
TDS interest & late filing fee	-	1,128,870	-
Volunteer Expenses	9,824,582	567,765	-
Volunteer Study Payments	21,762,754	-	-
Provision for Doubtful debts	1,164,207	21,063	-
Deposits Written Off	8,400	-	-
VAT Input Credit Written Off	49,637	-	-
Foreign Exchange Variance Loss	177,474	269,431	-
Water Bill Paid	152,192	-	-
Loss on Sale of Assets	3,995	-	278,285
Data Management Service Charges	18,461,300	96,858,393	94,660,403
Total	96,723,499	123,564,404	117,502,335

Twentieth Annual Report 2017-2018

Note-29: OTHER DISCLOSURES:

i. Gratuity:

The Company has conducted Actuarial valuation of its Gratuity as on 31st Mar 2018.

Accounting Disclosures Statement

GRATUITY

Period of accounting

1-Apr-17 to 31-Mar-18

(all figures in Indian Rupees)

Valuation Results as at

31-Mar-17

31-Mar-18

I Changes in present value of obligations

PVO at beginning of period	271,264	746,915
Interest cost	20,236	49,969
Current Service Cost	249,154	509,777
Past Service Cost- (non vested benefits)	-	-
Past Service Cost -(vested benefits)	-	-
Benefits Paid	-	-
Contributions by plan participants	-	-
Business Combinations	-	-
Curtailments	-	-
Settlements	-	-
Actuarial (Gain)/Loss on obligation	206,261	(322,869)
PVO at end of period	746,915	983,792

II Interest Expenses

Interest cost	20,236	49,969
---------------	--------	--------

III Fair Value of Plan Assets

Fair Value of Plan Assets at the beginning	-	-
Interest Income	-	-

IV Net Liability

PVO at beginning of period	271,264	746,915
Fair Value of the Assets at beginning report	-	-
Net Liability	271,264	746,915

V Net Interest

Interest Expenses	20,236	49,969
Interest Income	-	-
Net Interest	20,236	49,969

Jeevan Scientific Technology Limited

VI	Actual return on plan assets	-	-
	Less Interest income included above	-	-
	Return on plan assets excluding interest income	-	-
VII	Actuarial (Gain)/loss on obligation		
	Due to Demographic Assumption*	-	-
	Due to Financial Assumption	74,168	(144,417)
	Due to Experience	132,093	(178,452)
	Total Actuarial (Gain)/Loss	206,261	(322,869)
	*This figure does not reflect interrelationship between demographic assumption and financial assumption when a limit is applied on the benefit, the effect will be shown as an experience		
VIII	Fair Value of Plan Assets		
	Opening Fair Value of Plan Asset	-	-
	Adjustment to Opening Fair Value of Plan Asset	-	-
	Return on Plan Assets excl. interest income	-	-
	Interest Income	-	-
	Contributions by Employer	-	-
	Contributions by Employee	-	-
	Benefits Paid	-	-
	Fair Value of Plan Assets at end	-	-
IX	<u>Past Service Cost Recognised</u>		
	Past Service Cost- (non vested benefits)	-	-
	Past Service Cost -(vested benefits)	-	-
	Average remaining future service till vesting of the benefit	-	-
	Recognised Past service Cost- non vested benefits	-	-
	Recognised Past service Cost- vested benefits	-	-
	Unrecognised Past Service Cost- non vested benefits	-	-
X	<u>Amounts to be recognized in the balance sheet and statement of profit & loss account</u>		
	PVO at end of period	746,915	983,792
	Fair Value of Plan Assets at end of period	-	-
	Funded Status	(746,915)	(983,792)
	Net Asset/(Liability) recognized in the balance sheet	(746,915)	(983,792)
XI	Expense recognized in the statement of P & L A/C		
	Current Service Cost	249,154	509,777
	Net Interest	20,236	49,969

Twentieth Annual Report 2017-2018

Past Service Cost- (non vested benefits)	-	-
Past Service Cost -(vested benefits)	-	-
Curtailment Effect	-	-
Settlement Effect	-	-
Unrecognized Past Service Cost- non vested benefits	-	-
Expense recognized in the statement of P & L A/C	269,390	559,746
XII Other Comprehensive Income (OCI)		
Actuarial (Gain)/Loss recognized for the period	206,261	(322,869)
Asset limit effect	-	-
Return on Plan Assets excluding net interest	-	-
Unrecognized Actuarial (Gain)/Loss from previous period	-	-
Total Actuarial (Gain)/Loss recognized in (OCI)	206,261	(322,869)
XIII Movements in the Liability recognized in Balance Sheet		
Opening Net Liability	271,264	746,915
Adjustment to opening balance	-	-
Expenses as above	269,390	559,746
Contribution paid	-	-
Other Comprehensive Income(OCI)	206,261	(322,869)
Closing Net Liability	746,915	983,792
XIV Schedule III of The Companies Act 2013		
Current Liability	12,263	15,205
Non-Current Liability	734,652	968,587
XV Projected Service Cost 31 Mar 2019		641,174
Unrecognised Past Service Cost- non vested benefits		
Average remaining future service till vesting of the benefit		
XVI Asset Information	Total	Target Allocation
	Amount	%
Cash and Cash Equivalents		
Gratuity Fund ()	-	0%
Debt Security - Government Bond		
Equity Securities - Corporate debt securities		
Other Insurance contracts		
Property		
Total Itemized Assets	-	0%

Jeevan Scientific Technology Limited

Annexure 'A'

XVII Assumptions as at	31-Mar-17	31-Mar-18
Mortality	IALM (2006-08) Ult.	IALM (2006-08) Ult.
Interest / Discount Rate	6.69%	7.74%
Rate of increase in compensation	4.00%	4.00%
Annual increase in healthcare costs		
Future Changes in maximum state healthcare benefits		
Expected average remaining service	16.58	16.77
Employee Attrition Rate(Past Service (PS))	PS: 0 to 40 : 3%	PS: 0 to 40 : 3%

Note-30: Segment Reporting as per Ind-AS-108

A. Basis for segmentation

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses and for which discrete financial information is available. All operating segments' operating results are reviewed regularly by the Board of Directors to make decisions about resources to be allocated to the segments and assess their performance.

The Company has two reportable segments, (Previous Year three reportable segments) as described below, which are the company's strategic business units. These business units offer different services, and are managed separately because they require different technology and marketing strategies. For each of the business units, the company's Board reviews internal management reports on a periodic basis.

The following summary describes the operations in each of the Company's reportable segments:

B. Information about reportable segments

Information regarding the results of each reportable segment is included below. Performance is measured based on segment profit (before tax), segment revenue and segment capital employed as included in the internal management reports that are reviewed by the board of directors. Segment profit is used to measure performance as management believes that such information is the most relevant in evaluating the results of certain segments relative to other entities that operate within these industries.

Twentieth Annual Report 2017-2018

Reportable Segments

Segment Reporting as on 31-03-2018

Rs. In Lakhs

Particulars	Clinical Research Services	Data Management Services	Information Technology Services	Unallocated	Total
Revenue from External Customers	1727.25	199.18	-	90.48	2016.91
Segment Result	104.93	5.66	-	(62.10)	48.49
Assets	4105.22	555.87	-	268.38	4929.47
Liabilities	2588.95	-	-	2340.52	4929.47
Depreciation and Amortization	182.05	-	-	24.42	206.47
Capital Expenditure during the year	1243.54	-	-	-	1243.54

Segment Reporting as on 31-03-2017

Rs. In Lakhs

Particulars	Clinical Research Services	Data Management Services	Information Technology Services	Unallocated	Total
Revenue from External Customers	347.09	1,280.34	118.63	56.99	1,803.05
Segment Result	(126.23)	258.56	70.32	(91.88)	110.77
Assets	1564.53	1,085.40	256.93	424.62	3,331.48
Liabilities	1181.27	133.65	-	2016.56	3,331.48
Depreciation and Amortization	67.23	11.80	11.80	27.26	118.09
Capital Expenditure during the year	640.99	-	-	-	640.99

Jeevan Scientific Technology Limited

Note-31: Related parties

a. Key management personnel

Name of the personnel	Nature of relationship
K Krishna Kishore	Vice chairman & Managing Director
M Rajendra Prasad	Executive Director & CEO
K Vanaja	Non-Executive Director
S S R Koteswara Rao	Independent Director- Chairman
T Ravi Babu	Independent Director
G Bhanu Prakash	Independent Director
K Rama Krishna Prasad	Independent Director
B. Raghav*	Non-Executive Director
A Vijay Kumar**	Independent Director
G. Krishna Sowjanya***	Company secretary

* Resigned w.e.f 11-10-2017

** Resigned w.e.f 01-04-2018

*** Resigned w.e.f 28-04-2018

Name of the entity	Nature of relationship
Jeevana Mitra Finance Corporation	Enterprise owned by Key managerial person
Enhops Solutions Pvt Ltd	Wholly owned subsidiary
Enhops Inc, USA	Wholly owned subsidiary

(Amount in Rs.)

Particulars	As at March 31, 2018	As at March 31, 2017
Rent Paid		
a) Jeevana Mitra Finance corporation	8,40,000	8,40,000
b) K Krishna Kishore	4,80,000	4,80,000
c) K Vanaja	4,80,000	4,80,000
Long term Borrowings		
a) K Krishna Kishore	10,79,08,000	3,03,60,000
b) K Vanaja	1,80,76,000	2,74,15,000
c) M Rajendra Prasad	4,70,000	-
d) K Rama Krishna Prasad	45,37,500	67,00,000

Twentieth Annual Report 2017-2018

Interest paid on short term borrowings

a) K Krishna Kishore	32,96,330	28,32,852
b) K Vanaja	3,41,198	19,43,088
c) M Rajendra Prasad	7,315	4,30,107
d) K Gopi Krishna	-	12,097

Remuneration Paid

a) K Krishna Kishore	36,00,000	26,12,903
b) K Gopi Krishna	-	13,43,548
c) M Rajendra Prasad	30,99,996	30,99,996

Loans and Advances given

Enhops Solutions Pvt Ltd	3,93,07,611	3,08,26,058
--------------------------	-------------	-------------

d. The Company has the following amounts due from / to related parties:

(i) Due to related parties.

(Amount in Rs.)

Particulars	As at March 31, 2018	As at March 31, 2017
Long term Borrowings		
a) K Krishna Kishore	1,34,74,165	-
b) K Vanaja	14,51,000	-

(ii) Due from related parties.

(Amount in Rs.)

Particulars	As at March 31, 2018	As at March 31, 2017
Long term advances		
Enhops Solutions Pvt Ltd	3,52,26,109	2,43,26,338

Note No. 32: Earnings per share (IND AS-33): The details are as under:

(Amount in Rs.)

Particulars	As at March 31, 2018	As at March 31, 2017
1. Profit after Tax (Rs)	30,53,827	88,60,208
2. No of Equity shares	1,14,59,465	92,79,465
3. Nominal value per Equity share (Rs.)	10	10
4. Basic Earnings per share (Rs.)	0.27	0.95
5. Weighted Average No of Equity Shares	94,34,753	66,58,133
6. Diluted Earnings per share (Rs.)	0.32	1.33

Jeevan Scientific Technology Limited

Note No. 33 Accounting for Deferred Taxes on income (INDAS-12):

Necessary details have been disclosed in note no: 6.

Note No. 34

General:

- i. Expenses are accounted under prepaid expenses only where the amounts relating to unexpired period are material.
- ii. Some of the balances appearing under Trade receivables, Trade payables, advances, Security deposits and other payables are subject to confirmations.
- iii. Figures for the previous year have been regrouped/rearranged wherever considered necessary so as to confirm to the classification of the current year.

34.1 First Time Adoption of Ind AS

Explanation of Transition to Ind AS

These are the Company's first standalone financial statements prepared in accordance with Ind AS. The accounting policies set out in Note 1 have been applied in preparing the financial statements for the year ended 31 March 2018, the comparative information presented in these financial statements for the year ended 31 March 2017 and in the preparation of the opening Ind AS balance sheet as at 1 April 2016 (the Company's date of transition). In preparing its opening Ind AS balance sheet, the Company has adjusted amounts reported previously in financial statements prepared in accordance with the accounting standards notified under Companies (Accounting Standards) Rules, 2006 (as amended) and other relevant provisions of the Act (Indian GAAP or previous GAAP). An explanation of how the transition from previous GAAP to Ind AS has affected the Company's Balance Sheet, Statement of Profit and Loss and Statement of Cash Flows is set out in the following tables and the notes that accompany the tables.

A. Exemptions and exceptions availed

Set out below are the applicable Ind AS 101 optional exemptions and mandatory exceptions applied in the transition from previous GAAP to Ind AS.

A.1 Ind AS optional exemptions

A.1.1 Deemed Cost

Ind AS 101 permits a first-time adopter to continue with the carrying value for all its property, plant and equipment as recognised in the financial statements as at the date of transition to Ind AS, measured as per the previous GAAP and use that as its deemed cost as at the date of transition after making the necessary adjustments for the de-commissioning liabilities. This exemption can also be used for intangible assets covered by the Ind AS 38 intangible assets and investments in subsidiaries, associates and joint ventures. Accordingly, the Company has elected to measure all of its property, plant and equipment, intangible assets and investments in subsidiaries and associates at their previous GAAP carrying value.

A.1.2 Decommissioning liabilities included in the cost of property, plant and equipment

Appendix 'A' to Ind AS 16 Changes in Existing Decommissioning, Restoration and Similar Liabilities requires specified changes in a decommissioning, restoration or similar liability to be added to or deducted from the cost of the asset to which it relates; the adjusted depreciable

amount of the asset is then depreciated prospectively over its remaining useful life. A first-time adopter need not comply with these requirements for changes in such liabilities that occurred before the date of transition to Ind AS. In other words, a first-time adopter will not need to estimate what provision would have been calculated at earlier reporting dates. Instead, the decommissioning liability is calculated at the date of transition and it is assumed that the same liability (adjusted only for the time value of money) existed when the asset was first acquired/constructed.

A.2 Ind AS mandatory exemptions

A.2.1 Estimates

An entity's estimates in accordance with Ind AS' at the date of transition to Ind AS shall be consistent with the estimates made for the same date in accordance with the previous GAAP (after adjustments to reflect any difference in accounting policies) unless there is an objective evidence that those estimates were in error.

"Ind AS estimates as at 1 April 2016 are consistent with the estimates as at the same date made in conformity with the previous GAAP. The Company made estimates for the following items in accordance with Ind AS at the date of transition as there were not required under previous GAAP. Impairment of financial assets (Trade Receivables) based on the expected credit loss model.

A.2.2 Classification and measurement of financial assets (other than equity instruments)

Ind AS 101 requires an entity to assess classification and measurement of financial assets on the basis of the facts and circumstances that exists at the date of transition to Ind AS.

A.2.3 De-recognition of financial assets and financial liabilities

Ind AS 101 requires a first time adopter to apply the de-recognition provisions for Ind AS 109 prospectively for transactions occurring on or after the date of transition to Ind AS. However, Ind AS 101 allows first time adopter to apply the derecognition requirements provided that the information needed to apply Ind AS 109 to financial assets and financial liabilities derecognised as a result of past Ind AS 101 retrospectively from the date of entity's choosing, transactions was obtained at the time of initially accounting for the transactions.

The Company has elected to apply the de-recognition provisions of Ind AS 109 prospectively from the date of transition to Ind-AS.

Jeevan Scientific Technology Limited

B. Reconciliation between previous GAAP and Ind AS

B.1 The following tables represent the reconciliations from previous GAAP to Ind AS.

Particulars	Ast at 31.03.2017 Previous GAAP	Effect of Transition to Ind AS	As at 31.03.2017 As Per INDAS	As at 01.04.2016 Previous GAAP	Effect of Transition to Ind AS	As at 01.04.2016 as per INDAS
Assets						
(1)Non-current Assets						
a) Property, Plant and Equipment	1,052.30	-	1,052.30	810.23	-	810.23
b) Other Intangible Assets	46.59	-	46.59	19.45	-	19.45
c) Intangible Assets Process	284.12	-	284.12	30.42	-	30.42
d) Financial Assets						
i)Investments	52.69	-	52.69	52.69	-	52.69
ii)Loans	243.26	-	243.26	0.47	-	0.47
iii) Advances	58.14	12.54	45.60	52.55	-	52.55
c) Deferred tax asset (net)	12.82	-	12.82	22.45	-	22.45
(2)Current Assets						
a) Inventories	267.97	220.55	47.42	227.98	220.55	7.43
b) Financial Assets						
i) Trade receivables	1,110.69	-	1,110.69	722.64	-	722.64
ii) Cash and cash equivalents	6.89	-	6.89	4.65	-	4.65
iii)Bank balances other than (ii) above	12.80	-	12.80	11.92	-	11.92
iv)Loans	47.70	-	47.70	3.85	-	3.85
v)Other Financial Assets	15.33	-	15.33	-	-	-
c) Current Tax Assets (Net)	111.46	-	111.46	76.67	-	76.67
d) Other Current Assets	8.72	-	8.72	21.53	-	21.53
Total	3,331.48	233.09	3,098.39	2,057.50	220.55	1,836.95
Equity and Liabilities						
Equity						
a) Equity Share Capital	927.95	-	927.95	604.16	-	604.16
b) Other Equity	1,048.35	233.09	815.26	-184.51	220.55	-405.06
Liabilities						
(1)Non-current Liabilities						
a) Financial liabilities						
Borrowings	474.75	-	474.75	831.94	-	831.94
b) Provisions	7.47	-	7.47	2.71	-	2.71
c) Deferred tax Liability (net)	-	-	-	-	-	-
(2)Current Liabilities						
a)Financial Liabilities						
i) Borrowings	246.22	-	246.22	244.80	-	244.80
ii) Trade Payables	224.36	-	224.36	333.47	-	333.47
iii) Other Financial liabilities	155.70	-	155.70	54.93	-	54.93
iv) Other Financial Creditors	45.86	-	45.86	8.31	-	8.31
b) Other current liabilities	175.94	-	175.94	149.45	-	149.45
c) Provisions	24.88	-	24.88	12.24	-	12.24
Total	3,331.48	233.09	3,098.39	2,057.50	220.55	1,836.95

Twentieth Annual Report 2017-2018

B.2 Reconciliation of Profit and Reserve between Ind As and previous Indian Gaap for earlier period and as at march 31, 2017

(Rs.in Lakhs)

Sr. No.	Nature of adjustments	Reserve reconciliation As at 31-Mar-17
	Net Profit/Reserves as per Previous Indian GAAP	1048.35
1	Fair valuation as deemed cost for property, plant and Equipment	-
2	Fair valuation for financial assets	(233.09)
3	Deferred Tax	-
4	Others	-
	Total	(233.09)
	Net profit before OCI / Reserves as per Ind AS	815.26

Per our report of even Date
for PAVULURI & Co.
 Chartered Accountants
 Firm Regn No: 012194S

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
CA Kanthi Sree Kolli
 Partner
 Membership No:224434

Sd/-
K.Krishna Kishore
 Vice Chairman & Managing Director
 DIN: 00876539

Sd/-
M. Rajendra Prasad
 Executive Director & CEO
 DIN: 06781058

Sd/-
G. Ravi Kumar
 Chief Financial Officer

Place : Hyderabad
 Date : 26.05.2018

Jeevan Scientific Technology Limited

INDEPENDENT AUDITOR'S REPORT

**To the members of,
M/s. JEEVAN SCIENTIFIC TECHNOLOGY LIMITED,
Report on the Consolidated Financial Statements:**

We have audited the accompanying consolidated financial statements of Jeevan Scientific Technology Limited ("the Holding Company"), and its subsidiaries (collectively referred to as "the Group") which comprise the Consolidated Balance Sheet as at March 31, 2018, the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), the Consolidated statement of changes in equity and the Consolidated statement of Cash Flows for the year ended 31st March, 2018 and a summary of significant accounting policies and other explanatory information. (hereinafter referred to as "the consolidated financial statements")

Management's Responsibility for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the preparation of these consolidated financial statements in terms of the requirements of the Companies Act, 2013 ("the Act") that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Indian Accounting Standards) Rules, 2015. The respective Board of Directors of the companies are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

Auditor's Responsibility

Our responsibility is to express an opinion on the consolidated financial statements based on our audit. While conducting the audit we have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk

Twentieth Annual Report 2017-2018

assessments, the auditor considers internal financial control relevant to the holding Company's preparation of the consolidated financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the holding Company's Board of Directors, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in sub-paragraph (a) of the other matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, Ind AS Consolidated Financial Statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including the Ind AS, of the state of affairs of the Company as at March 31, 2018, its financial performance including other comprehensive income, its cash flows and the statement of changes in equity for the year ended on that date.

Other Matters

- a) We did not audit the financial statements of 2 subsidiaries, Enhops Solutions Inc. and Enhops Solutions Pvt Ltd. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and our report in terms of sub-sections (3) and (11) of Section 143 of the Act, insofar as it relates to the aforesaid subsidiaries is based solely on the reports of the other auditors.

Report on Other Legal and Regulatory Requirements:

1. As required by section 143(3) of the Act, we further report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - b) In our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;
 - c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Consolidated Statement of Cash Flow dealt with by this Report are in agreement with the books of account.
 - d) In our opinion, the aforesaid Consolidated financial statements comply with the applicable Indian accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (I) Rules, 2014;
 - e) On the basis of written representations received from the directors as on March 31, 2018, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2018, from being appointed as a director in terms of

Jeevan Scientific Technology Limited

Section 164(2) of the Act;

- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us
 - i. The Company doesn't have pending litigations which will have an impact on its financial position in the Standalone financial statements.
 - ii. The Company did not have any long-term contracts including derivative contracts; as such the question of commenting on any material foreseeable losses thereon does not arise.
 - iii. There have been no occasions in case of the company during the year under report to transfer any sums to the Investor Education and Protection Fund.

For PAVULURI&Co.
Chartered Accountants
Firm Reg. No:012194S

Sd/-
(CA KANTHI SREE KOLLI)
PARTNER
M.No : 224434

Place : Hyderabad

Date : 26.05.2018

Twentieth Annual Report 2017-2018

“Annexure A” to the Independent Auditor’s Report of even date on the Consolidated Financial Statements of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED (“the Company”) as of March 31, 2018 in conjunction with our audit of the Consolidated financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on “the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India”. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness.

Jeevan Scientific Technology Limited

Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

Twentieth Annual Report 2017-2018

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2018, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For PAVULURI & Co.
Chartered Accountants
Firm Reg. No: 012194S

Sd/-
(CA KANTHI SREE KOLLI)
PARTNER
M.No : 224434

Place : Hyderabad
Date : 26.05.2018

Jeevan Scientific Technology Limited

Consolidated Balance Sheet as at 31st March, 2018

(In Rupees)

Particulars	Note No.	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Assets				
(1) Non-current Assets				
a) Property, Plant and Equipment	2	180,522,171	106,232,671	81,683,669
b) Other Intangible Assets	2	7,145,709	5,066,142	2,012,800
c) Intangible Assets Process	2	94,025,878	52,202,550	3,042,333
d) Financial Assets				
i) Investments	3	-	-	-
ii) Loans	4	-	-	-
iii) Advances	5	5,034,310	4,559,785	5,254,906
c) Deferred tax asset (net)	6	-	1,170,872	2,244,508
(2) Current Assets				
a) Inventories	7	989,587	4,741,677	742,572
b) Financial Assets				
i) Trade receivables	8	163,018,038	113,252,532	72,368,159
ii) Cash and cash equivalents	9	7,208,246	1,294,191	895,468
iii) Bank balances other than (ii) above	10	7,016,821	1,279,642	1,192,436
iv) Loans	11	4,339,757	4,942,039	384,670
v) Other Financial Assets	12	2,702,750	1,533,733	-
c) Current Tax Assets (Net)	13	20,152,255	11,220,549	7,666,722
d) Other Current Assets	14	1,613,597	1,431,045	4,497,208
Total		<u>493,769,119</u>	<u>308,927,428</u>	<u>181,985,451</u>
Equity and Liabilities				
Equity				
a) Equity Share Capital	A	114,594,650	92,794,650	60,416,000
b) Other Equity	B	105,545,822	75,977,216	(44,766,637)
Liabilities				
(1) Non-current Liabilities				
a) Financial liabilities				
Borrowings	15	98,372,835	47,475,165	83,193,804
b) Provisions	16	968,587	746,915	271,264
c) Deferred tax Liability (net)	6	1,393,060	-	-
(2) Current Liabilities				
a) Financial Liabilities				
i) Borrowings	17	70,414,014	24,621,966	24,479,407
ii) Trade Payables	18	20,562,838	22,436,046	33,347,137
iii) Other Financial liabilities	19	28,542,516	15,570,174	5,493,360
iv) Other Financial Creditors	20	25,545,192	4,586,303	831,188
b) Other current liabilities	21	27,604,107	22,230,385	17,495,971
c) Provisions	22	225,498	2,488,608	1,223,957
Total		<u>493,769,119</u>	<u>308,927,428</u>	<u>181,985,451</u>
Summary of significant accounting policies & Notes	1			

Per our report of even Date

for PAVULURI & Co.

Chartered Accountants
Firm Regn No: 012194S

for and on behalf of the Board of Directors

Jeevan Scientific Technology Limited

Sd/-

CA Kanthi Sree Kolli

Partner

Membership No:224434

Place : Hyderabad

Date : 26.05.2018

Sd/-

K.Krishna Kishore

Vice Chairman & Managing Director

DIN: 00876539

Sd/-

M. Rajendra Prasad

Executive Director & CEO

DIN: 06781058

Sd/-

G. Ravi Kumar

Chief Financial Officer

Twentieth Annual Report 2017-2018

Consolidated Statement of Profit and Loss for the Period ended 31st March, 2018

(In Rupees)

Particulars	Note No.	For the Year 2017-2018	For the Year 2016-2017	For the Year 2015-2016
Continuing Operations				
Income				
I. Revenue from operations	23	203,984,736	182,128,906	173,860,362
II. Other Income	24	9,220,243	5,759,749	4,032,315
III. Total revenue(I+II)		213,204,979	187,888,655	177,892,677
IV. Expenses				
Cost of Material consumed	25	12,987,432	1,585,147	1,509,833
Employee benefits expenses	26	56,801,315	22,569,646	35,553,284
Finance costs	27	18,556,909	14,079,043	12,762,527
Depreciation	2	17,156,115	12,251,279	6,761,990
Amortisation on Process	2	4,058,837	-	-
Other expenses	28	100,024,197	127,297,049	119,142,657
Total expenses		209,584,805	177,782,164	175,730,291
V. Profit/ (Loss) before tax (III)-(IV)		3,620,174	10,106,491	2,162,386
Tax expenses				
Current Tax		924,077	2,488,608	1,223,957
Less: Mat Credit Entitlement		(985,600)	(2,488,608)	(1,223,957)
Deferred Tax		2,563,932	1,073,636	2,229,313
Total tax expenses		2,502,409	1,073,636	2,229,313
Profit / (Loss) for the period from continuing operations		1,117,765	9,032,855	(66,927)
Profit / (Loss) from discontinuing operations		-	-	-
Tax expense from discontinuing operations		-	-	-
Profit / (Loss) from discontinuing operations (After tax)		-	-	-
Profit/(loss) for the Period		1,117,765	9,032,855	(66,927)
Other Comprehensive Income				
A (i) Items that will not be reclassified to profit and loss Re-measurements of post-employment benefit obligations)		645,160	(1,460,270)	-
(ii) Income tax relating to items that will not be reclassified to profit and loss		61,523	-	-
B (i) Items that will be reclassified to profit and loss		-	-	-
(ii) Income tax relating to items that will be reclassified to profit and loss		-	-	-
Total Comprehensive Income		1,701,402	7,572,585	(66,927)
Earning per equity share				
(Face value of Rs.10/- each)				
Basic		0.15	0.82	(0.01)
Diluted		0.18	1.14	(0.01)

Per our report of even Date
for **PAVULURI & Co.**

Chartered Accountants
Firm Regn No: 012194S

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
CA Kanthi Sree Kolli
Partner
Membership No:224434

Sd/-
K.Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M. Rajendra Prasad
Executive Director & CEO
DIN: 06781058

Sd/-
G. Ravi Kumar
Chief Financial Officer

Place : Hyderabad
Date : 26.05.2018

Jeevan Scientific Technology Limited

Consolidated Cash Flow statement for the year ended 31st March, 2018

(In Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
A. Cash flow from operating activities			
Net Profit before tax and extraordinary items	3,620,174	9,900,230	2,162,386
Adjustments for:			
Depreciation	25,278,613	12,251,279	6,761,990
Loss on Sale of Assets	3,995	-	278,285
Interest	17,120,046	13,279,485	11,768,653
Operating profit before working capital changes	46,022,828	35,430,994	20,971,314
Adjustments for:			
Inventories	3,752,090	-3,999,105	-147,577
Trade and other receivables	-59,921,024	-48,022,026	-5,866,175
Trade and other Paybles	-83,746,288	26,323,085	32,269,160
Cash generated from operations	73,600,182	-42,913,222	47,226,722
Taxes Provision	-	-	-
Interest paid	17,120,046	13,279,485	11,768,653
Net cash from operating activity	56,480,136	-56,192,707	35,458,069
B. Cash flow from investing activities			
Purchase of fixed assets	143,484,004	89,013,841	36,954,319
Investments	-	-	-
Sale/ Transfer of fixed assets	9,000	-	697,966
Net cash used in investing activity	-143,475,004	-89,013,841	-36,256,353
C. Cash flow from financing activity			
Proceeds from loans	50,897,670	142,559	2304543
Increase in Capital	21,800,000	32,378,650	-
Increase in Other Equity	25,948,432	113,171,268	-
Net cash generated in financing activity	98,646,102	145,692,477	2,304,543
Net increase in cash and cash equivalents (A+B+C)	11,651,234	485,929	1,506,259
Cash and cash equivalents as at 31.03.2017	2,573,833	2,087,904	581,645
Cash and cash equivalents as at 31.03.2018	14,225,067	2,573,833	2,087,904

Per our report of even Date
for PAVULURI & Co.
Chartered Accountants
Firm Regn No: 012194S

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
CA Kanthi Sree Kolli
Partner
Membership No:224434

Sd/-
K.Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M. Rajendra Prasad
Executive Director & CEO
DIN: 06781058

Sd/-
G. Ravi Kumar
Chief Financial Officer

Place : Hyderabad
Date : 26.05.2018

Significant Accounting Policies and Notes on Accounts

Company Information

The Company was incorporated on 2nd February, 1999 to carry on the business Clinical research, Data management and Information Technology services.

Transition to Ind AS

The Company's consolidated financial statements for the quarter ended June 30, 2017 are the first interim consolidated financial statements prepared in accordance with Ind AS.

The adoption of Ind AS was carried out in accordance with Ind AS 101, using April 1, 2016 as the transition date. Ind AS 101 requires that all Ind AS standards and interpretations that are effective for the first Ind AS Consolidated Financial Statements for the quarter ended June 30, 2017, be applied consistently and retrospectively for all fiscal years presented.

All applicable Ind AS have been applied consistently and retrospectively wherever required. The resulting difference between the carrying amounts of the assets and liabilities in the Consolidated financial statements under both Ind AS and Indian GAAP as of the transition date have been recognized directly in equity at the transition date.

1. Significant Accounting Policies

1.1 Basis of Preparation

a) Statement of Compliance

The consolidated financial statements have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016 and other relevant provisions of the Act.

For all the periods up to and including the year ended March 31, 2017 the Company prepared its financial statements in accordance with accounting standards notified under the section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (Indian GAAP). These financial statements are the first, the Company has prepared in accordance with Ind AS. Refer to note on transition to Ind AS for information on how the Company adopted Ind AS.

b) Basis of measurement

The consolidated financial statements have been prepared on a historical cost convention and on an accrual basis, except for the following material items that have been measured at fair value as required by relevant Ind AS:

- i. Certain financial assets and liabilities measured at fair value (refer accounting policy on financial instruments);
- ii. Defined benefit and other long-term employee benefits.

c) Functional and presentation currency

The Consolidated financial statements are presented in Indian rupees, which is the functional currency of the Company and the currency of the primary economic environment in which the entity operates. All financial information presented in Indian rupees.

Jeevan Scientific Technology Limited

d) Use of estimates and judgment

The preparation of consolidated financial statements in conformity with Ind AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on a periodic basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

1.2 Summary of significant accounting policies

i. Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which these entities operate (i.e. the “functional currency”). The Consolidated financial statements are presented in Indian Rupee, the national currency of India, which is the functional currency of the Company.

ii. Foreign currency transactions and balances

Transactions in foreign currency are translated into the respective functional currencies using the exchange rates prevailing at the dates of the respective transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at the exchange rates prevailing at reporting date of monetary assets and liabilities denominated in foreign currencies are recognized in the statement of profit and loss and reported within foreign exchange gains / (losses).

Non-monetary assets and liabilities denominated in a foreign currency and measured at historical cost are translated at the exchange rate prevalent at the date of transaction.

iii. Investment in subsidiaries

Investment in subsidiaries is measured at cost. Dividend income from subsidiaries is recognized when its right to receive the dividend is established.

iv. Financial instruments

All financial instruments are recognized initially at fair value. Transaction costs that are attributable to the acquisition of the financial asset (other than financial assets recorded at fair value through profit or loss) are included in the fair value of the financial assets. Purchase or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trade) are recognized on trade date. While, loans and borrowings and payable are recognized net of directly attributable transactions costs.

For the purpose of subsequent measurement, financial instruments of the Company are classified in the following categories: non-derivative financial assets comprising amortized cost; non derivative financial liabilities at amortized cost.

The classification of financial instruments depends on the objective of the business model for which it is held. Management determines the classification of its financial instruments at initial recognition.

Twentieth Annual Report 2017-2018

Financial instrument is derecognized only when the Company has transferred its right to receive/ extinguish its obligation to pay cash flow from such financial instruments.

a) **Non-derivative financial assets**

Financial assets at amortized cost

A financial asset shall be measured at amortized cost if both of the following conditions are met:

- the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

They are presented as current assets, except for those maturing later than 12 months after the reporting date which are presented as non-current assets. Financial assets are measured initially at fair value plus transaction costs and subsequently carried at amortized cost using the effective interest method, less any impairment loss.

Amortized cost is represented by security deposits, cash and cash equivalents, employee and other advances and eligible current and non-current assets.

Cash and cash equivalents comprise cash on hand and in banks and demand deposits with banks which can be withdrawn at any time without prior notice or penalty on the principal.

For the purposes of the cash flow statement, cash and cash equivalents include cash on hand, in banks and demand deposits with banks, net of outstanding bank overdrafts that are repayable on demand and are considered part of the Company's cash management system.

b) **Non-derivative financial liabilities**

Financial liabilities at amortized cost

Financial liabilities at amortized cost represented by trade and other payables are initially recognized at fair value, and subsequently carried at amortized cost using the effective interest method.

v. **Property, plant and equipment:**

Recognition and measurement: Normally Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Cost includes expenditures directly attributable to the acquisition of the asset. The Company has elected to apply the optional exemption to use this previous GAAP value as deemed cost at 1 April 2015, the date of transition.

Depreciation: Normally the Company depreciates property, plant and equipment over the estimated useful life of the assets as prescribed in Schedule II of the Companies Act 2013 on a straight-line basis from the date the assets are ready for intended use. Wherever the useful life is determined by technical assessment for certain assets, such assets are depreciated as per their assessed life. Assets acquired under finance lease and leasehold improvements are amortized over the lower of estimated useful life and related term.

Jeevan Scientific Technology Limited

Depreciation methods, useful lives and residual values are reviewed at each reporting date.

When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Subsequent expenditure relating to property, plant and equipment is capitalized only when it is probable that future economic benefits associated with these will flow to the Company and the cost of the item can be measured reliably. Repairs and maintenance costs are recognized in the statement of profit and loss when incurred. The cost and related accumulated depreciation are eliminated from the Consolidated financial statements upon sale or disposition of the asset and the resultant gains or losses are recognized in the statement of profit and loss.

The management estimates the useful lives for the following class of assets, based on internal assessment and independent technical evaluation carried out by external valuers, the management believes that useful lives as given below best represents the period over which the management expects to use these assets. Hence the useful lives for these assets is different from the useful lives as prescribed under Part - C of schedule II of the companies act 2013.

Plant and machinery	21 years
Electrical Installations	21 years
Computers	6 years
Vehicles- Motor car	10 years
Furniture and Fixtures	15 years
Office Equipment	21 years

Fixed Assets costing Rs.5,000/- or less are fully depreciated in the year of purchase

vi. Intangible assets

Intangible assets are stated at cost less accumulated amortization and impairment. Intangible assets are amortized over their respective estimated useful lives on a straight-line basis, from the date that they are available for use. The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition and other economic factors (such as the stability of the industry and known technological advances) and the level of maintenance expenditures required to obtain the expected future cash flows from the asset.

Policy for accounting of expenses of Research & Development:

Clinical Research is a specified job and the ready availability of newly developed methods for BA/BE Analysis of drug samples is required to get the business from various Pharmaceutical Clients. JSTL has been in the process of developing process and new methods. Equipment, Machines, Manpower and consumables are used for development of new methods.

Twentieth Annual Report 2017-2018

Investment in development method is calculated on the basis of proportionate of time spent by manpower, machines and also consumable for developing that particular method and the relative expenditure is capitalised as intangible asset. Each method will be of use for a minimum period of 10-12 years. It is also decided by the Board that the amortisation of the investment in process for developing methods should take place in a period 7 years from the date of the method put to use on quarterly basis in straight line method.

vii. Inventory

- a) Raw materials, Stores and Consumables, work in process and finished products are valued at lower of cost and net realizable value of the respective units.
- b) The basis of determining the cost is
 - Raw materials : Weighted average cost
 - Stores and Consumables : Weighted average cost
 - Work in process and finished goods : valued at lower of cost and net realizable value
- c) In case of identified Obsolete/Surplus/Non-moving items necessary provision is made and charged to revenue.

viii. Impairment

a) Financial assets

In accordance with Ind AS 109, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss.

- i. The Company follows 'simplified approach' for recognition of impairment loss allowance on trade receivable.

The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

For recognition of impairment loss on other financial assets and risk exposure, the Company determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If in subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognising impairment loss allowance based on 12 month ECL.

Lifetime ECLs are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12 month ECL is a portion of the lifetime ECL which results from default events that are possible within 12 months after the reporting date.

ECL is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the entity expects to receive (i.e. all shortfalls), discounted at the original EIR. When estimating the cash

Jeevan Scientific Technology Limited

flows, an entity is required to consider:

- ii. All contractual terms of the financial instrument (including prepayment, extension etc.) over the expected life of the financial instrument. However, in rare cases when the expected life of the financial instrument cannot be estimated reliably, then the entity is required to use the remaining contractual term of the financial instrument.
- iii. Cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECL impairment loss allowance (or reversal) recognised during the period is recognised as income/ expense in the statement of profit and loss. The balance sheet presentation for various financial instruments is described below:

Financial assets measured at amortised cost, contractual revenue receivable: ECL is presented as an allowance, i.e. as an integral part of the measurement of those assets in the balance sheet. The allowance reduces the net carrying amount. Until the asset meets write off criteria, the Company does not reduce impairment allowance from the gross carrying amount.

b) Non-financial assets

The Company assesses at each reporting date whether there is any objective evidence that a non financial asset or a group of non financial assets is impaired. If any such indication exists, the Company estimates the amount of impairment loss.

An impairment loss is calculated as the difference between an asset's carrying amount and recoverable amount. Losses are recognised in profit or loss and reflected in an allowance account. When the Company considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, then the previously recognised impairment loss is reversed through profit or loss.

The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the "cash-generating unit").

ix. Employee benefits

a) Gratuity & Provident Fund:

The Company's liability towards retirement benefits in the form of gratuity is provided in accordance with the payment of Gratuity Act, 1972 to all the employees other than the whole time Directors which is made on the basis of actuarial valuation.

- b)** The Company's contribution to the provident fund is remitted to Government based on the percentage of the eligible employees' salary as per Provident Fund act.

c) **Accrued Leave Salary:**

Liability towards Accrued Leave Salary, as at the end of the year is recognized on the basis of valuation made on basic salary. The balance PL's earned by every employee in the previous year, a maximum of 8 days will be paid out during the month of January. These 8 days will be paid as per the last drawn basic salary and taxes will be applicable as per law

x. **Provisions**

All the provision are recognized as per Ind AS 37. Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation.

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset, if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Provisions for onerous contracts are recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable costs of meeting the future obligations under the contract. Provisions for onerous contracts are measured at the present value of lower of the expected net cost of fulfilling the contract and the expected cost of terminating the contract.

xi. **Revenue recognition:**

Revenue is recognised when the significant risks and rewards of ownership have been transferred to the customer, recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, there is no continuing management involvement with the goods, and the amount of revenue can be measured reliably. Revenue is measured net of returns, trade discounts and volume rebates. The timing of the transfer of risks and rewards varies depending on the individual terms of the sales agreement. Revenue is recognized only when there is no significant uncertainty as to the measurability / collectability of the amounts.

Export Services: Revenue from Export services are recognized on the date of Invoicing and is accounted for at the exchange rate prevailing at the time of sale or service. Gain/ Loss arising out of variances in the exchange rates is recognized as income / expenditure of the year.

a) **Domestic Services:** Domestic services are accounted on the date of Invoicing on recognized as per the terms of agreement on the basis of work completion stage.

b) **Obsolete Stores & Scrap:** Income is accounted on realization basis in respect of used / surplus / obsolete / unserviceable materials / waste products and scrap.

Jeevan Scientific Technology Limited

xii. Finance income and expense

Finance income consists of interest income on funds invested, dividend income and gains on the disposal of Fair value through profit and loss account financial assets. Interest income is recognized as it accrues in the statement of profit and loss, using the effective interest method.

Dividend income is recognized in the statement of profit and loss on the date that the Company's right to receive payment is established.

Finance expenses consist of interest expense on loans and borrowings. Borrowing costs are recognized in the statement of profit and loss using the effective interest method.

Foreign currency gains and losses are reported on a net basis. This includes changes in the fair value of foreign exchange derivative instruments, which are accounted at fair value through profit or loss.

xiii. Income tax

Income tax comprises current and deferred tax. Income tax expense is recognized in the statement of profit and loss except to the extent it relates to items directly recognized in equity or in other comprehensive income.

a) Current income tax

Current income tax for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities based on the taxable income for the period. The tax rates and tax laws used to compute the current tax amount are those that are enacted or substantively enacted by the reporting date and applicable for the period. The Company offsets current tax assets and current tax liabilities, where it has a legally enforceable right to set off the recognized amounts and where it intends either to settle on a net basis or to realize the asset and liability simultaneously.

b) MAT credit

Minimum Alternate Tax (MAT) credit is recognized as an asset only when and to the extent there is convincing evidence that the Company will pay normal income tax during the specified period. In the year in which the MAT credit becomes eligible to be recognized as an asset, in accordance with the provisions contained in the Guidance Note on Accounting for Credit Available under Minimum Alternative Tax, issued by the ICAI, the said asset is created by way of a credit to the Profit and Loss account and shown as "MAT Credit Entitlement". The Company reviews the same at each Balance Sheet date and writes down the carrying amount of MAT Credit Entitlement to the extent there is no longer convincing evidence to the effect that the Company will pay normal income tax during the specified period.

c) Deferred income tax

Deferred income tax is recognized using the balance sheet approach. Deferred income tax assets and liabilities are recognized for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount in financial statements, except when the deferred income tax arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business

Twentieth Annual Report 2017-2018

combination and affects neither accounting nor taxable profits or loss at the time of the transaction. Deferred income tax asset are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized. Deferred income tax liabilities are recognized for all taxable temporary differences. The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized. Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

xiv. Foreign currency transaction

i. Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

ii. Conversion

Foreign currency monetary items denominated in foreign currencies at the yearend are restated at year end rates. In case of monetary items which are covered by foreign exchange contracts, the difference between the original entry dates to forward contract date is recognized as an exchange difference.

iii. Exchange differences

Exchange differences arising on the settlement of monetary items, or on reporting such monetary items of company at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognized as income or as expenses in the year in which they arise.

iv. Foreign currency Transactions.

(in lakhs)

Particulars	Current Year	Previous Year
Earnings in Foreign exchange	566.53	329.71
Expenditure in Foreign exchange	NIL	NIL

xv. Earnings per share

Basic earnings per share is computed using the weighted average number of equity shares outstanding during the year.

Diluted EPS is computed by dividing the net profit after tax by the weighted average number of equity shares considered for deriving basic EPS and also weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the

Jeevan Scientific Technology Limited

year, unless issued at a later date. Dilutive potential equity shares are determined independently for each year presented. The number of equity shares and potentially dilutive equity shares are adjusted for bonus shares, as appropriate.

xvi. Borrowing costs

Borrowings costs directly attributable to acquisition or construction of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which it occurs. Borrowing costs consist of interest and other costs that the entity incurs in connection with the borrowing of funds.

xvii. Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence of non-occurrence of one or more uncertain future events beyond the control of the company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The company does not recognize a contingent liability but discloses its existence in the financial statements.

The contingent liability is Rs. 4.13 Lakhs during the financial year.

Twentieth Annual Report 2017-2018

2. Property, Plant and Equipment

(in Rupees)

I. Tangible Assets		GROSS BLOCK					DEPRECIATION					NET BLOCK				
		As at 01.04.2016	Additions	Deletions	As at 31.03.2017	Additions	Deletions	As at 31.03.2018	For the year 31.03.2017	Up to 31.03.2017/31.03.2018	Deletions 31.03.2018	For the year 31.03.2018	Up to 31.03.2018	As at 31.03.2018	As at 31.03.2017	As at 31.03.2016
1	LEASE HOLD BUILDINGS	8,165,864	-	-	8,165,864	6,551,976	-	806,940	7,358,916	8,165,864	-	806,948	8,165,864	-	806,948	1,613,888
2	PLANT & MACHINERY	8,165,864	-	-	8,165,864	6,551,976	-	806,940	7,358,916	8,165,864	-	806,948	8,165,864	-	806,948	1,613,888
	a. Electrical Installations	10,312,302	7,556,285	-	17,868,587	1,632,104	-	1,011,773	2,643,877	17,990,344	1,632,104	-	1,619,085	4,262,962	15,224,710	8,680,198
	b. Airconditioners	1,194,942	-	-	1,194,942	810,322	-	56,760	867,082	1,194,942	810,322	-	56,760	923,842	271,100	384,620
	c. U.P.S. Systems	1,048,582	-	-	1,048,582	782,802	-	49,808	1,053,638	1,048,582	782,802	-	49,808	1,066,164	215,972	265,780
	d. Inverter	275,203	-	-	275,203	162,554	-	13,072	175,626	275,203	162,554	-	13,072	86,505	99,577	112,649
		12,831,029	7,556,285	-	20,387,314	3,387,782	-	1,131,413	4,519,195	20,509,071	3,387,782	-	1,738,725	6,257,920	14,251,151	15,868,119
3	COMPUTERS	13,287,257	4,216,182	-	17,503,439	2,082,678	-	1,798,739	9,851,923	19,586,117	8,053,184	-	2,744,658	12,596,581	6,989,536	5,234,073
	a. Computers	13,287,257	4,216,182	-	17,503,439	2,082,678	-	1,798,739	9,851,923	19,586,117	8,053,184	-	2,744,658	12,596,581	6,989,536	5,234,073
4	VEHICLES	4,463,910	2,107,565	-	6,571,475	4,202,964	-	552,942	2,380,080	10,774,439	1,827,138	-	843,903	3,223,983	7,550,456	4,191,395
	a. Motor Car	131,086	-	-	131,086	93,185	-	12,453	105,638	131,086	93,185	-	12,453	81,916	25,448	37,901
	b. Scooter	4,332,824	2,107,565	-	6,440,389	4,109,779	-	540,489	2,274,342	10,643,353	1,733,953	-	831,448	3,142,067	7,525,008	4,153,494
		4,594,996	2,107,565	-	6,702,561	4,202,964	-	565,395	2,485,718	10,856,355	1,920,323	-	856,356	3,305,899	7,550,456	4,216,673
5	FURNITURE & FIXTURES	16,842,306	11,704,970	-	28,547,276	1,037,682	-	1,574,571	7,499,042	29,584,958	5,924,471	-	2,576,984	10,076,026	19,508,932	21,048,234
	a. Furniture	988,151	-	-	988,151	988,151	-	-	988,151	988,151	988,151	-	-	988,151	-	-
	b. Fixtures	17,830,457	11,704,970	-	29,535,427	1,037,682	-	1,574,571	8,487,193	30,573,109	6,912,622	-	2,576,984	11,064,177	19,508,932	21,048,234
		826,026	489,833	-	1,315,859	366,360	-	82,516	418,483	1,682,219	335,967	-	206,112	624,595	1,057,624	897,376
	a. Office Equipment	53,643,983	9,769,036	-	63,413,019	85,879,213	-	5,303,956	7,843,319	149,292,232	2,539,363	-	10,431,520	18,274,839	131,017,393	55,569,700
	b. Laboratory Equipments	460,323	-	-	460,323	274,794	-	21,865	296,659	460,323	274,794	-	21,865	318,524	141,799	163,664
	c. E.P.A.B.X & Telephones	15,100	-	-	15,100	12,035	-	717	12,752	15,100	12,035	-	717	13,469	1,631	2,348
	d. Fax Machine	366,841	-	-	366,841	362,358	-	4,483	366,841	366,841	362,358	-	366,841	-	-	4,483
	e. Projector with LCD Panel	55,312,273	10,258,869	-	65,571,142	86,245,573	-	5,413,537	8,938,054	151,816,715	3,524,517	-	10,660,214	19,598,268	132,218,447	56,633,088
		89,983	-	-	89,983	77,786	-	4,274	82,060	89,983	77,786	-	4,274	86,334	3,649	7,923
	a. Books	89,983	-	-	89,983	77,786	-	4,274	82,060	89,983	77,786	-	4,274	86,334	3,649	7,923
		89,983	-	-	89,983	77,786	-	4,274	82,060	89,983	77,786	-	4,274	86,334	3,649	7,923
		112,111,859	35,843,871	-	147,955,730	93,690,654	-	11,294,869	41,723,059	161,250,609	30,428,190	-	11,294,869	61,075,043	180,522,171	106,232,671
	Total:	34,974,781	78,250,540	-	1,113,462	112,111,859	35,843,871	-	137,212	6,269,367	30,428,190	-	11,294,869	41,723,059	106,232,671	81,683,669
	Previous year															10,678,746

II. Intangible Assets

(in Rupees)																		
GROSS BLOCK						DEPRECIATION						NET BLOCK						
S. No.	Description	As at 01.04.2016	Additions	Deletions	As at 31.03.2017	Additions	Deletions	As at 31.03.2018	Up to 01.04.2016	Deletions 31.03.2017	For the year 31.03.2017	Up to 31.03.2017	Deletions 31.03.2018	For the year 31.03.2018	Up to 31.03.2018	As at 31.03.2018	As at 31.03.2017	As at 31.03.2016
1	COMPUTERS Software	3,335,051	4,009,752	-	7,344,803	3,911,184	-	11,255,987	1,594,501	-	715,610	2,310,111	-	1,800,167	4,110,278	7,145,709	5,034,692	1,740,550
2	COPYRIGHTS	1,204,000	-	-	1,204,000	-	-	1,204,000	931,750	-	240,800	1,172,550	-	31,450	1,204,000	-	31,450	272,250
	Total:	4,539,051	4,009,752	-	8,548,803	3,911,184	-	12,459,987	2,526,251	-	956,410	3,482,661	-	1,831,617	5,314,278	7,145,709	5,066,142	2,012,800

III. Intangible Assets Process

(in Rupees)																		
GROSS BLOCK						DEPRECIATION						NET BLOCK						
S. No.	Description	As at 01.04.2016	Additions	Deletions	As at 31.03.2017	Additions	Deletions	As at 31.03.2018	Up to 01.04.2016	Deletions 31.03.2017	For the year 31.03.2017	Up to 31.03.2017	Deletions 31.03.2018	For the year 31.03.2018	Up to 31.03.2018	As at 31.03.2018	As at 31.03.2017	As at 31.03.2016
1	Process	3,042,333	49,160,217	-	52,202,550	45,882,165	-	98,084,715	-	-	-	4,058,837	-	4,058,837	4,058,837	94,025,878	52,202,550	3,042,333
	Total:	3,042,333	49,160,217	-	52,202,550	45,882,165	-	98,084,715	-	-	-	4,058,837	-	4,058,837	4,058,837	94,025,878	52,202,550	3,042,333
	Previous year	2,961,261	4,620,123	-	75,881,384	53,169,969	-	60751353	2,033,627	-	492,623	2,526,251	-	95,6410	3,482,661	57,268,692	5,095,133	927,634

Notes: An amount of Rs. 40,63,661/- has been transferred from depreciation to Process Knowhow since the assets are used to create process

Twentieth Annual Report 2017-2018

Consolidated Notes to financial statements for the year ended 31st March, 2018

3. Investments (in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Enhops Solutions Inc.	-	-	-
Enhops Solutions Pvt Ltd	-	-	-
Total	-	-	-

4. Long term Loans (in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
i) Loans and advances to related parties	-	-	-
ii) Other Loans and advances	-	-	-
Total	-	-	-

5. Advances (in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
i) Capital Advances	-	-	-
ii) Security Deposit	5,034,310	4,559,785	5,254,906
Total	5,034,310	4,559,785	5,254,906

6. Deferred Tax (Net) (in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Deferred Tax Asset Opening	1,170,872	2,244,508	4,473,821
Add/Less: Deferred Tax liability	(2,563,932)	(1,073,636)	(2,229,313)
Total	(1,393,060)	1,170,872	2,244,508

7. Inventories (in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Work in progress point of sale boxes	210,240	210,240	210,240
Consumables - R & D	779,346	4,531,437	532,332
Total	989,586	4,741,677	742,572

Jeevan Scientific Technology Limited

8. Trade receivables (Unsecured)

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Debtors outstanding for more than Six months- Considered good	79,644,969	14,461,036	5,720,444
Doubtful	1,164,207	-	-
Other debts	83,373,069	98,791,496	66,647,715
	164,182,245	113,252,532	72,368,159
Less: Provision for doubtful debts	1,164,207	-	-
Total	163,018,038	113,252,532	72,368,159

9. Cash and Cash Equivalents

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Cash and cash equivalents Balances with Banks in current accounts	833,206	777,284	529,050
Cash on hand	6,375,040	516,907	366,418
Total	7,208,246	1,294,191	895,468

10. Cash and Cash Equivalents

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Bank balances other than in fixed deposits more than 12 months	524,806	1,279,642	1,192,436
in fixed deposits Less than 12 months	6,492,015	0	0
Total	7,016,821	1,279,642	1,192,436

11. Loans (current)

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Loans	4,339,757	4,942,039	384,670
Total	4,339,757	4,942,039	384,670

Particulars

Twentieth Annual Report 2017-2018

12. Other Financial Assets

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Interest Receivable	2,702,750	1,533,733	-
Total	2,702,750	1,533,733	-

13. Current Tax Assets (Net)

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Tax deducted at source	13,223,279	5,277,173	4,211,954
MAT Credit	6,928,976	5,943,376	3,454,768
Total	20,152,255	11,220,549	7,666,722

14. Other Current Assets

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
VAT input Credit	-	49,637	49,637
Capitalization- Salries & Director Remuneration	-	-	1,662,084
Capitalization- Travelling Expenses	-	-	555,613
Prepaid Expenses	1,373,014	822,386	568,654
Hero Finance corporation	234,904	-	-
GST Input Credit	5,679	-	-
Service Tax Input Credit	-	559,022	1,661,220
Total	1,613,597	1,431,045	4,497,208

Jeevan Scientific Technology Limited

STATEMENT OF CHANGES IN EQUITY

Jeevan Scientific Technology Limited

Statement of changes in Equity for the Period ended 31st March 2018

(in Rupees)

A. Equity Share Capital	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Authorised 2,10,00,000 equity Shares of Rs.10/- each	210,000,000	210,000,000	99,900,000
Issued, subscribed and paid- up 1,14,59,465 (31st March 2018:1,14,59,465) equity Shares of Rs. 10/- each fully paid-up	114,594,650	92,794,650	60,416,000

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Issued, subscribed and paid- up			
Opening Balance	92,794,650	60,416,000	60,416,000
Add : issue of shares during the year	21,800,000	32,378,650	-
Total	114,594,650	92,794,650	60,416,000

The details of shares in the company held by each shareholder holding more than 5% shares :

Name of the Share Holder	As at 31.03.2018		As at 31.03.2017		As at 01.04.2016	
	No. of Shares	% of Share Holding	No. of Shares	% of Share Holding	No. of Shares	% of Share Holding
Sri K. Krishna Kishore	1,774,391	15.48%	1,324,391	14.28%	993,391	16.44%
Smt. K. Vanaja	1,257,800	10.98%	857,800	9.24%	373,800	6.19%
Sri. T. Chalapathi Rao	-	-	-	-	384,700	6.37%
Smt. Niramala Desaiah Durisala	-	-	-	-	480,000	7.94%
Dr. Desaiah Durisala	830,000	7.24%	830,000	8.94%	-	-

Twentieth Annual Report 2017-2018

B. Other Equity

Particulars	Share application money on pending allotment	Equity component of compound financial instruments	Reserves and Surplus				Debt instruments through other comprehensive income	Equity instruments through other comprehensive income	Effective portion of cash flow Hedges	Revaluation Surplus	Exchange differences on translating the financial statements of foreign operations	Other items of other comprehensive income	Money received against share warrants	Total
			Capital Reserve	Securities premium reserve	Other reserves	Retained Earnings								
Balance at the beginning of the reporting period i.e. 1st April 2016	-	-	-	-	(22,711,528)	-	-	-	-	-	-	-	-	(22,711,528)
Ind AS Adjustment	-	-	-	-	(22,055,109)	-	-	-	-	-	-	-	-	(22,055,109)
Restated balance at the beginning of the reporting period	-	-	-	-	(44,766,637)	-	-	-	-	-	-	-	-	(44,766,637)
Total comprehensive Income for the year	-	-	-	-	7,572,585	-	-	-	-	-	-	-	-	7,572,585
Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transfer to retained earnings	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issued during the Year	-	-	-	65,566,766	-	-	-	-	-	-	-	-	47,604,502	113,171,268
Balance at the end of the reporting period i.e. 31st March 2017	-	-	-	65,566,766	-	(37,194,052)	-	-	-	-	-	-	47,604,502	75,977,216

Particulars	Share application money on pending allotment	Equity component of compound financial instruments	Reserves and Surplus				Debt instruments through other comprehensive income	Equity instruments through other comprehensive income	Effective portion of cash flow Hedges	Revaluation Surplus	Exchange differences on translating the financial statements of foreign operations	Other items of other comprehensive income	Money received against share warrants	Total
			Capital Reserve	Securities premium reserve	Other reserves	Retained Earnings								
Balance at the beginning of the reporting period i.e. 1st April 2017	-	-	-	-	(37,194,052)	-	-	-	-	-	-	-	-	75,977,216
Changes in accounting policy or prior period errors	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restated balance at the beginning of the reporting period	-	-	-	-	(37,194,052)	-	-	-	-	-	-	-	-	75,977,216
Total comprehensive Income for the year	-	-	-	65,566,766	-	1,701,402	-	-	-	-	-	-	-	1,701,402
Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transfer to retained earnings	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issued during the Year	-	-	-	44,145,000	-	-	-	-	-	-	-	-	(16,277,796)	27,867,204
Balance at the end of the reporting period i.e. 31st March, 2018	-	-	-	109,711,766	-	(35,492,650)	-	-	-	-	-	-	31,326,706	105,545,822

Jeevan Scientific Technology Limited

15. Long term borrowings

(in Rupees)

Particulars	Non-current portion			Non-current portion		
	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Term Loan- secured						
A) From Banks						
i) Car Loans- Hypothecation against the Cars	2,748,553	646,036	13,540	1,497,467	621,238	641,436
ii) Machinery loans	71,699,117	38,829,129	27,316,375	17,568,540	11,807,578	2,483,307
B) Intercorporate Loans	9,000,000	8,000,000	5,000,000	-	-	-
C) Loans and advances from related parties	14,925,165	-	50,863,889	-	-	-
Total	98,372,835	47,475,165	83,193,804	19,066,007	12,428,816	3,124,743

16. Long Term Provisions

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Gratuity Payable	968,587	746,915	271,264
Total	968,587	746,915	271,264

17. Short Term Borrowings

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Loan repayable on Demand			
i) Loan From Banks (Guaranteed by Director)	70,414,014	24,621,966	24,479,407
Total	70,414,014	24,621,966	24,479,407

18. Trade Payables

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Trade payables (for services received)	20,562,838	22,436,046	33,347,137
Total	20,562,838	22,436,046	33,347,137

There are no dues to Micro Small and Medium Enterprises as defined under the MSMED Act, 2006

Twentieth Annual Report 2017-2018

19. Other Financial liabilities

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Current maturities of Long term borrowings	19,066,007	12,428,816	3,124,743
Interest Payable	5,308,711	-	1,513,617
Rent Payable	4,167,798	3,141,358	855,000
Total	28,542,516	15,570,174	5,493,360

20. Other Financial Creditors

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Creditors for Capital Assets	25,545,192	4,586,303	831,188
Total	25,545,192	4,586,303	831,188

21. Other Current Liabilities

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
TDS Payable	6,500,137	4,114,975	2,442,249
Professional tax payable	19,150	27,000	8,850
Service tax payable	-	3,412,296	1,255,133
GST Payable	9,017,963	-	-
Provident Fund payable	311,706	570,633	198,914
ESI payable	101,434	97,245	27,986
Salaries payable	5,118,757	4,262,725	2,703,293
Directors Remuneration Payable	1,324,994	2,170,291	560,466
Provision for expenses	1,391,275	2,135,635	1,618,942
Advance received from Customers	3,731,250	3,731,250	8,500,000
Other Payables	87,441	1,708,335	180,138
Total	27,604,107	22,230,385	17,495,971

22. Short Term Provisions

(in Rupees)

Particulars	As at 31.03.2018	As at 31.03.2017	As at 01.04.2016
Leave Encashment Payable	93,318	-	-
Bonus Payable	116,975	-	-
Gratuity Payable	15,205	-	-
Provision for tax		2,488,608	1,223,957
Total	225,498	2,488,608	1,223,957

Jeevan Scientific Technology Limited

23. Revenue from operations

(in Rupees)

Particulars	For the year 2017-2018	For the year 2016-2017	For the year 2015-2016
IT Consultancy Service Charges - Export	6,945,312	18,472,393	38,292,215
IT Consultancy Service Charges - Domestic	4,396,035	913,767	-
Clinical Research Services- Domestic	123,017,832	20,210,673	5,522,994
Clinical Research Services- Export	49,707,896	14,498,436	4,128,735
Data Management service charges	19,917,661	128,033,637	125,916,418
Total	203,984,736	182,128,906	173,860,362

24. Other non operating income

(in Rupees)

Particulars	For the year 2017-2018	For the year 2016-2017	For the year 2015-2016
Interest on Income Tax Refund	166,222	80,453	2,984
Interest Received from Others	5,010,019	1,801,045	-
Interest Received from Banks	63,188	-	-
Miscellaneous Income	225,844	153,001	670,125
Exchange Variance Profit	154,970	125,250	2,438,755
Rent Received	3,600,000	3,600,000	900,000
Excess Gratuity Provision	-	-	20,451
Total	9,220,243	5,759,749	4,032,315

25. Cost of Material Consumed

(in Rupees)

Particulars	For the year 2017-2018	For the year 2016-2017	For the year 2015-2016
Hardware			
Opening Stock	210,240	210,240	210,240
Purchases: Components & Software	-	-	-
	210,240	210,240	210,240
Less: Closing Stock	210,240	210,240	210,240
Total (A)	-	-	-

Twentieth Annual Report 2017-2018

Consumables - R & D

Particulars	For the year 2017-2018	For the year 2016-2017	For the year 2015-2016
Opening Stock	4,531,437	532,332	384,755.00
Purchases:Consumables	13,473,286	5,584,252	3,189,910
	18,004,723	6,116,584	3,574,665
Less: Closing Stock	779,346	4,531,437	532,332
Less: Trafer to Process Knowhow	4,237,945	-	1,532,500
Total (B)	12,987,432	1,585,147	1,509,833
Total (A+B)	12,987,432	1,585,147	1,509,833

26. Employees benefit expenses

(in Rupees)

Particulars	For the year 2017-2018	For the year 2016-2017	For the year 2015-2016
Salaries & Allowances	45,172,941	17,043,205	26,735,734
Contribution to Provident Fund&Others	2,415,218	970,777	595,017
Welfare Expenses	2,097,037	619,611	462,706
Gratuity	559,746	269,390	14,001
Bonus	116,975	-	-
Leave encashment	93,318	-	-
Director's Remuneration	6,346,080	3,666,663	7,745,826
Total	56,801,315	22,569,646	35,553,284

27. Finance Cost

(in Rupees)

Particulars	For the year 2017-2018	For the year 2016-2017	For the year 2015-2016
Bank charges	231,933	178,783	225,987
Loan Processing Charges	1,120,090	620,775	767,887
FLC Charges	84,840	-	-
Interest expense			
on Vehicle Loans	166,041	110,204	97,991
on Bank Overdraft	3,588,051	3,631,174	3,170,071
on Term loan from Bank	7,312,323	4,529,220	2,412,165
on Customduty	40,124	-	-
on Unsecured Loans	6,013,507	5,008,887	6,088,426
Total	18,556,909	14,079,043	12,762,527

Jeevan Scientific Technology Limited

28. Other expenses

(in Rupees)

Particulars	For the year 2017-2018	For the year 2016-2017	For the year 2015-2016
Rent	10,034,312	8,471,609	7,988,550
Electricity	4,691,596	3,370,755	2,941,762
Repairs & Maintenance:	2,038,088	924,161	763,331
Insurance	1,035,550	829,608	460,255
Rates & Taxes	1,563,854	302,465	294,118
Communication Charges	2,466,949	1,232,118	726,028
Travelling, Conveyance	1,841,128	1,906,050	1,785,354
Printing & Stationery	1,455,720	627,438	399,881
Advertisement, Publicity & Business Promotion	722,611	260,690	564,297
Professional Charges	12,658,593	3,769,039	3,967,231
Audit Fee: As Auditors	97,000	81,050	80,915
: For Certification	68,607	65,375	44,013
General Expenses	2,782,988	1,600,522	722,456
Office Maintenance	5,450,111	2,547,812	1,746,132
Security Service	-	283,399	577,205
Director's Sitting fees	337,000	440,500	190,000
Registrar's expenses	169,992	75,566	70,048
Web Designing Charges	8,626	8,626	91,910
Garden Maintenance	73,385	78,700	83,000
Conference Fee	17,250	-	233,683
BSE Listing Fee	287,500	201,000	200,000
ROC Filing Fee	37,200	1,112,272	-
PF Late Filing Fee	31,234	-	-
ESI Late Filing Fee	8,135	-	-
GST Late Filing Fee	5,400	-	-
Service Tax Late Filing Fee	59,300	-	-
Service Tax Paid	144,794	-	-
TDS interest & late filing fee	240,000	1,320,670	-
Volunteer Expenses	9,824,582	567,765	-
Volunteer Study Payments	21,762,754	-	-
Provision for Doubtful debts	1,164,207	21,063	-
Deposits Written Off	8,400	-	-
VAT Input Credit Written Off	49,637	-	-
Foreign Exchange Variance Loss	270,207	301,255	8,992
Incorporation Charges	-	-	225,920
Visa Fee	-	39,148	38,888
Water Bill Paid	152,192	-	-
Loss on Sale of Assets	3,995	-	278,285
Data Management Service Charges	18,461,300	96,858,393	94,660,403
Total	100,024,197	127,297,049	119,142,657

Twentieth Annual Report 2017-2018

Note-29: OTHER DISCLOSURES:

i. Gratuity:

The Company has conducted Actuarial valuation of its Gratuity as on 31st Mar 2018.

Accounting Disclosures Statement

GRATUITY

Period of accounting

1-Apr-17 to 31-Mar-18

(all figures in Indian Rupees)

Valuation Results as at

31-Mar-17

31-Mar-18

I Changes in present value of obligations

PVO at beginning of period	271,264	746,915
Interest cost	20,236	49,969
Current Service Cost	249,154	509,777
Past Service Cost- (non vested benefits)	-	-
Past Service Cost -(vested benefits)	-	-
Benefits Paid	-	-
Contributions by plan participants	-	-
Business Combinations	-	-
Curtailments	-	-
Settlements	-	-
Actuarial (Gain)/Loss on obligation	206,261	(322,869)
PVO at end of period	746,915	983,792
II Interest Expenses		
Interest cost	20,236	49,969
III Fair Value of Plan Assets		
Fair Value of Plan Assets at the beginning	-	-
Interest Income	-	-
IV Net Liability		
PVO at beginning of period	271,264	746,915
Fair Value of the Assets at beginning report	-	-
Net Liability	271,264	746,915
V Net Interest		
Interest Expenses	20,236	49,969
Interest Income	-	-
Net Interest	20,236	49,969
VI Actual return on plan assets		
Less Interest income included above	-	-
Return on plan assets excluding interest income	-	-

Jeevan Scientific Technology Limited

VII	Actuarial (Gain)/loss on obligation		
	Due to Demographic Assumption*	-	-
	Due to Financial Assumption	74,168	(144,417)
	Due to Experience	132,093	(178,452)
	Total Actuarial (Gain)/Loss	206,261	(322,869)
	*This figure does not reflect interrelationship between demographic assumption and financial assumption when a limit is applied on the benefit, the effect will be shown as an experience		
VIII	Fair Value of Plan Assets		
	Opening Fair Value of Plan Asset	-	-
	Adjustment to Opening Fair Value of Plan Asset	-	-
	Return on Plan Assets excl. interest income	-	-
	Interest Income	-	-
	Contributions by Employer	-	-
	Contributions by Employee	-	-
	Benefits Paid	-	-
	Fair Value of Plan Assets at end	-	-
IX	<u>Past Service Cost Recognised</u>		
	Past Service Cost- (non vested benefits)	-	-
	Past Service Cost -(vested benefits)	-	-
	Average remaining future service till vesting of the benefit	-	-
	Recognised Past service Cost- non vested benefits	-	-
	Recognised Past service Cost- vested benefits	-	-
	Unrecognised Past Service Cost- non vested benefits	-	-
X	<u>Amounts to be recognized in the balance sheet and statement of profit & loss account</u>		
	PVO at end of period	746,915	983,792
	Fair Value of Plan Assets at end of period	-	-
	Funded Status	(746,915)	(983,792)
	Net Asset/(Liability) recognized in the balance sheet	(746,915)	(983,792)
XI	<u>Expense recognized in the statement of P & L A/C</u>		
	Current Service Cost	249,154	509,777
	Net Interest	20,236	49,969
	Past Service Cost- (non vested benefits)	-	-
	Past Service Cost -(vested benefits)	-	-
	Curtailment Effect	-	-
	Settlement Effect	-	-
	Unrecognized Past Service Cost- non vested benefits	-	-
	Expense recognized in the statement of P & L A/C	269,390	559,746

Twentieth Annual Report 2017-2018

XII Other Comprehensive Income (OCI)		
Actuarial (Gain)/Loss recognized for the period	206,261	(322,869)
Asset limit effect	-	-
Return on Plan Assets excluding net interest	-	-
Unrecognized Actuarial (Gain)/Loss from previous period	-	-
Total Actuarial (Gain)/Loss recognized in (OCI)	206,261	(322,869)
XIII Movements in the Liability recognized in Balance Sheet		
Opening Net Liability	271,264	746,915
Adjustment to opening balance	-	-
Expenses as above	269,390	559,746
Contribution paid	-	-
Other Comprehensive Income(OCI)	206,261	(322,869)
Closing Net Liability	746,915	983,792
XIV Schedule III of The Companies Act 2013		
Current Liability	12,263	15,205
Non-Current Liability	734,652	968,587
XV Projected Service Cost 31 Mar 2019		
Unrecognised Past Service Cost- non vested benefits		641,174
Average remaining future service till vesting of the benefit		
XVI Asset Information		
	Total	Target Allocation
	Amount	%
Cash and Cash Equivalents		
Gratuity Fund ()	-	0%
Debt Security - Government Bond		
Equity Securities - Corporate debt securities		
Other Insurance contracts		
Property		
Total Itemized Assets	-	0%
XVII Assumptions as at		
	31-Mar-17	31-Mar-18
Mortality	IALM (2006-08) Ult.	IALM (2006-08) Ult.
Interest / Discount Rate	6.69%	7.74%
Rate of increase in compensation	4.00%	4.00%
Annual increase in healthcare costs		
Future Changes in maximum state healthcare benefits		
Expected average remaining service	16.58	16.77
Employee Attrition Rate(Past Service (PS))	PS: 0 to 40 : 3%	PS: 0 to 40 : 3%

Jeevan Scientific Technology Limited

Note-30: Segment Reporting as per Ind-AS-108

A. Basis for segmentation

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses and for which discrete financial information is available. All operating segments' operating results are reviewed regularly by the Board of Directors to make decisions about resources to be allocated to the segments and assess their performance.

The Company has three reportable segments, as described below, which are the company's strategic business units. These business units offer different services, and are managed separately because they require different technology and marketing strategies. For each of the business units, the company's Board reviews internal management reports on a periodic basis.

The following summary describes the operations in each of the Company's reportable segments:

B. Information about reportable segments

Information regarding the results of each reportable segment is included below. Performance is measured based on segment profit (before tax), segment revenue and segment capital employed as included in the internal management reports that are reviewed by the board of directors. Segment profit is used to measure performance as management believes that such information is the most relevant in evaluating the results of certain segments relative to other entities that operate within these industries.

Twentieth Annual Report 2017-2018

Reportable Segments

Segment Reporting as on 31-03-2018

Rs. In Lakhs

Particulars	Clinical Research Services	Data Management Services	Information Technology Services	Unallocated	Total
Revenue from External Customers	1727.25	199.18	115.13	90.48	2132.04
Segment Result	104.93	5.66	-12.29	-62.10	36.20
Assets	4105.22	555.87	209.07	67.53	4937.69
Liabilities	2588.95	-	77.22	2271.52	4937.69
Depreciation and Amortization	182.05	-	5.68	24.42	212.15
Capital Expenditure during the year	1243.54	-	191.30	-	1434.84

Segment Reporting as on 31-03-2017

Rs. In Lakhs

Particulars	Clinical Research Services	Data Management Services	Information Technology Services	Unallocated	Total
Revenue from External Customers	347.09	1,280.34	194.28	57.17	1,878.88
Segment Result	-126.23	258.56	62.64	-95.96	99.01
Assets	1564.53	1,085.40	524.42	148.02	3,322.37
Liabilities	1181.27	133.65	46.36	1,961.09	3,322.37
Depreciation and Amortization	67.23	11.80	16.22	27.26	122.51
Capital Expenditure during the year	640.99	-	249.15	-	890.14

Jeevan Scientific Technology Limited

Note-31: Related parties

a. Key management personnel

Name of the personnel	Nature of relationship
K Krishna Kishore	Vice chairman & Managing Director
M Rajendra Prasad	Executive Director & CEO
K Vanaja	Non-Executive Director
S S R Koteswara Rao	Independent Director- Chairman
T Ravi Babu	Independent Director
G Bhanu Prakash	Independent Director
K Rama Krishna Prasad	Independent Director
B. Raghav*	Non-Executive Director
A Vijay Kumar**	Independent Director
G. Krishna Sowjanya***	Company secretary

* Resigned w.e.f 11-10-2017

** Resigned w.e.f 01-04-2018

*** Resigned w.e.f 28-04-2018

b. Name of the related party

Name of the entity	Nature of relationship
JeevanaMitra Finance corporation	Enterprise owned by Key managerial person
Enhops Solutions Pvt Ltd	Wholly owned subsidiary
EnhopsInc, USA	Wholly owned subsidiary

c. Particulars of transactions with related party

(Amount in Rs.)

Particulars	As at	As at
	March 31, 2018	March 31, 2017
Rent Paid		
a) JeevanaMitra Finance corporation	8,40,000	8,40,000
b) K Krishna Kishore	4,80,000	4,80,000
c) K Vanaja	4,80,000	4,80,000
Long term Borrowings		
a) K Krishna Kishore	10,79,08,000	3,03,60,000
b) K Vanaja	1,80,76,000	2,74,15,000
c) M Rajendra Prasad	4,70,000	-
d) K Rama Krishna Prasad	45,37,500	67,00,000

Twentieth Annual Report 2017-2018

Interest paid on short term borrowings		
a) K Krishna Kishore	32,96,330	28,32,852
b) K Vanaja	3,41,198	19,43,088
c) M Rajendra Prasad	7,315	4,30,107
d) K Gopi Krishna	-	12,097
Remuneration Paid		
a) K Krishna Kishore	36,00,000	26,12,903
b) K Gopi Krishna	-	13,43,548
c) M Rajendra Prasad	30,99,996	30,99,996
d) B Raghav	12,91,665	30,99,996

d. The Company has the following amounts due from / to related parties:

(i) Due to related parties.

(Amount in Rs.)

Particulars	As at March 31, 2018	As at March 31, 2017
Long term Borrowings		
a) K Krishna Kishore	1,34,74,165	-
b) K Vanaja	14,51,000	-

Note No. 32: Earnings per share (IND AS-33): The details are as under:

(Amount in Rs.)

Particulars	As at March 31, 2018	As at March 31, 2017
1. Profit after Tax (Rs)	17,01,402	75,72,585
2. No of Equity shares	1,14,59,465	92,79,465
3. Nominal value per Equity share (Rs.)	10	10
4. Basic Earnings per share (Rs.)	0.15	0.82
5. Weighted Average No of Equity Shares	94,34,753	66,58,133
6. Diluted Earnings per share (Rs.)	0.18	1.14

Note No. 33 Accounting for Deferred Taxes on income (INDAS-12):

Necessary details have been disclosed in note no: 6.

Note No. 34

General:

- i. Expenses are accounted under prepaid expenses only where the amounts relating to unexpired period are material.

Jeevan Scientific Technology Limited

- ii. Some of the balances appearing under Trade receivables, Trade payables, advances, Security deposits and other payables are subject to confirmations.
- iii. Figures for the previous year have been regrouped/rearranged wherever considered necessary so as to confirm to the classification of the current year.

34.1 First Time Adoption of Ind AS

Explanation of Transition to Ind AS

These are the Company's first consolidated financial statements prepared in accordance with Ind AS. The accounting policies set out in Note 1 have been applied in preparing the financial statements for the year ended 31 March 2018, the comparative information presented in these financial statements for the year ended 31 March 2017 and in the preparation of the opening Ind AS balance sheet as at 1 April 2016 (the Company's date of transition). In preparing its opening Ind AS balance sheet, the Company has adjusted amounts reported previously in financial statements prepared in accordance with the accounting standards notified under Companies (Accounting Standards) Rules, 2006 (as amended) and other relevant provisions of the Act (Indian GAAP or previous GAAP). An explanation of how the transition from previous GAAP to Ind AS has affected the Company's Balance Sheet, Statement of Profit and Loss and Statement of Cash Flows is set out in the following tables and the notes that accompany the tables.

A. Exemptions and exceptions availed

Set out below are the applicable Ind AS 101 optional exemptions and mandatory exceptions applied in the transition from previous GAAP to Ind AS.

A.1 Ind AS optional exemptions

A.1.1 Deemed Cost

Ind AS 101 permits a first-time adopter to continue with the carrying value for all its property, plant and equipment as recognised in the financial statements as at the date of transition to Ind AS, measured as per the previous GAAP and use that as its deemed cost as at the date of transition after making the necessary adjustments for the de-commissioning liabilities. This exemption can also be used for intangible assets covered by the Ind AS 38 intangible assets and investments in subsidiaries, associates and joint ventures. Accordingly, the Company has elected to measure all of its property, plant and equipment, intangible assets and investments in subsidiaries and associates at their previous GAAP carrying value.

A.1.2 Decommissioning liabilities included in the cost of property, plant and equipment

Appendix 'A' to Ind AS 16 Changes in Existing Decommissioning, Restoration and Similar Liabilities requires specified changes in a decommissioning, restoration or similar liability to be added to or deducted from the cost of the asset to which it relates; the adjusted depreciable amount of the asset is then depreciated prospectively over its remaining useful life. A first-time adopter need not comply with these requirements for changes in such liabilities that occurred before the date of transition to Ind AS. In other words, a first-time adopter will not need to estimate what provision would have been calculated at earlier reporting dates. Instead, the decommissioning liability is calculated at the date of transition and it is assumed that the same liability (adjusted only for the time value of money) existed when the asset was first acquired/constructed.

Twentieth Annual Report 2017-2018

A.2 Ind AS mandatory exemptions

A.2.1 Estimates

An entity's estimates in accordance with Ind AS' at the date of transition to Ind AS shall be consistent with the estimates made for the same date in accordance with the previous GAAP (after adjustments to reflect any difference in accounting policies) unless there is an objective evidence that those estimates were in error.

"Ind AS estimates as at 1 April 2016 are consistent with the estimates as at the same date made in conformity with the previous GAAP. The Company made estimates for the following items in accordance with Ind AS at the date of transition as there were not required under previous GAAP. Impairment of financial assets (Trade Receivables) based on the expected credit loss model.

A.2.2 Classification and measurement of financial assets (other than equity instruments)

Ind AS 101 requires an entity to assess classification and measurement of financial assets on the basis of the facts and circumstances that exists at the date of transition to Ind AS.

A.2.3 De-recognition of financial assets and financial liabilities

Ind AS 101 requires a first time adopter to apply the de-recognition provisions for Ind AS 109 prospectively for transactions occurring on or after the date of transition to Ind AS. However, Ind AS 101 allows first time adopter to apply the derecognition requirements provided that the information needed to apply Ind AS 109 to financial assets and financial liabilities derecognised as a result of past Ind AS 101 retrospectively from the date of entity's choosing, transactions was obtained at the time of initially accounting for the transactions.

The Company has elected to apply the de-recognition provisions of Ind AS 109 prospectively from the date of transition to Ind-AS.

B. Reconciliation between previous GAAP and Ind AS

B.1 The following tables represent the reconciliations from previous GAAP to Ind AS.

Particulars	Ast at 31.03.2017 Previous GAAP	Effect of Transition to Ind AS	As at 31.03.2017 As Per INDAS	As at 01.04.2016 Previous GAAP	Effect of Transition to Ind AS	As at 01.04.2016 as per INDAS
Assets						
(1) Non-current Assets						
a) Property, Plant and Equipment	1,062.33	-	1,062.33	816.84	-	816.84
b) Other Intangible Assets	50.66	-	50.66	20.13	-	20.13
c) Intangible Assets Process	522.03	-	522.03	30.42	-	30.42
d) Financial Assets						
i) Investments	-	-	-	-	-	-
ii) Loans 0.00	-	-	-	-	-	-
iii) Advances	58.14	12.54	45.60	52.55	-	52.55
c) Deferred tax asset (net)	11.71	-	11.71	22.45	-	22.45

Jeevan Scientific Technology Limited

Particulars	Ast at 31.03.2017 Previous GAAP	Effect of Transition to Ind AS	As at 31.03.2017 As Per INDAS	As at 01.04.2016 Previous GAAP	Effect of Transition to Ind AS	As at 01.04.2016 as per INDAS
(2) Current Assets						
a) Inventories	267.97	220.55	47.42	227.98	220.55	7.43
b) Financial Assets						
i) Trade receivables	1,132.52	-	1,132.52	723.68	-	723.68
ii) Cash and cash equivalents	12.94	-	12.94	8.95	-	8.95
iii) Bank balances other than (ii) above	12.80	-	12.80	11.92	-	11.92
iv) Loans	49.41	-	49.41	3.85	-	3.85
v) Other Financial Assets	15.34	-	15.34	-	-	-
c) Current Tax Assets (Net)	112.20	-	112.20	76.67	-	76.67
d) Other Current Assets	14.31	-	14.31	44.97	-	44.97
Total	3,322.36	233.09	3,089.27	2,040.41	220.55	1,819.86
Equity and Liabilities						
Equity						
a) Equity Share Capital	927.95	-	927.95	604.16	-	604.16
b) Other Equity	992.86	233.09	759.77	-227.11	220.55	-447.66
Liabilities						
(1) Non-current Liabilities						
a) Financial liabilities Borrowings	474.75	-	474.75	831.94	-	831.94
b) Provisions	7.47	-	7.47	2.71	-	2.71
c) Deferred tax Liability (net)	-	-	-	-	-	-
(2) Current Liabilities						
a) Financial Liabilities						
i) Borrowings	246.22	-	246.22	244.80	-	244.80
ii) Trade Payables	224.36	-	224.36	333.47	-	333.47
iii) Other Financial liabilities	155.70	-	155.70	54.93	-	54.93
iv) Other Financial Creditors	45.86	-	45.86	8.31	-	8.31
b) Other current liabilities	222.30	-	222.30	174.96	-	174.96
c) Provisions	24.89	-	24.89	12.24	-	12.24
Total	3,322.36	233.09	3,089.27	2,040.41	220.55	1,819.86

Twentieth Annual Report 2017-2018

B.2 Reconciliation of Profit and Reserve between Ind As and previous Indian Gaap for earlier period and as at march 31, 2017

(Rs.in Lakhs)

Sr. No.	Nature of adjustments	Reserve reconciliation As at 31-Mar-17
	Net Profit/Reserves as per Previous Indian GAAP	992.86
1	Fair valuation as deemed cost for property, plant and Equipment	-
2	Fair valuation for financial assets	(233.09)
3	Deferred Tax	-
4	Others	-
	Total	(233.09)
	Net profit before OCI / Reserves as per Ind AS	759.77

Per our report of even Date
for **PAVULURI & Co.**
Chartered Accountants
Firm Regn No: 012194S

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
CA Kanthi Sree Kolli
Partner
Membership No:224434

Sd/-
K.Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M. Rajendra Prasad
Executive Director & CEO
DIN: 06781058

Sd/-
G. Ravi Kumar
Chief Financial Officer

Place : Hyderabad
Date : 26.05.2018

This page was intentionally
left blank

Twentieth Annual Report 2017-2018

Form No. MGT-11

Proxy form

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN: L72200TG1999PLC031016

Name of the Company: **Jeevan Scientific Technology Limited**

Registered office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda, Near Lanco Hills,
Golconda Post, Hyderabad – 500 008

Name of the member(s):

Registered Address:

E-mail Id:

Folio No./Client Id:

DP ID:

I/We, being the member (s) of shares of the above named company, hereby appoint

1. Name :
Address : _
E-mail Id :
Signature:, or failing him
2. Name :
Address:
E-mail Id :
Signature:, or failing him
3. Name :
Address:
E-mail Id:
Signature:

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 20th Annual General Meeting of the Company, to be held on 28th day of September, 2018 at 9.30 A.M. at 3rd floor, North Block, Raghava Ratna Towers, Chirag Ali Lane, Abids, Hyderabad – 500001 and at any adjournment thereof in respect of such resolutions as are indicated below:

Jeevan Scientific Technology Limited


Resolution No.

1. Approval of Financial Statements (including consolidated financial statements) for the year ended 31-Mar-2018.
2. To Appoint a director in place of Mrs. Kuchipudi Vanaja (DIN: 01030437) who retires by rotation and being eligible, offers herself for re-appointment.
3. To Appointment and revision of remuneration of Mr. K. Krishna Kishore (DIN: 00876539) as Managing Director of the company.
4. To Re-Appointment of Mr. S. S. R. Koteswara Rao (DIN: 00964290) as an Independent Director of the company.
5. To Re-Appointment and revision of remuneration of Mr. M. Rajendra Prasad (DIN: 06781058) as Whole-Time Director cum CEO of the company.

Signed this day of..... 2018

Signature of shareholder

Signature of Proxy holder(s)



Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.

Jeevan Scientific Technology Limited

Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills,
Hyderabad – 500 008

ATTENDANCE SLIP

(Please present this slip at the Meeting venue)

I hereby record my presence at the 20th Annual General Meeting of the members of the company to be held on 28th day of September, 2017 at 9.30 A.M. at 3rd floor, North Block, Raghava Ratna Towers, Chirag Ali Lane, Abids, Hyderabad – 500001 and at any adjourned meeting thereof.

Shareholders/Proxy's Signature_____

Shareholders/Proxy's full name_____

(In block letters)

Folio No./ Client ID_____

No. of shares held_____

Note: Shareholders attending the meeting in person or by proxy are required to complete the attendance slip and hand it over at the entrance of the meeting hall.

Twentieth Annual Report 2017-2018

Form No. MGT-12

Polling Paper

[Pursuant to section 109(5) of the Companies Act, 2013 and rule 21(1)(c) of the Companies (Management and Administration) Rules, 2014]

Name of the Company: **M/s. Jeevan Scientific Technology Limited**

Registered office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir,
Near Lanco Hills, Golconda Post, Hyderabad – 500 008

BALLOT PAPER

Sl.No.	Particulars	Details
1.	Name of the First Named Shareholder (In block letters)	
2.	Postal address	
3.	Registered folio No. / *Client IDNo. (*Applicable to investorsholding shares in dematerializedform)	
4.	Class of Share	Equity

Jeevan Scientific Technology Limited

I hereby exercise my vote in respect of Ordinary/ Special resolution enumerated below by recording my assent or dissent to the said resolution in the following manner:

Resol- ution No.	Description	No. of Shares held by me	I assent to the resolution	I dissent from the resolution
1.	Approval Of Financial Statements (including consolidated financial statements) for The Year Ended 31-Mar-2018.			
2.	To appoint a director in place of Mrs. Kuchipudi Vanaja (DIN: 01030437) who retires by rotation and being eligible, offers herself for re-appointment			
3.	Appointment and revision of remuneration of Mr. K. Krishna Kishore (DIN: 00876539) as Managing Director of the company.			
4.	Re-Appointment of Mr. S. S. R. Koteswara Rao (DIN: 00964290) as an Independent Director of the company.			
5.	Re-Appointment and revision of remuneration of Mr. M. Rajendra Prasad (DIN: 06781058) as Whole-Time Director cum CEO of the company.			

Place:

Date:

(Signature of the shareholder)



Enhops Solutions Pvt. Ltd., India and Enhops, Inc., USA are fully owned “subsidiary” companies of **Jeevan Scientific Technology Limited.**

Services Overview



Test Advisory Services



Test Automation



Performance Testing



Security Testing



Mobile Testing



TCoE



DevOps



Functional Manual Testing



Process Framework Establishment

**Clinical Pharmacology Unit
Balanagar, Hyderabad**



js JEEVAN SCIENTIFIC
TECHNOLOGY LIMITED

If undelivered, please return to :



Jeevan Scientific Technology Limited

Registered Office: Plot No. 1&2, Sai Krupa Enclave,
Manikonda Jagir, Near Lanco Hills,
Golconda (PO) Hyderabad - 500 008.

Ph : +91-40-67364700, Fax : +91-40-67364707

Email: info@jeevanscientific.com, Web : www.jeevanscientific.com